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“I've loved, I've laughed, and cried 
I've had my fill, my share of losing 
And now, as tears subside 
I find it all so amusing 
To think I did all that 
And may I say, not in a shy way 
Oh no, oh no, not me 
I did it my way” 
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 Described herein are two projects in the field of natural product synthesis unified by their 
use of convergent strategies. An introduction into a relevant subclass of natural products, the 
bis(monoterpenoid) indole alkaloids, precedes our synthetic efforts. The molecules in this class 
are comprised of two monoterpenoid indole alkaloids conjoined by at least one carbon–carbon 
bond, and we review efforts to construct these dimers using semi-, partial, and total synthesis. 
 The account of our synthetic work begins with a detailed approach to the 
bis(monoterpenoid) indole alkaloid leucophyllidine. An enantioselective Pd-catalyzed 
decarboxylative allylic alkylation generates an α-quaternary-substituted lactam, which serves as a 
building block for both monomeric subunits. The northern fragment, eburnamonine, is constructed 
through a five-step sequence comprised of Fischer indole synthesis, Bischler–Napieralski 
cyclization, and diastereoselective hydrogenation. The southern fragment, eucophylline, is 
constructed through a ten-step formal synthesis comprised of a Friedländer quinoline synthesis, 
followed by two orthogonal C–H functionalizations that each displayed unexpected reactivity.  
 We then describe the evolution of a convergent coupling strategy to unify the two 
polycyclic fragments. While the “biomimetic” Friedel–Crafts and “bio-inspired” organometallic 
addition approaches failed, a Pd-catalyzed cross-coupling was ultimately successful in forging the 
key C–C bond. Extensive efforts to install the final stereogenic center with a variety of reducing 
agents were unsuccessful, and DFT modeling was utilized to probe the recalcitrant nature of the 
trisubstituted alkene. Preliminary investigations of a directed hydrogenation are then discussed. 
Finally, we report an approach to the first total synthesis of the polyoxygenated diterpenoid 
(–)-scabrolide A.  The route begins with the synthesis of an enantioenriched cyclopentendiol 
building block and an acyclic diyne from (R)-linalool and (R)-carvone, respectively. A Stieglich 
esterification and thermal [4+2] cycloaddition affords a tricylic intermediate bearing all 19 carbons 
observed in the natural product. The cycloheptenoid motif is installed through a photochemical 
[2+2]/fragmentation sequence, exploiting an unusual alkene protecting group strategy to 
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The Synthesis of Heterodimeric 
Bis(monoterpenoid) Indole Alkaloids 
 
1.1  INTRODUCTION 
 The bis(monoterpenoid) indole alkaloids1 comprise a diverse class of plant-derived natural 
products with over 200 isolated members to date.2 Unlike many natural product families which 
exhibit a high degree of analogy with respect to their molecular architectures due to conserved 
biosynthetic pathways, “bis(monoterpenoid) indole alkaloid” is a general descriptor which applies 
to any natural product composed of two monoterpene-derived indole alkaloids joined by at least 
one C–C bond.3,4,5 As a result of this broad definition, the molecules in this class exhibit 
exceptional variation in structure, reactivity, and function with no one member constituting an 
“archetypal” bisindole alkaloid (Figure 1.1). Consequently, the chemodiversity within this class 
has attracted the attention of chemists and biologists from various sub-disciplines for over sixty 
years. 
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Voacorine, X = OH,  (2)
(XX) Conophylline, X = -O- ,               (15)
(XX) Conophyllidine, X = Δ-14’,15’    (16)
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Vinblastine, R = Me,    (6)
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To the synthetic chemist, dimeric indole alkaloids present a number of challenging aspects, 
which have limited the number of successful synthetic efforts compared to their monomeric 
counterparts. Because of the broad definition, the members of this family often display multiple 
iconic alkaloid architectures—including aspidosperma, corynanthe, eburnea, macroline, 
vobasine, and others within a single chemical entity; in effect, one must complete two separate 
total syntheses en route to one of these higher order monomers, a challenge that is exacerbated by 
the need to construct or conjoin these two fragments in a single, sterically congested molecule. 
Furthermore, while classic retrosynthetic logic indicates that “dimerizing” C–C bonds are 
strategic disconnections,6 the execution in the forward sense is rarely facile. Convergent coupling 
reactions must construct sterically encumbered bonds with complete chemo-, regio-, and 
stereoselectivity between densely functionalized natural product frameworks.7 For this reason, 
many synthetic strategies have centered on biomimetic coupling reactions, typically a combination 
of electrophilic aromatic substitution, condensation, or Michael addition.2 However, the ability to 
replicate this reactivity ex vivo is far from guaranteed, while the requirement for distinction 
between “electron-rich” and “electron-poor” coupling partners can limit the extension to non-
natural products and natural-product analogs.  
 Beyond these intrinsic chemical obstacles, the bis(monoterpenoid) alkaloids have also 
received attention because of their rich biological activity. A number of newly isolated natural 
products in this class have demonstrated bioactivities including, but not limited to, antileukemic, 
antimicrobial, antioxidant, antiulcer, cytotoxic, norepinephrine reuptake-inhibiting, platelet 
inhibiting, and radical scavenging.3,4,5 In general, the dimeric alkaloids exhibit more potent 
activities than their individual component monomers,8,9,10,11 which is hypothesized to occur 
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through higher target affinity or greater stabilization of the protein-ligand complex.12,13 For most 
molecules in this class however, the nature of these biological interactions are poorly understood.  
The most well-studied members of this class, vinblastine (6) and vincristine (7) are FDA-
approved to treat a variety of rapidly-dividing cancers like Hodgkin’s lymphoma, melanoma, and 
Non-small-cell lung cancer. Mechanistically,14 vinblastine (6) and vincristine (7) inhibit mitotic 
spindle through disruption of microtubule binding, leading to cell cycle arrest, aberrant division, 
and necrosis of tumor cells. Small molecule antagonists of protein-protein interactions (PPI’s) have 
been branded “the holy grail of drug discovery,”15 and natural products that disrupt PPI’s have 
immense value as starting points for the evaluation of new leads.16,17 The independent bioactivity 
of component monomers and structural similarity to established PPI inhibitors have led us to 
hypothesize that other members of this family could modulate similar interactions. 
The goal of this account is to provide a comprehensive review of successful synthetic 
efforts to date as a resource for chemists who may wish to study bis(monoterpenoid) indole 
alkaloids through semi-, partial-, or total synthesis. Although a number of excellent book chapters 
have been dedicated to the subject,2,3,4,5  most are broadly focused, and they do not provide a 
comprehensive summary of synthetic efforts in a single resource. Furthermore, a number of other 
reviews on the topic of synthesis are either out-of-date18 or focused on specific subclass of 
bisindole alkaloids.19 We hope that this resource will help to facilitate future synthetic efforts by 
highlighting key developments in strategies and tactics.    
 Our discussion will be limited to heterodimeric bisindole alkaloids, which we define as 
alkaloids composed of two structurally unique monomeric subunits that are each monoterpene-
derived in origin; thus, the coupling strategies require an element of substrate or reagent control 
to engender cross-selectivity. This serves to distinguish from homodimeric alkaloids, which are 
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composed of identical subunits resulting from spontaneous dimerization under reaction conditions. 
Dimeric alkaloids in which one component is not monoterpene-derived (e.g. from a condensed 
tryptamine or isoquinoline-derived unit) fall out of the scope of this review. Polypyrroloindoline 
alkaloids also will not be included in this discussion, despite the structural analogy to many of the 
structures discussed herein, though interested parties may be directed to the following reviews.20,21  
 
1.2  SEMI- AND PARTIAL SYNTHESES OF BISINDOLE ALKALOIDS 
1.2.1  Buchi’s Partial Synthesis of Voacamine and Related Alkaloids 
The earliest synthesis of a bisindole alkaloid was that of voacamine (1) and voacorine (2), 
reported by Büchi in the early 1960’s.22,23 After performing a number of degradation studies to 
elucidate the structure of the component monomers, Büchi performed a semi-synthesis to confirm 
the identity of the dimeric structure. Treating of a mixture of naturally isolated alkaloids 
voacangine (17) and vobasinol (18) with 2% HCl in methanol produced voacamine (1) in 14% 
yield, along with an undisclosed quantity of its constitutional isomer voacamidine (20) (Scheme 
1.1A). This is hypothesized to proceed through the intermediacy of iminium 19 via a Friedel–
Crafts alkylation at either the indole C(6) of voacangine (blue) to form voacamine (1) or at C(8) 
(red) to form voacamidine (20). It was subsequently shown that the latter isomer can be 
equilibrated back to voacamine (1) under more strongly acidic conditions.24 
Under identical reaction conditions, Büchi showed that voacorine (2) could be accessed 
through the condensation of voacangarine (21) and vobasinol (18) (Scheme 1.1B). Analogous 
acid-mediated condensations would later be utilized to access vobasine-based alkaloids 
tabernamine25 (24), bisindole alkaloids from E. orientalis26,27 (22)–(23) and T. accedens28 (25)–
(26), ervahaimines A and B,29 and several unnatural dimers30 (Scheme 1.1C). 
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Scheme 1.1. Büchi’s semi-synthesis of voacamine, voacamidine, voacorine (1963). 
 
 
1.2.2  LeQuesne and Cook’s Semi-synthesis of Alstonisidine  
In 1972, LeQuesne and Cook reported the semi-synthesis of alstonisidine (3)31,32 from 
naturally isolated quebrachidine (27) and macroline (28), obtained via the degradation of the 
related natural product villamine33 (Scheme 1.2A). In the presence of 0.2 M HCl, quebrachidine 
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(25), R = H
(26), R = OH
A. Semi-synthesis of voacamine and voacamidine
B. Semi-synthesis of voacorine
C. Other dimeric alkaloids synthesized via acid-mediated condensation
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via conjugate addition of the indoline nitrogen into the enone, which following protonation yields 
ketone 30  (Scheme 1.2B); intramolecular ketalization then occurs to condense the primary alcohol 
and generate hemiketal 29. Upon subsequent treatment with BF3•OEt2 at 0 °C, oxocarbenium 31 
is generated and intercepted via electrophilic aromatic substitution to afford Wheland intermediate 
32, which upon deprotonation generates alstonisidine (3). Although this target has yet to be 
generated by total synthesis, both quebachadine precursors34  and macroline (28)35,36,37,38,39  were 
later independently accessed through synthetic efforts.40 
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A. Two-step coupling toward the synthesis of alstonisidine
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1.2.3  LeQuesne and Cook’s Semi-synthesis of Villalstonine  
LeQuesne and coworkers also applied this reactivity to the synthesis of the related alkaloid 
villalstonine (4)32,41 from pleiocarpamine (33) and macroline (28) (Scheme 1.3A). In contrast to 
quebrachidine (27), the N-alkylated indole pleiocarpamine (34) reacts with the conjugate acceptor 
of macroline (28) at indole C(3), generating ketone 34; addition of the macroline primary alcohol 
into the carbonyl then promotes intramolecular aminal formation via addition of the oxygen into 
the C(2) iminium to form villalstonine (4) in 38% yield. (Scheme 1.3B)  
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A. Semi-synthesis of villalstonine
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1.2.4  LeQuesne and Cook’s Semi-synthesis of Macralstonine  
 Shortly thereafter, these conditions were applied a third time to the semi-synthesis of 
macralstonine (5)42 from macroline (28) and alstophylline (34) (Scheme 1.4A). Though this 
initially was proposed to occur via electrophilic aromatic substitution akin to that of villastronine, 
an alternative mechanism was later proposed43 where macroline (28) first equilibrates to 
oxocarbenium species 36 upon loss of water (Scheme 1.4B). This species is then intercepted by 
the electron rich indole ring of alstophylline (35) to afford conjugate adduct 37; hydration of the 
dihydropyran via oxocarbenium 38 then generates the natural product (5) in 40% yield. A total 
synthesis of alstophylline was later accomplished by Cook.44,45 
Scheme 1.4. LeQuesne and Cook’s semi-synthesis of macralstonine (1972). 
 
A. Two-step coupling toward the synthesis of macralstonine
B. Proposed coupling mechanism
0.2 M HCl (aq.)












































































Chapter 1: The Synthesis of Heterodimeric Bis(monoterpenoid) Indole Alkaloids 
 
10 
1.2.5  Portier and Langlois’s Partial Synthesis of Vinblastine  
 Vinblastine (6) and vincristine (7) are the most well-studied members of this natural 
product class from a synthetic perspective (Figure 1.2). Isolated from the Madigascar periwinkle 
Cantharanthus roseus G. don in 1958,46,47,48 these natural products are composed of a northern 
fragment derived from cleavamine (39) —which is synthesized in vivo via C–C bond cleavage of 
the related natural product cantharanthine (40) —and a southern fragment derived from vindoline 
(41). Early attempts to couple cleavamine (39) and vindoline (41) directly through SEAr forged 
the undesired epimer of vinblastine at C(16’) as the exclusive product.49 
Figure 1.2 Vinblastine, vincristine, and their subunits. 
 
Due to their high potency and treatment in low doses, clinical supplies continue to be 
derived from natural sources. Nevertheless, the chemical complexity of these molecules, in 
conjunction with questions about their structure-activity relationship and potential derivatives, 
have attracted significant attention from the synthetic community over the years, starting from 
semi-synthetic efforts through the late 20th century and, later, total-synthetic efforts through the 
early 21st century.  
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Scheme 1.5. Portier and Langlois’s semi-synthesis of vinblastine (1979). 
 
In 1979, Portier and Langlois published the first partial synthesis of vinblastine (6) from 
natural cantharanthine (40) and vindoline (41) (Scheme 1.5).50 Following a three-step procedure 
developed concurrently by the Portier-Langlois51,52 and Kutney53,54 groups, cantharanthine (40) is 
transformed to N-oxide 42 before subjection to trifluoroacetic anhydride initiates a Polonovski–
Portier rearrangement to cleave the C(16)–C(21) bond (red) of the iboga framework. The resultant 
di-cation is intercepted by vindoline (41) at C(16) through electrophilic aromatic substitution to 
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anhydrovinblastine (44) in 62% yield. Low temperatures were essential, as warming from –78 to 
0 °C eroded the diastereoselectivity from 4:1 to 1:1 d.r. at C(16’).52  
 Anhydrovinblastine (44) is then hydrogenated selectively at the Δ−15’,20’ olefin and N-
oxidized with m-CPBA to N-oxide 45. TFAA then initiates a second Polonovski-Portier 
rearrangement to generate enamine 46 upon subsequent elimination. Oxidation with thallium 
acetate then promotes β-acetloxylation to vinblastine-20’-acetate 47 before reductive deprotection 
with NaBH4 generates vinblastine (6) in 30% yield. While other oxidants (e.g. OsO4) oxidized 
from the less-hindered α-face, the thallium reagent offered the desired β-face oxidation due to 
direction by the enamine nitrogen lone pair.55 
 
1.2.6  Kutney’s Partial Synthesis of Vinblastine  
Kutney would follow up with an improved route to vinblastine using a similar strategy 
(Scheme 1.6).56 Following the tandem Polonovski–Portier rearrangement of N-oxide 42 and 
electrophilic aromatic substitution with vindoline (41), iminium 43 is subsequently treated with 
nicotinamide derivative 48 to promote 1,4-reduction of α,β-unsaturated iminium 43 preferentially 
at C(15’) (blue) over C(21’) (red) and generate enamine 46 directly. Circumventing the use of 
toxic thallium reagents, Kutney discovered that aerobic oxidation with iron (III) chloride could 
advance enamine 46 to vinblastine (6) following subsequent exposure to sodium borohydride in 
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Scheme 1.6. Kutney’s semi-synthesis of vinblastine (1988). 
 
 
1.2.7  Kuehne’s Partial Synthesis of Vinblastine  
Kuehne’s partial synthesis in 199157 targeted a deconstructed cleavamine unit to be used 
in the key coupling reaction (Scheme 1.7). Aldehyde 51, obtained in four steps from 2-ethyl-prop-
2-enol 50 via Sharpless epoxidation, was condensed with azepine 52 and alkylated with benzyl 
bromide to generate quaternary ammonium 53. Heating promotes C–C bond cleavage (red), which 
following treatment with base initiates a formal [4+2] cycloaddition of enamine 54; subsequent 
diol deprotection affords tetracycle 55 in modest yield, largely due to poor diastereoselectivity in 
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Scheme 1.7. Kuehne’s partial synthesis of vinblastine (1991). 
 
 Exposure to t-butyl hypochlorite affords chloride 57 which is followed by halide 
abstraction and heterodimerization; C–C bond cleavage (red) with potassium borohydride 
produces dimer 58 in 80% yield. While attempts to use cleavamine-derived chloroindenes in 
coupling reactions had previously49 led to poor diastereocontrol at C(16’), this research 
demonstrated that deconstruction of the piperidine ring was enough to overturn this inherent 
selectivity. To complete the natural product, dimer 58 is then advanced to vinblastine (6) over a 
three-step sequence consisting of: 1) intramolecular alkylation to generate a quaternary ammonium 
salt, 2) cleavage of the benzyl protecting group and 3) deprotection of the tertiary alcohol. A second 
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1.2.8  Magnus’s Partial Synthesis of Vinblastine   
Scheme 1.8. Magnus’s partial synthesis of vinblastine (1993). 
 
In 1993, Magnus59 disclosed an approach to vinblastine relying on “non-oxidative” 
formation of the electrophilic iminium (Scheme 1.8). N-benzyl tryptamine 59 was first advanced 
to thioamide 60 over a five-step sequence involving Pictet–Spengler cyclization and Barton 
decarboxylation, while 2-ethyl-prop-2-enol 50 was advanced to aldehyde 61 over a four-step 
sequence involving Sharpless epoxidation. A tin (II)-mediated aldol first affords alcohol 62 in 75% 
yield, before tosylation and elimination generates a mixture of alkenes (not shown). Raney nickel-
mediated desulfuration reduces thioamide to the tertiary amine before hydrogenation accesses 
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Treatment with nosyl chloroformate and base promotes acylation of the tertiary amine and 
C–C bond cleavage to indolene 64, which is intercepted by vindoline (41) to generate dimer 65 
with ~2:1 d.r. This intermediate is then advanced to vinblastine (6) over three-step sequence 
consisting of: 1) acetonide cleavage, 2) Swern oxidation and 3) carbamate cleavage/reductive 
amination to close the piperidine ring and complete the natural product.  
 
1.2.9  Cook’s Partial Synthesis of Villalstonine   
 In 1994, Cook reported a synthesis35,60 of macroline (28) en route to the first formal 
synthesis of villalstonine (4) (Scheme 1.9A). Tryptophan (66) was first elaborated to bridging 
lactam 67 over 4 steps via Pictet–Spengler and Dieckman cyclizations.61 Methylation of the benzyl 
protected amine is followed by hydrogenolysis and a two-step homologation sequence to access 
enal 68. Reduction and oxa-Michael addition affords vinyl ether 69, which is heated to promote a 
Claisen rearrangement, doubly reduced, and protected as acetonide 70. Hydroboration/oxidation 
of the exo-methylene occurs with complete selectivity for the β-face, before silylation and 
acetonide cleavage affords diol 71. Acetylation of the primary alcohol, oxidation of the secondary 
alcohol, and elimination of the acetoxy group affords enone 72. TBAF deprotection then affords 
the natural product macroline (28).   
Using a modified version of conditions described by LeQuesne,32 Friedel–Crafts alkylation 
generates the C–C bond (blue) before TBAF-triggered C–O bond formation (red) completes the 
synthesis of villalstonine (4) (Scheme 1.9B). Though a high yield is observed via qNMR, the 
isolated yield was comparable to that of the previously disclosed 38% yield in the one-step 
coupling (Scheme 1.9B). 
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1.2.10  Magnus’s Partial Synthesis of Macrocarpamine   
Scheme 1.10. Cook’s partial synthesis of macrocarpamine (1996).  
 
 Shortly thereafter, Cook also completed a partial synthesis of macrocarpamine (8). 
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reduction and hydroboration/oxidation to triol 73 (Scheme 1.10A). Mono-tosylation is then 
followed by Swern oxidation and condensation to dihydropyran 74. Reduction of the remaining 
ketone and elimination then affords anhydromacrosalhinine-methine (75). Combining this with 
natural pleiocarpamine (33) in anhydrous HCl in methanol then produces macrocarpamine (8) in 
83% yield (Scheme 1.10B). Mechanistically, this proceeds through protonation of indole C(3), 
followed by addition of the vinylogous enol ether of (76) to the in-situ generated iminium ion, 
forming oxocarbenium 77. Deprotonation then affords the natural product (8) (Scheme 1.10C).  
Scheme 1.11. Poupon, Evanno, and Vincent’s semi-synthesis of bipleiophylline (1996). 
 
 In 2017, Poupon, Evanno, and Vincent published a semi-synthesis62 of bipleiophylline (9) 
from pleiocarpamine (33) and voacalgine A (79) (Scheme 1.11). Though the natural product 
contains two pleiocarpamine units, classifying it as homodimeric, we were obliged to include it in 
this account due to the challenge of installing an aromatic spacer unit with the correct 
regioselectivity. Coupling of 2,3-dihydroxybenzoic acid 78 and the formate salt of pleiocarpamine 
(33) affords voacalgine A (79), a structure that was missassigned in the initial report.63 Repeating 
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1.3  TOTAL SYNTHESES OF BISINDOLE ALKALOIDS 
1.3.1 Magnus’s Total Synthesis of Norpleiomutine 
In 1984, Magnus published a route64 to the eburan–kopsia dimer norpleiomutine (10). 
Amine 80 is first elaborated to tetracyclic indole 81 through a five-step sequence65 involving 
intramolecular [4+2] cycloaddition (Scheme 1.12A). Esterification with enantioenriched sulfinyl 
acetic acid and l-cyclohexyl-3-(2-morpholinoethyl)carbodi-imide-metho-p-toluene sulfonate 
(CMS) allows for chromatographic separation of diastereomers, affording enantiomerically pure 
82. Acylation with TFAA at elevated temperatures generates lactam 83 via an interrupted 
Pummerer rearrangement, before α-alkylation with allyl bromide and heating affords caged Diels–
Alder adduct 84 in 72% yield. Following reduction of the olefin with diimide, oxidation of the 
thioether at 240 °C triggers a formal 1,3-migration to sulfoxide 85. Oxidation to the ketone 
followed by methoxide-mediated C–C bond cleavage generates hexacyclic intermediate 86. 
Deprotection of the indole nitrogen is followed by reesterification; conversion of the lactam to the 
thioamide with Lawesson’s reagent and desulfurization affords kopsonilam (87). 
To access the eburan fragment, Diels–Alder adduct 88 is subjected to oxidative cleavage 
and acetal hydrolysis to lactone 89 (Scheme 1.12B). Condensation with tryptamine under acidic 
conditions promotes a Pictet–Spengler cyclization, affording cis-fused pentacycle 90. A 
reduction/oxidation sequence then generates rac-eburnamonine (91), before a classical resolution 
and lithium aluminum hydride reduction affords a mixture of (–)-eburnamine (92) and 
isoeburnamine (93). Subjecting a mixture of the two isomers with kopsanilam (87) under acidic 
conditions then affords norpleiomutine (10) in 20 steps LLS from amine 80 (Scheme 1.12C).66 
This marks the first synthesis of a dimeric indole alkaloid in which both monomeric precursors are 
synthetically derived and enantioenriched. 
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1.3.2 Cook’s Total Synthesis of Macralstonidine 
 In 2002, Cook and coworkers reported the first total synthesis of macralstonidine (12) from 
macroline (28) and (+)-Na-methylsarpagine (94).67 6-methoxytryptophan 95 was accessed from 4-
methoxyaniline through a Japp–Klingemann synthesis68 and advanced to lactam 96 (Scheme 
1.13A).69 N-alkylation generates a vinyl iodide, which then undergoes an intramolecular Pd-
catalyzed enolate alkenylation to afford bridging ketone 97. Wittig homologation with acidic 
workup produces an aldehyde before demethylation and borohydride reduction generates Na-
methylsarpagine (94). Acid-mediated condensation with synthetic macroline (28) under Gannick’s 
conditions70 then affords the dimer (+)-macralstonidine (Scheme 1.13B).  
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1.3.3 Fukuyama’s First Generation Total Synthesis of Vinblastine 
The first total synthesis of vinblastine (5) was completed by the Fukuyama group in 2002.71 
Starting from aldehyde 98, cyanohydrin formation and acetylation generates a racemic mixture of 
acetates, which undergoes enzymatic resolution to generate alcohol 99 in 42% yield and 97% ee 
(Scheme 1.14A). Following ozonolysis of the styrenyl olefin, the alcohol is activated with mesyl 
chloride before a tandem lithium aluminum hydride reduction and protection sequence advances 
to dihydrofuran 100. 
 In parallel, quinoline 101 is cleaved with thiophosgene, which following THP-protection 
affords isocyanate 102 (Scheme 1.14B). Addition of benzyl methyl malonate precedes a Fukuyama 
indole synthesis72 and Boc protection to afford indole 103 in 60% yield. Hydrogenolysis of the 
benzyl ether is followed by a decarboxylative Mannich reaction with elimination and THP 
deprotection to form enoate 104, which is coupled with dihydrofuran 100 through a convergent 
Mitsunobu reaction to access ether 105. TFA promotes hydration of the enol ether and Boc 
deprotection, while addition of pyrrolidine at high temperatures opens the hydrated furan ring and 
promotes an intramolecular [4+2] cycloaddition to construct pentacycle 106. This is advanced 
through a previously published 7-step sequence73 to vindoline (41). 
 To construct the cleavamine-derived northern fragment, oxazolidinone 107 is advanced to 
nitrile 108 through a diastereoselective Michael addition to acrylonitrile, reductive auxiliary 
cleavage, and TBDPS-protection (Scheme 1.14C). The nitrile is reduced to the aldehyde and 
condensed with hydroxylamine to an oxime, which undergoes a nitrone-olefin 1,3-dipolar 
cycloaddition to bicycle 109; reduction with zinc then unmasks β-hydroxy ketone 110. Baeyer-
Villiger oxidation promotes C–C bond cleavage to a lactone (not shown), which is hydrolyzed 
with basic methanol and orthogonally protected to afford acyclic fragment 111.   
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C. Total synthesis of cleavamine derivative
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Base-mediated addition of ester 111 into isocyanate 112 is followed by an additional three-
step sequence to generate indole 113 as a mixture of diastereomers α to the ester. Bis-tosylation of 
the primary alcohols is followed by base-mediated epoxidation and intermolecular SN2 to afford 
amine 114. Treatment with K2CO3 at elevated temperatures then affords the 11-membered cyclic 
amine, 115 which is advanced through an additional three steps to dimerization precursor 116. 
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B. Total synthesis of vincristine
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To link the two monomeric subunits, indole 116 is treated with t-BuOCl to chloroenamine 
117, which upon addition of vindoline (41) and acid generates dimerized product 118 in 97% yield 
as a single diastereomer (Scheme 1.15A). Deprotections of the trifluoroacetate and nosyl groups 
are then followed by base-mediated closure of the 6-membered ring, affording vinblastine (5) in 
28 steps longest linear sequence from 101. Fukuyama later showed that an analogous sequence 
could be used to advance desmethylvindoline 119 to vincristine (6) (Scheme 1.15B).74 
 
1.3.4 Fukuyama’s Second Generation Total Synthesis of Vinblastine 
Fukuyama then published a second generation approach to vinblastine in 2007 (Scheme 
1.16).75 Instrumental to this route was a functional handle at C(20’) to allow for derivatization at 
this position. Starting from enantioenriched cyclopentene 124, Krapcho decarboxylation and 
saponification affords acid 125, which is then lactonized and BOM-protected to afford bicycle 
126. A three-step sequence then advances the intermediate to dihydropyran 127 before 
hydroboration/oxidation generates ketone 128. Grignard addition of TMS-acetylene installs the 
two-carbon handle before acid-mediated BOM-deprotection accesses pyran 129. Oxidation of the 
secondary alcohol and Baeyer-Villager oxidation advances to hemiacetal 130. Ethanolysis of the 
lactone, lactol reduction, acid-catalyzed lactonization, and silylation then affords key protected 
diol 131 in 85% yield. Addition to isothiocyanate 132 and Fukuyama synthesis then generates 
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An additional eight steps are required to advance to azide 134, which is reduced and nosyl 
protected to amine 135. Protecting group manipulations are then used to access cyclization 
precursor 136, which undergoes a Mitsunobu reaction to generate cyclic amine 137. MOM-
deprotection and tosylation of the primary alcohol is followed by re-protection of the tertiary 
alcohol to dimerization precursor 138. The analogous dimerization sequence generates 139 in 84% 
yield, before an additional four steps afford vinblastine (5). Several derivatives of alkyne 139 were 
generated as well, but all analogs were less biologically active than vinblastine (5). 
 
1.3.5 Boger’s Total Synthesis of Vinblastine 
 A third total synthesis of vinblastine was reported by Boger in 2008.76,77 Their previously 
reported synthesis of vindoline78 begins with 6-methoxytryptamine (140), which is treated with 
CDI and 141 to afford urea 142 (Scheme 1.17A). Tosyl chloride induces cyclization to the 1,3,4-
oxadiazole before coupling with acid 143 to afford amide 144. Heating in 1,3,5-tri-iso-
propylbenzene (1,3,5-TIPB) at 230 °C promotes a tandem [4+2]/[3+2] cycloaddition to forge the 
alkaloid core as a mixture of enantiomers which are separated by chiral HPLC to afford 
enantiomerically pure 145. α-Oxidation of the lactam is isolated as silyl ether 146 before amide 
reduction and acetylation generates piperidine 147. Finally, hydrogenolysis of the cyclic ether, 
TIPS deprotection, and elimination affords vindoline (41) in 11 steps from 140. A second 
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Using cantharanthine (40) obtained from Raucher’s route8081, Boger developed a one-pot 
oxidative coupling/alkene hydration to synthesize vinblastine (5) directly from the component 
monomers (Scheme 1.17B). Originally, Fe(III) was proposed to oxidize cantharanthine (40) to 
radical cation 148, which undergoes C–C bond cleavage to stabilized radical 149 (Scheme 1.17C); 
this is oxidized to carbocation 150 before undergoing SEAr with vindoline (41) to iminium 43. The 
addition of iron (III) oxalate and sodium borohydride then initiate H• addition to the trisubstituted 
olefin (via the intermediate Fe–H species), generating a tertiary radical 151 that traps a molecule 
of singlet oxygen to the peroxide radical 152. A second hydrogen atom addition then generates the 
peroxide 153, which is reduced to vinblastine (5) in 42% yield, with 24% of leurosine (49) also 
isolated. The intermediates on this route were then elaborated to a number of analogues to study 
structure activity relationship.82 
However, this mechanistic proposal failed to explain two key observations: 1) the coupling 
reaction proceeded with perfect diastereoselectivity at C(16’) when conducted at 23 °C, while 
Kutney and Portier’s procedure, which implicated identical intermediates, favored the undesired 
epimer, and 2) no fragmented cleavamine-type derivatives were observed, as all mass balance 
returned as unreacted cantharanthine (40). A follow-up study83 proposed a new hypothesis where 
cantharanthine (40) is reversibly oxidized to charge-separated radical cation 154 which lies in 
equilibrium with iminium radical 155; nucleophilic attack by vindoline forms stabilized radical 
156 which is sequentially oxidized and deprotonated to anhydrovinblastine (44) and hydrated to 
vinblastine (5) through the mechanism described above (Scheme 1.17C). Boger further supported 
this hypothesis by publishing a new radical-cation based coupling method in 2019 (Scheme 
1.18B)84 
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Scheme 1.18. Boger’s revised mechanistic proposal and radical cation coupling (2019). 
 
1.3.6 Cook’s Total Synthesis of Accedinisine 
In 2008, Cook published the first total synthesis of accedinisine (13).85,86 Tryptophan (66) 
was advanced to pentacycle 97 over six steps (Scheme 1.19A); in a previous report, Liu and 
coworkers showed that this intermediate could be advanced to the nucleophilic affinisine (157) 
monomer via Wittig homologation and reduction in the opposite enantiomeric series,87 though the 
correct enantiomer was later correctly accessed en route to macroline (28).37 To access the 
electrophilic coupling partner (Scheme 1.19B), pentacycle 97 was converted to alcohol 158 via 
hydroboration/oxidation of an intermediate Wittig methylenation product. Conversion to 
pericyclivine (159) over three steps is followed by Cbz-protection and methanol-induced C–C 
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coupling partner 161. Mixture of methyl ether 161 and affinisine (157) in acidic methanol then 
affords (–)-accedinisine (13) in 35% yield (Scheme 1.19C). Use of Cbz-protected amine 160 in 
the coupling reaction was also utilized to afford N-desmethyl accedinisine.   
Scheme 1.19. Cook’s total synthesis of accedinisine (2008). 
 
 

















     t-BuOK; then HCl
2. NaBH4





















































    t-BuOK
2. 9-BBN;






















































C. Biomimetic coupling of accedinisine
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1.3.7 Fukuyama and Tokuyama’s Total Synthesis of Haplophytine 
Aside from vinblastine (5) and its congeners, haplophytine (14) is perhaps the most well-
studied bis(monoterpenoid) indole alkaloid. Isolated from the leaves of the plant Haplophyton 
cimicidum and noted for its insecticidal properties,88,89,90,91 it is the dimeric combination of the 
component alkaloids canthiphytine (158) and aspidophytine (159)  (Scheme 1.20A). Degradation 
studies by Cava and Yates showed that the western portion of the molecule readily undergoes a 
reversible rearrangement in the presence of acid or base (Scheme 1.20B).92,93 Despite several 
elegant syntheses of the aspidophytine moiety,94,95,96,97,98 all were unsuccessful at advancing 
directly to haplophytine (14). The three published routes to date all utilize simpler precursors in 
the coupling/rearrangement.   
Scheme 1.20. Haplophytine and proposed biosynthetic precursors. 
 
The Fukuyama and Tokuyama route99 to haplophytine (15) begins with auxiliary-










































A. Haplophytine and its component monomers


















Chapter 1: The Synthesis of Heterodimeric Bis(monoterpenoid) Indole Alkaloids 
 
34 
in 74% yield and 98% ee (Scheme 1.21A). Reduction and mesylation are followed by a Fukuyama 
ketone synthesis100 to produce pthtalamido-ketone 163, before ketalization and elimination of the 
mesylate forges cyclopentene 164. Following a protecting group exchange (164 → 165), 
ozonolysis with reductive workup generates diol 166. Leveraging the difference in steric 
environments between two primary alcohols, orthogonal mesylation and oxidation precede 
alkylation of the nosyl amine to generate cyclic amine 167. Finally, ketal and nosyl cleavage 
promotes an intramolecular Mannich reaction, which following reesterification accesses the key 
tricyclic ketone 168.  
In a separate sequence, Vilsmeier–Haack formylation and Henry addition to indole 169 
affords nitroolefin 170 (Scheme 1.21B). Exhaustive reduction with LiAlH4, followed by acylation 
and esterification generates amide 171 which undergoes protecting group exchange at the phenol 
oxygen to mesylate 172. A Bischler–Napieralski cyclization then accesses the cyclic iminium, 
which undergoes Noyori-type asymmetric transfer hydrogenation101 and Cbz-protection to afford 
tricycle 173 in 97% ee. At this juncture, a coupling occurs to install the aryl ring of the southern 
fragment; iodination of the indole C(3) is followed by treatment with silver (I) to produce 
carbocation 174 which reacts with aniline derivative 175 to generate quaternary adduct 176 in 61% 
yield with 2.0–2.4:1 d.r. This is advanced to tetracycle 177 through a lactamization/protecting 
group exchange sequence. Treatment of the enamine with m-CPBA produces an epoxide 178, 
which undergoes a spontaneous semi-pinacol rearrangement to forge the rearranged northern 
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Scheme 1.21. Fukuyama and Tokuyama’s total synthesis of haplophytine monomers (2009). 
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To complete the synthesis, fragments 168 and 180 were coupled through a two-step Fischer 
indole synthesis to access dimer 181 bearing the full skeleton of haplophytine (Scheme 1.22). 
Desaturation of the imine with benzeneselenic anhydride and Cbz-deprotection then occur before 
the final two methyl groups of 182 are installed by reductive amination. Finally, mesyl 
deprotection/saponification and oxidative lactonization then complete haplophytine (14) in 27 
steps LLS from indole 169. 
Scheme 1.22. Fukuyama and Tokuyama’s total synthesis of haplophytine (2009). 
 
 
1.3.8 Nicolaou and Chen’s Total Synthesis of Haplophytine 
The Nicolaou and Chen approach102 begins with a nearly identical sequence to the 
Fukuyama route, accessing tricycle 183 (Scheme 1.23). A PIFA-mediated oxidative coupling then 
occurs with indoline 184. Mechanistically, this proceeds through ligand exchange between the 
hypervalent iodine and ortho-phenol to generate electrophilic species 185, which reacts with the 
C(3) indole of tricycle to afford arylated intermediate 186. Deprotonation then promotes addition 
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in 23% yield (albeit with only 25% conversion.) Following a seven-step sequence to advance to 
lactam 188, a similar m-CPBA initiated rearrangement occurs to forge the bridging tetracyclic 
fragment on the western fragment. Subsequent treatment with DDQ then oxidizes the intermediate 
to indole 189. 
Lithiation/borylation at C(2) of the newly formed indole is followed by Suzuki coupling 
with reported vinyl iodide103 190 and methylation of the indole to afford heptacycle 191. Amide 
activation with triflic anhydride promotes intramolecular cyclization with the indole C(3), 
followed by reduction of the resultant iminium. Deprotection of the primary alcohol and activation 
as the xanthate allows for a 5-exo trig radical cyclization into the indole104 to access 192, bearing 
the full carbocyclic skeleton of haplophytine. Deprotection of the carboxylic acid and oxidative 
lactonization then occurs, followed by debenzylation of the phenol oxygen and silylation to 
intermediate 193. Reductive amination installs the final methyl group, but it is unfortunately 
accompanied by reductive lactone opening. This bond is reformed with K3[Fe(CN)6] before 
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1.3.9 Fukuyama and Tokuyama’s Total Synthesis of Conophylline 
In 2011, Fukuyama and Tokuyama published a route towards the dimeric aspidosperma 
alkaloids conophylline (15) and conophyllidine (16).105 Commercial phenol 194 was first 
advanced to ester 195 over an eight-step sequence (Scheme 1.24A). Nitro reduction, followed by 
acylation and dehydration affords isocyanate 196 which undergoes a Fukuyama indole synthesis 
followed by iodine quench to afford 2-iodoindole 197. After DIBAL reduction and orthogonal 
protections, indole 198 undergoes Stille coupling with vinylstannane 199 and THP deprotection to 
afford enoate 200. This is advanced upon coupling with dihydrofuran 100, previously implemented 
in their first-generation vinblastine synthesis,71 to tetracycle 201 in 49% yield over three steps. 
Following elimination of the secondary alcohol to pentacycle 202, indole protection and 
epoxidation affords the electrophilic coupling partner 203, a protected version of the natural 
product taberhanine. 
The nucleophilic coupling partner is synthesized from tetracycle 106, an intermediate that 
was also accessed during the vinblastine route (Scheme 1.24B).71 Through an analogous three-step 
sequence, 106 is advanced to epoxide 204. Following Troc-deprotection, mesyl group hydrolysis 
and allylation accesses nucleophilic coupling partner 205. 
To couple the monomeric subunits, electrophilic coupling partner is transformed to N-
oxide 206 with m-CPBA (Scheme 1.25). Subjection to TFAA generates acylated species 207 
which undergoes regioselective Polonovski-Portier rearrangement106 to iminium 208, which is 
intercepted by nucleophilic fragment 205 to access dimer 209 in 50% yield over two steps. Allyl 
deprotection with palladium promotes concomitant epoxide opening to forge the final 
dihydrofuran ring before global deprotection with LDA affords conophylline (15) in 27 steps LLS. 
A similar procedure is used to access the congener conophylline (16). 
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Scheme 1.25. Fukuyama and Tokuyama’s total synthesis of conophylline (2011). 
 
1.3.10 Tokuyama’s Second Generation Total Synthesis of Haplophytine 
In 2016, Tokuyama published a bio-inspired second-generation total synthesis of 
haplophytine107, improving upon previously developed chemistry by performing the coupling and 
rearrangement at a late-stage (Scheme 1.26). Tricycle 20999 and aspidosperma skeleton 210108 are 
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Saponification is followed by lactamization and protecting group exchange at the indole nitrogen 
to afford rearrangement precursor 212.  
Scheme 1.26. Tokuyama’s total synthesis of haplophytine (2016). 
 
Using a modified aerobic rearrangement, treatment with 2-chlorothiophenol, cesium 
carbonate, and air generates carbamate radical 213, which undergoes decarboxylation and trapping 
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affords peroxide 215, which is reduced to alkoxide 216 before semi-pinacol rearrangement 
produces the full carbocyclic skeleton 217 in 70% yield. Thermal Boc-deprotection and double 
reductive amination install the final two carbons, before mesyl deprotection and oxidative 
lactamization affords haplophytine (14) in 15 steps from previously published intermediates. 
  
1.4  CONCLUDING REMARKS 
In summary, the bis(monoterpenoid) indole alkaloids have inspired a deep and fascinating 
body of research over the past sixty years. Despite this substantial history, it is surprising that such 
a storied natural product class remains so dramatically underexplored. While other alkaloid 
subclasses are subject of dozens of accounts per year, successful bisindole alkaloid syntheses are 
scarce—especially relative to the continued focus on the monoterpenoid indole alkaloids which 
frequently compose these dimeric structures. Modern synthetic chemists have largely moved on 
from the “tour-de-force” approach to natural product total synthesis that were frequently 
implemented to construct these synthetically challenging targets. By implementing aspects of 
modern synthetic planning, we can construct these targets with improved efficiency and facilitate 
the completion of total synthetic efforts.  
One such strategy to facilitate studies is the implementation of divergent109 or diversity-
oriented synthesis110 in the construction of monomeric subunits. Inefficient monomer synthesis 
continues to be the bottleneck of progress, both in material throughput and time invested in 
optimizing new routes (vide infra). Monoterpenoid indole alkaloids, despite substantial structural 
variation, all arise from the same biosynthetic precursor strictosidine;111 these monomers are, thus, 
particularly well-suited for diversity-oriented synthesis, as evidenced by reports from Zhu,112 
MacMillan,113 and Stoltz.114 Fukuyama’s skillful repurposing of vinblastine intermediates toward 
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the synthesis of conophylline105 offers concrete proof-of-principle that this design element can 
improve the efficiency of route development. 
Another area of development is the incorporation of modern advances in cross-coupling to 
accomplish the convergent linkage of monomeric subunits. Successful efforts to-date have become 
overreliant on the biomimetic hypotheses to forge the key dimerizing bond; this has thwarted some 
efforts when these hypotheses have proven unsubstantiated and limited other attempts to expand 
the scope of coupling partners beyond the natural product. Generalizable cross-couplings can be 
utilized in multiple natural product syntheses, as evidenced by work on oligomeric 
polypyrrolidinoindolines by MacMillan115 and Movassaghi.116 Given the recent advances in 
C(sp3)–C(sp2) cross coupling, the viability of catalyst-controlled coupling strategies has never 
been greater.  
From origins in structural elucidation via semi-synthesis to modern implementation in 
analog development for structure-activity relationship studies, interest in this natural product class 
has evolved with the changing demands of modern synthetic chemistry. Given the designation of 
several accounts described herein as landmark syntheses,117,118 there remains little doubt that this 
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Divergent Synthesis of 
Eburnamonine and Eucophylline 
 
2.1  INTRODUCTION 
2.1.1.  Isolation, Bioactivity, and Biosynthetic Hypotheses  
Leucophyllidine (230) is a bis(monoterpenoid) indole alkaloid that was first isolated from 
the bark of the Malaysian woody climber Leuconotis griffithi in 2009.1 It is composed of two 
polycyclic fragments: a northern pentacyclic indole-containing fragment derived from 
eburnamonine (91) and a southern tetracyclic vinylquinoline fragment derived from eucophylline 
(231) (Figure 2.1). Structurally, the molecule contains nine rings, four stereogenic carbons 
(including two all-carbon quaternary stereogenic centers) and a sterically hindered C(sp)3–C(sp)2 
bond which joins the two polycyclic fragments. The molecule demonstrates in vitro cytotoxicity 
toward drug-sensitive and drug-resistant human KB cells (IC50 = 5.16, 5.10 µM) while also acting 
as a dose-dependent inhibitor of nitrous oxide (NO) synthase.2 
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Figure 2.1 Leucophyllidine and its component monomers. 
 
 The two monomeric components of leucophyllidine (230) have each been independently 
isolated from separate biological sources (Figure 2.1). Eburnamonine (91) and its reduced form 
eburnamine (92) were first isolated in 1959 by Bartlett and Taylor3 from the plant Hunteria 
eburnea, and it was later demonstrated to show anticholinergic4 and cerebratonic5 properties. 
Eucophylline (231) was first isolated in 2010 from the related plant species Leuconotis 
eugenifolius. Though noteworthy for its unique tetrahydro-benzo[b][1,8]naphthyridine core, 
eucophylline (231) displays no known biological activity to date. 
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 Biosynthetically, eburnamine (92) is hypothesized to arise from aspidospermidine (232), 
which is first oxidized to hydroxylated alkaloid 233 (Scheme 2.1). A fragmentation then occurs to 
reform iminium 234, which undergoes subsequent attack from indole C(2) to form rearranged 
pentacycle 235. Cleavage of the five-membered ring affords α-ketoester 236, before nucleophilic 
attack of the indole nitrogen closes the 6-membered ring of vincamine (237), thus completing the 
pentacyclic framework. Methyl ester hydrolysis to acid 238, followed by decarboxylation then 
affords eburnamine (91).6   
Scheme 2.2. Proposed biosynthesis of eucophylline. 
 
 Eucophylline (92) is hypothesized to arise from 11-hydroxyleuconolam (239), which 
undergoes an intramolecular 6-exo trig conjugate addition to form pentacycle 240, which is 
reduced to hemiaminal 241 (Scheme 2.2).2 Formation of iminium 242 precedes an E2 elimination 
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alkaloid 244. At this juncture, reduction of the piperidine motif occurs before a 
fragmentation/oxidation establishes aromatic quinolone 246. This then participates in nucleophilic 
aromatic substitution to complete the tetrahydro[b][1.8]naphthyridine core of eucophylline (231). 
Scheme 2.3. Proposed biosynthesis of leucophyllidine. 
 
 The coupling of monomers is proposed to occur upon dehydration of eburnamine (92) to 
the corresponding iminium ion 246, followed by electrophilic aromatic substitution with the 
electron-rich eucophylline (231) to complete leucophyllidine (230) (Scheme 2.3). Based on 
synthetic work by Panday, the C(6) position of eucophylline is much less nucleophilic than C(8) 
to Friedel-Crafts type reactivity due to greater stabilization of the Weiland intermediate. Therefore, 
it is very likely that the corresponding dimerization event is enzyme-mediated.7 
 
2.1.2.   Previous Synthetic Efforts toward Eburnamine 
Scheme 2.4. Strategically significant bonds in eburnamonine. 
 
 In the 60 years since its initial discovery, there have been over two dozen reported 
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than discuss each synthesis individually, we will focus on select examples that identified three 
strategic bonds (Scheme 2.4), disconnecting the pentacycle into a “tryptamine” and “lactam”-
derived fragments. These examples were the most influential in our retrosynthetic analysis.  
Scheme 2.5. Harley-Mason’s synthesis of (±) eburnamonine (1965). 
 
The first noteworthy example by Barton and Harley-Mason8b exploits a Pictet-Spengler 
approach to construct the eburnan core (Scheme 2.5). Starting from 4-formylhexanoate 247, 
enamine alkylation with allyl bromide generates quaternary adduct 248 in racemic fashion 
(Scheme 2.5). Treatment with tryptamine promotes a tandem condensation/Pictet-Spengler 
cyclization to lactam 249 in 75% yield. While this was initially believed to forge a single C(21) 
diastereomer, additional studies11 revealed that following Johnson-Lemieux oxidation and careful 
chromatography affords eburnamine N(b) lactam 250a and its C(21) epimer 250b as a 1:6 mixture. 
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Scheme 2.6. Wenkert’s synthesis of (±) eburnamonine (1988). 
 
 Wenkert and coworkers8l later disclosed a route that utilizes a Pictet-Spengler cyclization 
into a cyclic iminium rather than an acyclic iminium (Scheme 2.6). Enaminone 252 is first 
converted to dithiolane 253, which is followed by Raney Nickel-mediated desulfurization to access 
cyclic enamine 254 (Scheme 2.6). Treatment with ethyl diazoacetate in the presence of copper 
bronze generates cyclopropane 255 in racemic fashion before base-mediated hydrolysis produces 
lactone 256. Alkylation with tryptophyl bromide affords tetracycle 257, and heating in glacial 
acetic acid generates eburnamonine (91) and epi-eburnamonine (251) in good yield but low 
diastereoselectivity (1.4:1). Degradiation studies by Lounasmaa12 determined that the unnatural 
trans-ring fusion is thermodynamically preferred, leading us to hypothesize that the further 
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Scheme 2.7. Schlessinger’s synthesis of (±) eburnamonine (1979). 
 
 The route by Schlessinger and coworkers,8f in contrast, utilized a Bischler–Napieralski 
cyclization to access the eburnan core (Scheme 2.7). t-Butyl butyrate 258 is advanced over five 
steps to indole-substituted lactam 259. Enolate alkylation with methyl bromoacetate generates 
quaternary lactam 260 in racemic fashion, which is subsequently subjected to Bischler–Napieralski 
cyclization conditions and anion exchange to yield iminium perchlorate 261. Hydrogenation with 
10% palladium on carbon yields tertiary amine 262 in quantitative yield as a 3:1 mixture of 
diastereomers in favor of the cis-ring fusion; this selectivity arises from preferential addition of 
hydrogen from the less-hindered β-face of the natural product, generating the kinetically favorable 
cis product as the major diastereomer. Base-mediated lactamization then produces eburnamonine 
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2.1.3.   Previous Synthetic Efforts toward Eucophylline 
Scheme 2.8. Landais’s synthesis of (±) eucophylline (2015). 
 
 In sharp contrast to eburnamonine (91), eucophylline (231) has only been synthesized twice 
since its initial isolation. The first report by Landais and coworkers13 begins with a three-
component radical coupling of alkyl iodide 263, alkene 264, and O-benzyloxime 265 to afford 
quaternary adduct 267 in racemic fashion (Scheme 2.8). Treatment with sodium borohydride, 
followed by hydrogenolysis with Raney-Ni affords cyclized lactam 268 in 66% yield over two 
steps. A one-pot mesylation/SN2 displacement generates fused bicycle 269 which, upon treatment 
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Cyclization is then initiated with LDA to generate 4-aminopyridine 272, then advanced to triflate 
273 over two steps. Suzuki coupling with 274 appends the vinyl fragment in O-methyleucophylline 
275 before demethylation affords eucophylline (231) in 10% yield over 10 steps. 
Scheme 2.9. Panday’s asymmetric synthesis of eucophylline (2017). 
 
 In 2017, Panday and coworkers described the first asymmetric synthesis of eucophylline 
(231) as part of their unsuccessful efforts toward leucophyllidine (230) (Scheme 2.9). δ-
valerolactam 276 is advanced to α-quaternary lactam 277 in five steps through a stereospecific 
Johnson-Claisen rearrangement from chiral pool starting materials, then advanced ten additional 
steps to aldehyde 278. A Friedländer synthesis with amino aldehyde 279 forges the quinoline core 
before treatment with m-CPBA affords quinoline N-oxide 280. This intermediate is then subjected 
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chloroquinoline 281 in modest yield. Demethylation under forcing conditions accesses phenol 282 
before a final Stille coupling stannane 283 with appends the vinyl fragment, accessing 
eucophylline (231) in 22 steps from commercial material. 
 
2.1.4.  Inspiration 
For nearly two decades, our laboratory has studied the transition-metal catalyzed 
asymmetric allylic alkylation of prochiral enolates;14 these powerful methods allow us to access 
substrates bearing all-carbon quaternary stereogenic centers in good yield and enantioselectivity. 
The functionality incorporated in these products has enabled their utility as building blocks and 
inspired new disconnection strategies in natural products total synthesis. 
Recent advances in our technology has allowed the incorporation of nitrogenated 
functionality, providing new entry points into alkaloid total synthesis (Scheme 2.10). Our first 
extension of this methodology to N-containing heterocycles in 2012 used the decarboxylation 
allylic alkylation of racemic carboxylactam 284 to access enantioenriched lactam 286 in excellent 
yield and enantioselectivity while accomplishing formal syntheses of the natural products 
quebrachamine (287) and rhazinilam (288)15 (Scheme 2.10A). In subsequent years, we illustrated 
that decarboxylative allylic alkylation of dihydropyrido[1,2-a]indolone (DHPI) frameworks (289 
→ 290) could be elaborated into cis-fused Aspidosperma alkaloids limaspermidine (291) and 
aspidospermidine (232), trans-fused Kopsia alkaloids kopsihainanine A (292), and the rearranged 
alkaloid goniomatine (293) via stereodivergent cyclizations (Scheme 2.10B).16 The allylic 
alkylation of racemic Mannich adducts (294 → 295) has also enabled efficient syntheses of 
sibirinine  (296) and α,β-myrifabral A (297) (Scheme 2.10C).17 
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Scheme 2.10. Application of Pd-catalyzed asymmetric allylic alkylation to the synthesis of 
monoterpenoid indole alkaloids in the Stoltz laboratory. 
 
 
2.1.5.  General Synthetic Strategy 
Given the diverse range of monoterpenoid indole alkaloids accessible from these 
enantioenriched building blocks, we hypothesized that a similar strategy could be utilized to access 
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A. Application of enantioenriched α-quaternary valerolactam derivatives
B. Application of enantioenriched α-quaternary DHPI frameworks
C. Application of enantioenriched α-quaternary Mannich products
R = CH2CHOBn or CH2CH2CN
X = H or Br
295294
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1). Numerous bis(monoterpenoid) indole alkaloids including leucophyllidine (230) contain all-
carbon quaternary stereogenic center at the three position of a piperidine ring in both monomeric 
subunits (blue, Figure 2.2), and the eburnan monomer is conserved in several natural products 
such as strempeliopidine (298) and norpleiomutine (11). Furthermore, many alkaloids are joined 
at an α-amino stereogenic center (green, Figure 2.2). The conserved structural analogy between 
these fragments suggests that our technology, in combination with a generalized cross-coupling 
method, could provide a foundation for a general strategy to access bis(monoterpenoid) indole 
alkaloids. 
Figure 2.2. Conserved structural elements observed in bis(monoterpenoid) indole alkaloids. 
 
 Retrosynthetically, we envision constructing leucophyllidine (290) through a “convergent-
divergent” strategy. Leucophyllidine (290) would be forged in a convergent manner through late-
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method to forge the α-amino stereogenic center. The monomeric subunits would be synthesized 
through divergent routes to access both natural product cores from a conserved building block, 
enantioenriched lactam 300. 
Scheme 2.11. The divergent-convergent strategy to access leucophyllidine.  
 
2.2  TOTAL SYNTHESIS OF EBURNAMINE 
2.2.1.  Retrosynthetic Analysis 
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Retrosynthetically, we envisioned that eburnamonine (91) could be accessed through a 
reduction of iminium perchlorate 261 with subsequent lactamization as is observed in the 
Schlessinger route (Scheme 2.12).8f This would be formed via the oxidative cleavage and Bischler–
Napieralski cyclization of indole substituted lactam 301. The indole would be installed through N- 
with a tryptophol-derived electrophile alkylation of building block 300 that, in turn, is accessible 
from δ-valerolactam (276) using our asymmetric allylic alkylation methodology. 
 
2.2.2.  Scalable Synthesis of the Enantioenriched Lactam Building Block 
Though the synthesis of lactam 300 had been previously reported, we elected to develop a 
modified route that would be both shorter and more efficient to perform on large-scale.15,18 Starting 
from δ-valerolactam (276), we first perform benzoyl protection to generate lactam 303. This is 
followed by C-acylation using allyl cyanoformate to produce allyl ester 304, which is then 
alkylated with ethyl iodide to generate racemic β-keto ester 284. Our decarboxylative allylic 
alkylation then generates the enantioenriched α-quaternary lactam 286 before benzoyl 
deprotection accesses key lactam precursor 300 in only five steps. 














THF, –78 → –30 °C
then allyl cyanoformate


























30061–91% yield78–97% ee 286
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While our first generation conditions were effective at generating lactam 300 in high yield 
and ee, there were several aspects of this reaction that were prohibitive to perform on large scale.15 
First, the conditions required 5 mol% loading of Pd(0) precatalyst with a pmdba ligand that would 
frequently co-elute with desired products upon purification. Second, the conditions also required 
12.5 mol % loading of ligand 285, which was accessible through a scalable, yet tedious 7-step 
route.19 Finally, the dilute concentrations of toluene greatly complicated the setup and workup. 
 To solve these problems, we sought to adapt our low-catalyst loading conditions, which 
required a less-expensive and robust Pd(II) source, lower ligand loadings, and higher 
concentrations in MTBE.20 While the yield was slightly lower, the enantioselectivity of this 
transformation was retained in the reported examples. Furthermore, the facile purification allowed 
excess ligand to be recovered and reused.  
Table 2.1. Development of gram-scale decarboxylative allylic alkylation.  
 
 While we were able to replicate the results of our initial publication on 60 mg scale (Table 
2.1, Entry 1), we were disappointed to notice a sharp decrease in yield and enantioselectivity when 
conducted on 9.5 gram scale (Entry 2). Reasoning that the lower concentrations of active catalyst 
may be more air-sensitive, we were pleased to see that switching to a Schlenk flask greatly 
improved the enantioselectivity of the transformation, albeit with only minimal increase in yield 
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(Entry 3). As the remainder of mass balance returned as starting material, we found that adding 
equimolar amounts of Pd and ligand 285 at 2 and 3 days, respectively, allowed us to restart the 
reaction and improve conversion and yield (Entry 4). By increasing the initial Pd and ligand 
loading to 1 mol % and 5 mol %, respectively, we obtained the desired product in 91% yield and 
92 % ee on 15-gram scale (Entry 5). 
 
2.2.3.  Advancement to the Bischler–Napieralski Product 
 With sufficient quantities of lactam 300 in hand, we turned our attention to advancing this 
intermediate to indole 301. We were disappointed to observe that all attempts to N-alkylate lactam 
300 with tryptophol-derived electrophiles failed to deliver the product in our hands; though we 
had successfully alkylated similar nucleophiles, we determined that the β-indolyl electrophiles 
were unstable under the basic conditions required for these reactions. Thus, we first N-alkylated 
indole with known21 dioxolane 305 in excellent yield, which was advanced to indole 306 through 
an optimized Fischer synthesis. 







NaH DMF, 0 °C; then
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Scheme 2.15. Unexpected aza-Prins rearrangement and mechanistic proposal. 
 
We then turned our attention to the key Bischler–Napieralski cyclization. Though we did 
successfully obtain our desired iminium perchlorate 307 as the major product, we were surprised 
to observe variable amounts of a minor side product, which we later determined to be fused [5,6] 
system 308 as a single diastereomer (Scheme 2.15A). Mechanistically, one can envision this 
forming from activated amide 309 through an aza-Prins cyclization of the allyl fragment to 
carbocation 310, which reacts with the phosphonate to form bridged species 311 (Scheme 2.15B). 











































































80% yield ~13% yield
A. Unexpected aza-Prins cyclization.
B. Proposed mechanism for rearragement
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phosphonate affords secondary alcohol 313. Though this was a minor component, it could not be 
purified without careful HPLC separation, complicating analysis of the subsequent reaction. 
 To avoid this issue, we decided to perform oxidative cleavage of the allyl fragment first 
prior to the Bischler–Napieralski rearrangement, assuming that an ester or carboxylate at that 
position would be less nucleophilic or reversibly nucleophilic. Despite Harley-Mason’s precedent 
using Johnson–Lemieux conditions,8a we were disappointed to see that all attempts to perform 
oxidative functionalization in the presence of the indole ring (301 → 313) were unsuccessful 
(Scheme 2.16A). Though we briefly investigated protecting the indole nitrogen, this would add 
numerous steps to what was previously a very efficient sequence. 
Scheme 2.16. Alternate Bischler–Napieralski cyclization.   
 
 To solve this problem, we first performed oxidative cleavage on dioxolane intermediate 
306, affording the carboxylic acid in 75% yield (Scheme 2.16B). Though our previously optimized 
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PhNHNH2•HCl, p-TsOH • H2O
MeOH, reflux, 16 h
53% yield
PhNHNH2
4% H2SO4/MeOH, reflux, 1 h
































A. Unsuccessful oxidative cleavage
B. Successful Oxidative Clevage and Bischler-Napieralski Sequence
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optimization that use of a milder acid (p-TsOH•H2O) and the hydrochloride salt of 
phenylhydrazine afforded our desired product 315 in good yield. Using Schlessinger’s 
conditions,8f the Bischler–Napieralski cyclization and anion exchange proceeded smoothly to 
perchlorate 261. 
 
2.2.4.  Final Steps 
 Although we had completed a formal synthesis of eburnamonine (91) according to 
Schlessinger’s route,8f we were disappointed to observe that the reported diastereoselective 
hydrogenation failed to produce any reduced amine in our hands (Scheme 2.17A). Though this 
was surprising at first, we later learned of other reports which had difficulty reproducing these 
conditions.22 Attempts to reduce the iminium ion with hydride-based reductants (e.g. LiAlH4, 
NaBH4, (n-Bu)3SnH, and Li(O-t-Bu)3AlH) led to lactamization prior to reduction, and afforded 
the trans-fused epi-eburnamonine 251 as the exclusive product (Scheme 2.17B). 













H H1. H2, 10% Pd/C,
    MeOH, 23 °C
2. NaOMe
    MeOH, 23 °C
Reported (Ref XX):    99% yield, 3.0:1 d.r.
Observed:                  No conversion
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Lactamization prior to reduction leads to undesired trans-fusion
ClO4ClO4
ClO4
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Scheme 2.18. The effect of solvent on diastereoselectivity. 
 
Seeking to optimize the hydrogenation, we found a report by Szabo and coworkers23 
describing a solvent effect in the diastereoselective hydrogenation of homologous intermediates 
(Scheme 2.18A). The authors note that while hydrogenation in methanol afforded modest 
diastereoselectivity, performing the reduction in DMF offered a dramatic improvement in yield 
and d.r.; furthermore, while the diastereoselectivity in methanol was highly sensitive to the sterics 
of the non-ethyl chain, comparable degrees of cis-selectivity was observed in DMF regardless of 
the substituent at this position, provided it was larger than ethyl. Applying these conditions in our 
system, we were delighted to find that the hydrogenation proceeded in excellent yield and 
















MeOH:   71% yield, 2.5:1 d.r.
DMF:      88% yield, 11.5:1 d.r.261
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intermediate could then undergo lactamization with basic methanol to afford eburnamonine (91) 
in quantitative yield and reduction with lithium aluminum hydride to form eburnamine (92). 
Gratifyingly, treatment with DBU following the hydrogenation also allowed for 
lactamization in one-pot, synthesizing eburnamonine (91) and epi-eburnamonine 251 in 78% 
combined yield on gram-scale, but a modest 3.4:1 d.r on gram scale. (Table 2.2, entry 1). The 
lower diastereoselectivity and reaction times could be prevented on smaller scale using more dilute 
concentrations in DMF (entry 2), yet further dilutions were found to decrease yields (entry 3), 
potentially due to greater product loss on workup. Nevertheless, this route has allowed us to 
successfully synthesize up to 700 mg of eburnamonine in a single pass, facilitating studies of the 
subsequent late-stage chemistry. 
Table 2.2. Optimization of one-pot hydrogenation/lactamization. 
  
 
2.2.5 Concluding Remarks 
 In summary, we have completed an 11-step synthesis of eburnamine (91) from δ-
valerolactam (6 steps from conserved lactam building block (300)). Key steps in this route include 
a Fischer indole synthesis, Bischler–Napieralski cyclization, and diastereoselective hydrogenation. 
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date, this marks the shortest asymmetric synthesis of eburnamonine (91) or eburnamine (92) and 
the first to utilize asymmetric catalysis.  
 
2.3  TOTAL SYNTHESIS OF EUCOPHYLLINE 
2.3.1.   Retrosynthetic Analysis 
Scheme 2.19. Retrosynthetic analysis of eucophylline coupling partner. 
 
To facilitate our eventual late-stage coupling to access leucophyllidine (203), we elected 
to target brominated coupling partner 318 to provide a functional handle at the eventual site of 
dimerization (Scheme 2.20). Retrosynthetically, we envisioned appending the vinyl fragment 
through an intermolecular alkylation at C(4) from tetracycle 319, and constructing the C–N bond 
through an intramolecular amination at C(2) from quinoline 320, we believed this orthogonal C–
H functionalization strategy would remove a number of inefficient functional group 
interconversion (FGI) steps and allow for a broader range of quinoline synthesis methods to be 
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central heterocyclic ring to aldehyde 321 and o-aminoaldehyde 322. The former would be accessed 
from enantioenriched lactam 300, while the latter would be synthesized from commercially 
available 2-amino-4-methoxybenzoic acid 323.    
 
2.3.2.   Advancement to the Friedländer Quinoline Synthesis Product 
 Starting from lactam 300, reduction with lithium aluminum hydride followed by Boc 
protection affords piperidine 324 in 69% yield over two steps (Scheme 2.20). Our initial attempts 
to functionalize the allyl fragment using hydroboration/oxidation reactions were met with 
surprisingly low yields. However, we found that the anti-Markovnikov selective Wacker oxidation 
developed by the Grubbs24 and Stoltz25 groups could provide aldehyde 321 directly on gram-scale 
with no detectable amount of the ketone isomer.  
Scheme 2.20. Synthesis of Friedländer precursors. 
 
 To access the aryl coupling partner, 2-amino-4-methoxybenzoic acid 323 is advanced to 





1. LiAlH4, Et2O, reflux
2. Boc2O, DMAP
    MeCN, 23 °C
Pd(PhCN)2Cl2 (15 mol %)
CuCl2 • 2H2O (15 mol %)






COOH NBS (1.1 equiv)




69% yield, 2 steps 72% yield
74% yield, 2 steps
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lithium aluminum hydride to benzyl alcohol 327 then oxidized to o-aminoaldehyde 322 under 
conditions described by Stahl.26 
Scheme 2.21. Unsuccessful Friedländer attempts. 
 
After a screen of Lewis acidic and Brønsted basic conditions, we were unable to successful 
synthesize the quinoline 320 from our precursors 321 and 322 (Scheme 2.21).27 Attempts to 
perform this reaction stepwise—first through condensation to form the N-aryl imine 328, then 
subjection to basic conditions to cyclize—revealed that imine condensation with the desired 
aniline derivative was extremely slow. Even under conditions described by the Cid group to 
catalyze aldimine formations28 yielded only trace condensation. 
To circumvent this issue, we implemented conditions described by Verpoort and coworkers 
for the synthesis of 3-monosubstituted quinolines29 starting from amino alcohol 327; 
mechanistically, the benzyl alcohol is hypothesized to participate more readily in imine 
condensations before an in-situ Oppenauer-Woodward oxidation30 (KOt-Bu and benzophenone) 
generates the carbonyl prior to cyclization. While Verpoort’s standard conditions were 
unsuccessful (entry 1), we found that the desired quinoline 320 could be obtained in good yield by 
increasing the proportion of base and oxidant (entry 2-4), with 2.5 equivalents of KOt-Bu and 5.0 
pyrrolidine (10 mol%)
4 Å MS
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equivalents of benzophenone proving optimal. Changing the oxidant to fluorenone (entry 5) or 
DDQ (entry 6) diminished the yield, and no product was observed when the temperature was 
lowered to 60 °C (Entry 7). When scaled to 0.5 mmol of aldehyde however, we observed a decrease 
to 45% yield (entry 8). By adding the base as a solution in 1,4-dioxane over 30 minutes (entry 9), 
we improved the yield to 74% on gram-scale. 
Table 2.3. Optimization of the Friedländer quinoline synthesis. 
 
 
2.3.3.   Intramolecular C–H Amination: Discovery of a Sn(II)-mediated method 
 With quinoline 320 in hand, we turned our attention to the first of two C–H 
functionalizations. Though 2-fluoroquinoline 329a and 4-fluoroquinoline 329b could be accessed 
using the Ag(II) protocol described by Hartwig,31 the yield was modest and subsequent 
deprotection led only to decomposition (Scheme 2.22A). While Boc-deprotection afforded free 
amine 330 in excellent yield, the subsequent treatment with AgF2 led to a complex mixture of 































2.5 equiv Benzophenone (5.0 equiv) 2 80
3.0 equiv Benzophenone (10.0 equiv) 2 80
2.5 equiv Fluorenone 5.0 equiv) 2 80











2.5 equiv Benzophenone (5.0 equiv) 1 80 45%











1.0 mmol scale. Slow addition of KOt-Bu
2.5 equiv Benzophenone (5.0 equiv) 1 80 74%9 3.6 mmol scale. Slow addition of KOt-Bu
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Scheme 2.22. Initial C(2)–H functionalization studies. 
 
We then turned our attention to quinoline N-oxide functionalization. Quinoline 320 was 
successfully oxidized under Sharpless’ conditions to access N-oxide 332,32  but advancement to 
the corresponding 2-chloroquinoline 333 was not successful (Scheme 2.22B). Motivated by recent 
TFA, CH2Cl2
0 → 23 °C
91% yield
Various fluorinated products or decomposition
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advances in direct N-oxide functionalization, we performed the Re-catalyzed N-oxidation followed 
by Boc-deprotection in one-pot (Scheme 2.22C). Intermediate 334 then was subjected to the 
PyBroP-mediated amination33 developed by Londregan and coworkers to afford tetracycle 319, 
albeit in 10% yield over 2 steps. 
 Due to the polarity and instability of Boc-deprotected N-oxide 334, we elected to modify 
our order of steps to avoid the direct isolation of this product. First, we subjected Boc-protected 
N-oxide 319 to Sn(OTf)2 deprotection as described by Reddy34, then added PyBroP and Hünig’s 
base in the same pot to promote the subsequent cyclization. Though no product was observed at 
room temperature (Table 2.4, entry 1), increasing to 40 °C generated tetracycle 319 in 41% yield 
(Entry 2), though further heating caused yield to diminish (Entry 3); switching to other solvents 
like THF led to a complete shutdown of cyclization (Entry 4). Triethylamine boosted the yield 
slightly (entry 5), while utilizing a 1M NaOH workup led to a significant improvement (entry 6).  





















1.3 equiv i-Pr2NEt (3.8 equiv)
PyBroP
50
1.3 equiv i-Pr2NEt (3.8 equiv) 50
1.3 equiv i-Pr2NEt (3.8 equiv) 40
1.3 equiv i-Pr2NEt (3.8 equiv) 23















1.3 equiv Et3N (3.8 equiv) 40





a) 0.1 mmol scale reactions unless noted. b) NMR yields using 1,3,5-trimethoxybenzene as internal 
standard unless noted. c) 1N NaOH workup. d) 2.5 equiv Sn(OTf)2. e) isolated yield, f) Combined 
yield of twelve 0.1mmol reactions run in parallel.
8c,d,e None Et3N (5.0 equiv) 40 81%CH2Cl2
9c,d,e,f None Et3N (5.0 equiv) 40 79%CH2Cl2
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While performing order-of-addition studies, we observed trace product formation by 
LCMS when base was added before PyBroP. Upon heating this reaction, we were surprised to 
observe identical yields in the absence of PyBroP altogether (Entry 7), suggesting Sn(II) was the 
N-oxide activating agent. Finally, we found rigorous exclusion of water and an increase of reagent 
equivalents could generate the desired tetracycle in 81% yield (Entry 8). Though scalability issues 
were experienced due to the heterogeneous nature of the reactions, we were able to obtain 750 mg 
of tetracycle 319 by conducting a series of reactions in parallel (Entry 9). 
 
2.3.4.   Intermolecular C–H Alkylation: Investigation of a Minisci Alkylation 
Scheme 2.23. Reported Minisci conditions and application to the eucophylline tetracycle. 
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 To accomplish our second C–H functionalization, we elected to investigate the Minsici 
reaction35 due to its established utility in C(4) quinoline functionalization of densely functionalized 
natural products such as camptothecin36 ((335) → 336, Scheme 2.23A). While “classical” 
conditions lead to numerous oxidized side products, we were delighted to find that the mild 
photoredox-mediated conditions described by DiRocco and Krska37 (Scheme 2.23B) were much 
more tolerant of our system. While we successfully obtained alcohol 340 on our first attempt, we 
were disappointed to observe that the reaction was poorly reproducible and frequently generated 
methylated product 341 as the exclusive product (2.23B). Attributing this issue to inconsistencies 
in reaction setup, we found that switching our reaction setup from a Dewar with suspended LED 
to a Hepatochem photobox with an internal fan consistently provided alcohol 340 as the major 
product in good yield (Figure 1.2). 
While a consistent reaction was obtained, we noted that the reaction remained unusually 
fast (40 minutes) in comparison to the reported examples (~16 hours), and we began to suspect 
that a background reaction may be occurring. Upon conducting control experiments (Table 2.5), 
we were surprised to discover that the reaction proceeded in the absence of iridium complex (339), 
suggesting that our substrate itself is serving as its own photocatalyst for this reaction. Electron-
deficient quinolines have been reported to promote hydroxyalkylations under photochemical 
conditions,38 and DiRocco and Krska note that this “autophotocatalysis” occurs with several 
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Figure 2.3. First and second generation Minisci reaction setup. 
   
Table 2.5. Control experiments for Minisci alkylation. 
 
We acquired UV/vis data for tetracycle 319 (Figure 2.4) to better understand its 
photophysical properties. While the maximum wavelength of absorption (λabs) for tetracycle 319 
lies soundly in the ultraviolet region, the addition of 10 equivalents of TFA to mimic reaction 
conditions caused a significant red shift (λabs = 346 → 378 nm); when the protonated tetracycle 
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was irradiated at 380 nm, it recorded a maximum wavelength of emission (λem) at 476 nm. These 
values are remarkably similar to iridium complex (339) (λabs = 380 nm and 470 nm in MeCN),39 
lending support to this “autophotocatalytic” hypothesis. Further investigations of this 
transformation are ongoing.  
Figure 2.4. Absorption and emission spectra for Minsici precursor. 
 
   
2.3.5 Final Steps 
 Following our Minisci investigations, we found that the hydroxymethylation could be 
easily scaled to access alcohol 340. This intermediate is subsequently oxidized to aldehyde 342 
with DMP. Though methylenation under Wittig conditions were low yielding, we found that the 
modified Julia-Kocienski methylenation with sulfone 343 described by Aïssa40 could afford the 
targeted coupling partner, alkene 318, in 87% yield. To complete the formal synthesis, we 
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Scheme 2.24. Formal synthesis of eucophylline. 
 
 
2.3.6 Concluding Remarks 
 In summary, we have completed a 16-step formal synthesis of eucophylline (231) from δ-
valerolactam (11 steps from conserved lactam building block 300). Key steps in this route include 
a Friedländer quinoline synthesis, an unprecedented Sn(II)-mediated C–H amination, and a 
photoredox-mediated Minisci hydroxymethylation promoted by a photoactive substrate. This route 
provides us with ample access to key coupling partner 318 to investigate our key cross-coupling 
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2.5   EXPERIMENTAL SECTION 
2.5.1   Materials and Methods 
Unless otherwise stated, reactions were performed in flame-dried glassware under an 
argon or nitrogen atmosphere using dry, deoxygenated solvents. Solvents were dried by passage 
through an activated alumina column under argon.1 Reaction progress was monitored by thin-
layer chromatography (TLC) or Agilent 1290 UHPLC-LCMS. TLC was performed using E. 
Merck silica gel 60 F254 precoated glass plates (0.25 mm) and visualized by UV fluorescence 
quenching, p-anisaldehyde, CAM, or KMnO4 staining. Silicycle SiliaFlash® P60 Academic 
Silica gel (particle size 40–63 nm) was used for flash chromatography. 1H and 13C NMR spectra 
were recorded on a Varian Inova 500 (500  MHz and 126 MHz, respectively) and a Bruker AV 
III HD spectrometer equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 MHz 
and 101 MHz, respectively) and are reported in terms of chemical shift relative to CHCl3 (δ 7.26 
and δ 77.16, respectively), CD2Cl2 (δ 5.32 and δ 53.84, respectively), (CD3)2SO (δ 2.50 and δ 
39.52, respectively) and CD3CN (δ 1.94 and 118.26). Data for 1H NMR are reported as follows: 
chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are 
reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = septuplet, 
m = multiplet, br s = broad singlet, br d = broad doublet, br t = broad triplet, app = apparent. 
Some reported spectra in CDCl3 include minor solvent impurities of water (δ 1.56ppm), ethyl 
acetate (δ 4.12, 2.05, 1.26 ppm), dichloromethane (δ 5.30 ppm), acetone (δ 2.17 ppm), grease (δ 
1.26, 0.86 ppm), and/or silicon grease (δ 0.07 ppm), which do not impact product assignments.2 
Data for 13C NMR are reported in terms of chemical shifts (δ ppm). IR spectra were obtained by 
use of a Perkin Elmer Spectrum BXII spectrometer using thin films deposited on NaCl plates and 
reported in frequency of absorption (cm-1). Optical rotations were measured with a Jasco P-2000 
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polarimeter operating on the sodium D-line (589 nm), using a 100 mm path-length cell, and are 
reported as [α] T (concentration in g/100 mL, solvent). Analytical SFC was performed with a 
Mettler SFC supercritical CO2 analytical chromatography system utilizing Chiralpak OD-J 
column (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd. High resolution mass 
spectra (HRMS) were obtained from the Caltech Mass Spectral Facility using a JEOL JMS-600H 
High Resolution Mass Spectrometer in fast atom bombardment (FAB+) or electron ionization 
(EI+) mode, or Agilent 6200 Series TOF with an Agilent G1978A Multimode source in mixed 
ionization mode (MM: ESI/APCI).  
Reagents were purchased from Sigma-Aldrich, Acros Organics, Strem, or Alfa Aesar and 
used as received unless otherwise stated. n-butyllithium was titrated prior to use according to the 
method of Gilman.3 Di-iso-propylamine was distilled from calcium hydride immediately prior to 
use. NBS was purchased from Sigma Aldrich, recrystallized from H2O, and stored in a –25 °C 
freezer. PhNHNH2•HCl was purchased from Sigma Aldrich, recrystallized from H2O and EtOH, 
and stored in a –25 °C freezer. MeOH was distilled from magnesium methoxide immediately 
prior to use. Allyl cyanoformate4, (R)-(CF3)3-t-Bu-PHOX 2855, dioxolane6 305 and tetrazole7 
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2.4.2   Experimental Procedures 
 
N-Benzoyl δ-valerolactam 303: Following a modified procedure described by Gigant,8 a flame-
dried 1L flask with stir bar was charged with δ-valerolactam 276 (9.9 g, 100.0 mmol, 1.0 equiv) 
and THF (500 mL, 0.2 M), then cooled to –78 °C. n-butyllithium (2.30M in hexanes, 43.0 mL, 
99.0 mmol, 0.99 equiv) was added slowly and the solution was stirred at –78 °C for 30 minutes. 
Benzoyl chloride (12.8 mL, 110.0 mmol, 1.1 equiv) was added dropwise, then stirred at –78 °C 
for 30 minutes, removed from the cooling bath, and warmed to 23 °C over 30 minutes. The 
reaction was quenched with saturated ammonium chloride, transferred to a separatory funnel, 
and extracted with ether three times. The combined organic extracts were washed with brine, 
dried with magnesium sulfate, and concentrated in vacuo to produce an amorphous solid. This 
solid was recrystallized from toluene to afford N-benzoyl δ-valerolactam 303 (18.41 grams, 
94%) as a white crystalline solid. 1H NMR (400 MHz, CDCl3) δ 7.61 – 7.52 (m, 2H), 7.52 – 7.42 
(m, 1H), 7.42 – 7.33 (m, 2H), 3.80 (ddd, J = 6.3, 5.0, 1.0 Hz, 2H), 2.63 – 2.49 (m, 2H), 2.06 – 
1.88 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 174.8, 173.6, 136.2, 131.6, 128.26, 128.0, 77.5, 
77.4, 77.2, 76.8, 46.3, 34.8, 23.0, 21.6; IR (Neat Film, NaCl) 2961, 1673, 1388, 1286, 1265, 
1159, 1146, 734 cm-1; HRMS (FAB+) m/z calculated for C12H13NO2 [M+H+]: 204.1025, found 






THF, –78 °C, 30 min
then BzCl
–78 → 23 °C, 1h
276 94% yield 303




Allyl ester 304: Following the procedure described by Behenna,9 a flame-dried 1L three-neck 
round bottom flask equipped with low temperature thermometer and stir bar was charged with 
THF (460 mL) and freshly distilled di-iso-propylamine (12.93 mL, 91.62 mmol, 1.2 equiv). The 
flask was cooled to –78 °C and a solution of n-butyllithium (2.44M in hexanes, 34.4 mL, 84.0 
mmol, 1.1 equiv) was added slowly. The flask was warmed to 0 °C and stirred for 30 minutes, at 
which point the solution turns pale yellow, then re-cooled to –78 °C. 
 A separate 250-mL round-bottom flask was charged with benzoyl lactam 303 (15.50 g, 
76.4 mmol, 1.0 equiv) and THF (95 mL). The solution was slowly transferred to the reaction 
flask via cannula (NOTE: the internal temperature of the reaction should not exceed –70 °C). 
Upon complete addition, the reaction mixture was stirred for 2 hours at –78 °C, then 1 hour at –
30 °C. The flask was re-cooled to –78 °C before neat allyl cyanoformate was added dropwise 
(9.33g, 84.0 mmol, 1.1 equiv). The reaction mixture was stirred at –78 °C for 2 hours, then 
slowly warmed up to 23 °C over 14 hours. 
 The reaction was quenched with saturated ammonium chloride, transferred to a 
separatory funnel, and extracted with diethyl ether (3X). The combined organic extracts were 
washed with brine, dried with sodium suflate, and concentrated in vacuo. Flash column 
chromatography (15→ 20 → 25 → 30% ethyl acetate/hexanes) afforded allyl ester 304 (15.34 g, 
70% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.66 (m, 2H), 7.51 – 7.45 (m, 





–78 → –30 °C, 3h
then allyl cyanoformate
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5.29 (dq, J = 10.4, 1.2 Hz, 1H), 4.69 (dq, J = 5.9, 1.4 Hz, 2H), 3.88 – 3.76 (m, 2H), 3.59 (t, J = 
6.3 Hz, 1H), 2.39 – 2.30 (m, 1H), 2.22 – 2.13 (m, 1H), 2.12 – 2.02 (m, 1H), 2.01 – 1.90 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 174.6, 169.6, 169.3, 135.4, 131.9, 131.4, 128.3, 128.2, 119.3, 
66.4, 51.1, 46.3, 25.5, 20.7. IR (Neat Film, NaCl) 2960, 1737, 1674, 1448, 1389, 1285, 1259, 
1146, 986, 946, 824, 799, 732, 704, 670 cm-1; HRMS (FAB+) m/z calculated for C16H18NO4 
[M+H+]: 288.1236, found 288.1265. Data were consistent with literature values.9  
 
 
β-amidoester 284: To a flame-dried 1L round-bottom flask with stir bar was added allyl ester 
304 (15.33 g, 53.4 mmol, 1.0 equiv) and dichloromethane (390 mL). Cesium carbonate (76.7 g, 
235.5 mmol, 4.4 equiv) was added, and the heterogeneous mixture was stirred for 10 minutes. 
Ethyl iodide (18.8 mL, 235.5 mmol, 4.4 equiv) was then added dropwise, and the reaction 
mixture was stirred for 24 hours. The reaction was quenched with ammonium chloride and 
extracted with dichloromethane (5X). The combined organic extracts were washed with brine, 
dried with sodium sulfate, and concentrated in vacuo. Flash column chromatography 
(15%→20%→25%→30% diethyl ether/hexanes) afforded the desired β-ketoester 304 (14.95g, 
89% yield) as a light yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.68 (m, 2H), 7.50 – 7.44 
(m, 1H), 7.40 – 7.34 (m, 2H), 5.98 (ddt, J = 17.2, 10.4, 5.9 Hz, 1H), 5.40 (dq, J = 17.2, 1.5 Hz, 
1H), 5.33 (dq, J = 10.4, 1.2 Hz, 1H), 4.73 (dt, J = 5.9, 1.3 Hz, 2H), 3.86 – 3.71 (m, 2H), 2.47 – 
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175.1, 172.1, 171.9, 136.0, 131.7, 131.5, 128.1 (2C), 119.7, 66.5, 57.0, 46.6, 29.9, 28.7, 20.4, 
9.2. IR (Neat Film, NaCl) 2963, 1731, 1680, 1448, 1386, 1264, 1187, 1136, 1025, 797, 723, 694, 
660 cm-1 HRMS (FAB+) m/z calculated for C18H22NO4 [M+H+]: 316.1549, found 316.1547.  
Data were consistent with literature values.9 
 
 
Enantioenriched N-benzoyl lactam 286: A 500-mL Schlenk flask with stir bar was flame-dried 
and brought into a nitrogen-filled glove box. The flask was charged with palladium (II) acetate 
(103.5 mg, 0.461 mmol, 0.010 equiv), (R)-CF3-t-Bu-PHOX 285 (1.37g, 2.31 mmol, 0.05 equiv), 
and MTBE (190 mL) before it was sealed, removed from the glovebox, and heated to 40 °C for 
30 minutes.  
 In a separate flask, racemic β-amidoester 284 (14.53 g, 46.1 mmol, 1.00 equiv) was 
dissolved in MTBE, then transferred to the Schlenk flask via cannula. The Schlenk flask was 
sealed once again and heated to 60 °C for 48 hours; to remove the overpressure of carbon 
dioxide generated during the reaction, the flask was connected to a nitrogen-containing Schlenk 
line and vented for about 3 seconds every hour for the first eight hours, then every 12 hours 
thereafter.  
 After complete consumption of the starting material, as determined by TLC, the flask was 
cooled to room temperature, transferred to a round-bottom flask, and concentrated in vacuo. 
Flash column chromatography (15%→20%→25% diethyl ether/hexanes) then afforded 
enantioenriched lactam 286 (11.40 g, 91% yield, 92% ee) as a colorless oil. 1H NMR (400 MHz, 
91% yield, 92% ee
Pd(OAc)2 (1 mol %)
285 (5 mol %)
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CDCl3) δ 7.54 – 7.49 (m, 2H), 7.49 – 7.43 (m, 1H), 7.41 – 7.35 (m, 2H), 5.73 (dddd, J = 16.5, 
10.6, 7.6, 7.0 Hz, 1H), 5.17 – 5.04 (m, 2H), 3.85 – 3.71 (m, 2H), 2.51 (ddt, J = 13.8, 7.0, 1.3 Hz, 
1H), 2.27 (ddt, J = 13.7, 7.6, 1.1 Hz, 1H), 2.08 – 1.92 (m, 2H), 1.92 – 1.78 (m, 3H), 1.78 – 1.63 
(m, 1H), 0.91 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 178.2, 175.8, 136.9, 133.8, 
131.4, 128.3, 127.6, 118.9, 47.6, 47.1, 41.5, 30.5, 30.4, 19.7, 8.4. IR (Neat Film, NaCl) 3075, 
2940, 2881, 1679, 1448, 1384, 1281, 1148, 916, 726, 658 cm-1; 1 HRMS (FAB+) m/z calculated 
for C17H22NO2 [M+H+]: 272.1651, found 272.1675; [α]D22.2 35.3 (c 0.24, CHCl3, 92% ee); SFC 
conditions: 3% MeOH, 3.5 mL/min, Chiralpak OJ-H column, λ = 210 nm, tR (min): major = 
4.07, minor = 6.42. Data were consistent with literature values.9 
Figure 2.5. Reaction setup for large-scale decarboxylative allylic alkylation. 
 




Lactam 300: Following a modified procedure by Behenna and coworkers,8 a 2L round-bottom 
flask with stir bar was charged with N-benzoyl lactam 286 (5.44 g, 20.1 mmol, 1.0 equiv) in 
methanol (500 mL). A solution of lithium hydroxide monohydrate (1.25 g, 30.1 mmol, 1.5 equiv) 
water (200 mL) was added, and the reaction mixture was stirred at 23 °C, for 20 hours.  
 The reaction was then partially concentrated in vacuo to remove methanol, then 
transferred to separatory funnel. The reaction mixture was diluted with ethyl acetate and 
saturated sodium bicarbonate, then extracted with ethyl acetate (4X). The combined organic 
extracts were washed with brine, dried with sodium sulfate, and concentrated in vacuo to afford 
neat lactam 300 (3.26 g, 98% yield) as a light yellow oil without any further purification. 1H 
NMR (400 MHz, CDCl3) δ 6.03 (br s, 1H), 5.88 – 5.68 (m, 1H), 5.12 – 5.03 (m, 2H), 3.26 (td, J 
= 5.9, 2.5 Hz, 2H), 2.49 (ddt, J = 13.6, 6.7, 1.3 Hz, 1H), 2.27 – 2.12 (m, 1H), 1.87 – 1.65 (m, 
5H), 1.50 (dq, J = 13.7, 7.4 Hz, 1H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) 
176.8, 134,8, 110.0, 45.0, 42.9, 42,9, 31.2, 28.7, 31.2, 28.7, 19.9, 8.8. IR (Neat Film, NaCl) 
2972, 1718, 1286, 1147, 700, 676, 649 cm-1; [α]D25 5.3 (c 0.09, CHCl3, 92% ee). Data were 



















Acetal 306: To a flame-dried 100 mL round bottom flask with stir bar was added lactam 300 
(4.00 g, 24.0 mmol, 1.0 equiv) and DMF (24.0 mL). The flask was cooled to 0 °C before sodium 
hydride (1.41 g, 60% dispersion in mineral oil, 35.3 mmol, 1.47 equiv) was added portionwise 
(CAUTION: Evolution of hydrogen gas). The reaction mixture was stirred at 0 °C for 1 hr before 
dioxolane 305 (6.88 g, 35.28 mmol, 1.47 equiv) was added dropwise. The flask was slowly 
warmed to 23 °C over 36 hours. 
When the starting material was consumed, as determined by TLC, the flask was re-cooled 
to 0 °C, then quenched with water. The mixture was transferred to a separatory funnel and 
extracted with ethyl acetate (5X). The organic extracts were combined and washed with 10% 
lithium chloride solution (2X), brine (1X), and dried with sodium suflate, then concentrated in 
vacuo. Flash column chromotography (30% → 40% → 50% ethyl acetate/hexanes) afforded 
desired acetal 306 (6.28g, 92% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3)) δ 5.82 – 
5.67 (m, 1H), 5.09 – 5.00 (m, 2H), 4.92 – 4.82 (m, 1H), 4.00 – 3.91 (m, 2H), 3.90 – 3.79 (m, 
2H), 3.46 – 3.30 (m, 2H), 3.24 (td, J = 5.9, 1.8 Hz, 2H), 2.48 (ddt, J = 13.5, 6.6, 1.4 Hz, 1H), 
2.14 (ddt, J = 13.5, 8.1, 0.9 Hz, 1H), 1.84 – 1.72 (m, 3H), 1.71 – 1.59 (m, 6H), 1.45 (dq, J = 
13.5, 7.4 Hz, 1H), 0.84 (t, J = 7.5 Hz, 3H).; 13C NMR (101 MHz, CDCl3) δ 174.2, 135.2, 117.7, 
104.3, 65.0, 48.5, 47.5, 45.2, 43.5, 31.7, 31.3, 29.0, 21.8, 20.1, 8.9. IR (Neat Film, NaCl) 3072, 
2941, 2876, 1632, 1490, 1490, 1461, 1429, 1359, 1284, 1239, 11197, 1138, 1041, 944, 912; 
HRMS (FAB+) m/z calculated for C16H28NO3 [M+H+] 282.2069, found 282.2069. [α]D22.4 8.9° 
(c 0.49, CHCl3., 92% ee). 
92% yield
NaH, DMF, 0 °C













Indole 301: To a 50-mL flask with stir bar was added acetal 306 (144 mg, 0.50 mmol, 1.0 equiv) 
in 4% sulfuric acid in ethanol (10.0 mL) and phenylhydrazine (0.10 mL, 1.0 mmol, 2.0 equiv). 
The flask was equipped with a reflux condenser and heated to 80 °C for 45 minutes.  
 After completion, as determined by LCMS, the reaction was quenched with bicarbonate 
and transferred to a separatory funnel, and extracted with ethyl acetate (3X). The combined 
organic extracts were washed with brine, dried with sodium sulfate, and concentrated in vacuo. 
Flash column chromatography (30 → 40 → 50% ethyl acetate/hexanes) afforded indole 301 
(97.0 mg, 63% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.15 (s, 1H), 7.69 (ddt, J = 
7.8, 1.4, 0.8 Hz, 1H), 7.36 (dt, J = 8.1, 1.0 Hz, 1H), 7.19 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 7.12 
(ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 7.08 – 7.03 (m, 1H), 5.74 (dddd, J = 16.8, 10.2, 8.1, 6.6 Hz, 1H), 
5.10 – 4.99 (m, 2H), 3.72 – 3.61 (m, 2H), 3.28 – 3.15 (m, 2H), 3.02 (ddd, J = 8.3, 6.1, 0.9 Hz, 
2H), 2.51 (ddt, J = 13.6, 6.6, 1.4 Hz, 1H), 2.18 (ddt, J = 13.4, 8.1, 1.0 Hz, 1H), 1.86 – 1.61 (m, 
5H), 1.48 (dq, J = 13.6, 7.4 Hz, 1H), 0.86 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
174.1, 136.3, 135.1, 127.5, 122.0, 121.9, 119.3, 118.9, 117.6, 113.3, 111.1, 49.0, 48.7, 45.0, 43.4, 
31.5, 28.8, 23.2, 20.0, 8.8. IR (Neat Film, NaCl) 3261, 3072, 2937, 2876, 1611, 1490, 1458, 
1340, 1292, 1234, 1119, 1168, 1103, 999, 914, 876, 741, 687; HRMS (FAB+) m/z calculated for 

















Iminiums 307 and 308: To an oven-dried 20-mL scintillation vial was added indole 301 (60.0 
mg, 0.193 mmol, 1.0 equiv) in acetonitrile (0.4 mL). Phosphorous (V) oxychloride (0.54 mL, 5.8 
mmol, 30.0 equiv) was added dropwise and the reaction was sealed with a Teflon-lined cap and 
stirred for 2.5 hours. When starting material was consumed, as determined by LCMS, the 
reaction mixture was cooled to room temperature and concentrated in vacuo. Residual 
phosphoryl chloride was removed azeotropically with acetonitrile (3 x 1.0 mL) to yield a brown, 
amorphous solid. 
The crude mixture was redissolved in dichloromethane (1.0 mL), transferred to a one-
dram vial, and stirred at 23 °C. 1M aq. lithium perchlorate (0.4 mL) was added and the 
heterogeneous mixture was rapidly stirred for 30 minutes. The mixture was transferred to a 
separatory funnel and extracted with dichloromethane (3X). The combined organic extracts were 
washed with 1M lithium perchlorate (2 X), dried with sodium sulfate, and concentrated in vacuo 
to afford crude iminium perchlorate as a light yellow oil. Preparative HPLC afforded both 
iminium perchlorate 307 (62.3 mg, 0.152 mmol, 79%) and rearranged product 308 (9.0 mg, 
0.021 mmol, 11% with grease impurity), both as light yellow solids.  
Iminium Perchlorate 307: 1H NMR (400 MHz, CDCl3) δ 13.03 (s, 1H), 7.86 (dt, J = 8.6, 1.0 Hz, 
1H), 7.46 (d, J = 8.2 Hz, 1H), 7.37 (ddd, J = 8.3, 6.9, 1.1 Hz, 1H), 7.13 (ddd, J = 8.1, 7.0, 0.9 Hz, 
1H), 5.50 – 5.32 (m, 1H), 4.92 (dd, J = 10.1, 1.8 Hz, 1H), 4.80 (dd, J = 17.0, 1.7 Hz, 1H), 3.97 (t, 
J = 8.2 Hz, 2H), 3.88 (s, 2H), 3.02 (t, J = 8.2 Hz, 2H), 2.84 (dd, J = 14.2, 7.8 Hz, 1H), 2.60 (dd, J 
79% yield
POCl3,
MeCN, 100 °C 2.5 h
then 1M LiClO4
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= 14.2, 7.1 Hz, 1H), 2.17 (dq, J = 14.6, 7.4 Hz, 1H), 2.03 (dt, J = 14.6, 7.4 Hz, 1H), 1.92 (d, J = 
6.1 Hz, 2H), 1.82 – 1.73 (m, 2H), 0.69 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) 13C 
NMR (101 MHz, CDCl3) δ 172.9, 142.3, 131.6, 129.1, 125.2, 124.4, 122.8, 121.7, 120.6, 120.4, 
115.1, 54.8, 53.7, 44.7, 41.0, 29.8, 26.3, 19.3, 17.7, 8.0.; IR (Neat Film, NaCl) 2924, 1682, 1593, 
1521, 1434, 1337, 1198, 1168, 926, 798, 753, 716, 620 cm-1; + HRMS (FAB+) m/z calculated 
for C20H25N2 [M] XXX, found YYY.  
Alcohol 308: 1H NMR (600 MHz, CD2Cl2) δ 10.64 (s, 1H), 7.48 (t, J = 8.2 Hz, 2H), 7.20 – 7.11 
(m, 2H), 7.07 (td, J = 7.5, 6.4 Hz, 1H), 4.76 (dt, J = 11.2, 5.6 Hz, 1H), 4.04 (dt, J = 13.2, 6.5 Hz, 
1H), 3.78 (dt, J = 12.8, 6.2 Hz, 1H), 3.57 – 3.51 (m, 2H), 3.19 (t, J = 6.4 Hz, 2H), 2.34 (dd, J = 
13.1, 4.8 Hz, 1H), 2.04 (dt, J = 13.7, 4.1 Hz, 1H), 1.93 (d, J = 14.5 Hz, 1H), 1.86 – 1.76 (m, 0H), 
1.46 (q, J = 11.7, 11.2 Hz, 2H), 1.32 – 1.27 (m, 1H), 1.20 (q, J = 7.4 Hz, 2H), 1.16 (d, J = 6.1 
Hz, 3H), 0.81 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, CD3CN) δ 172.7, 141.9, 132.9, 129.7, 
126.5, 126.3, 124.1, 122.6, 122.3, 120.4, 114.3, 55.7, 54.8, 45.3, 42.2, 31.0, 27.3, 19.5, 18.3, 8.4. 
IR (Neat Film, NaCl) 3223, 2924, 2853, 1775, 1690, 1459, 1421, 1199, 1131, 1036, 916, 798, 
746, 718 cm-1; HRMS (FAB+) m/z calculated for C20H27N2O [M +] XXX, found YYY. 
 
 
Carboxylic acid 314: To a 500-mL round-bottom flask with stir bar was added acetal 306 (2.00 
g, 6.97 mmol, 1.0 equiv) in acetonitrile (105 mL). Water (35 mL) was added and the flask cooled 
to 0 °C. Ruthenium (III) trichloride hydrate (43.4 mg, 0.21 mmol, 0.03 equiv) was added, 
75% yield
RuCl3•xH2O (3 mol %)
NaIO4
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followed by sodium periodate (7.42 g, 34.8 mmol, 5.0 equiv) in a single portion. The 
heterogeneous mixture was rapidly stirred for 5 hours and monitored closely by LCMS.  
Upon completion, the reaction mixture was quickly filtered through a plug of Celite 
(washing with acetonitrile) and concentrated in vacuo to remove organic solvents. The aqueous 
mixture was extracted with dichloromethane (5X), dried with sodium sulfate, and concentrated in 
vacuo. Flash column chromatography (1 → 2 → 3 → 4 → 5% methanol/dichloromethane) 
afforded acid 314 (1.58 g, 75% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.87 (t, J 
= 4.0 Hz, 1H), 4.04 – 3.93 (m, 2H), 3.93 – 3.77 (m, 2H), 3.55 – 3.46 (m, 1H), 3.32 (tt, J = 13.3, 
6.1 Hz, 3H), 2.66 (d, J = 15.7 Hz, 1H), 2.48 (d, J = 15.7 Hz, 1H), 1.95 – 1.63 (m, 7H), 1.63 – 
1.52 (m, 1H), 1.33 – 1.21 (m, 1H), 0.90 (dt, J = 17.8, 7.4 Hz, 4H); 13C NMR (101 MHz, CDCl3) 
δ 177.4, 172.3, 103.9, 65.0, 48.2, 48.0, 44.5, 42.8, 30.8, 30.5, 28.0, 21.1, 18.7, 7.8; IR (Neat 
Film, NaCl) 2948, 2880, 1729, 1630, 1598, 1579, 1498, 1456, 1438, 1359, 1290, 1186, 1142, 
1030, 946; HRMS (FAB+) m/z calculated for C15H26NO5 [M + H+] 300.1811, found 300.1810; 
[α]D22.2 –17.4° (c 0.31, CHCl3, 92% ee). 
 
NOTE: We have observed that the times of this reaction were highly variable (between 1 and 6 
hours) depending on the scale and bottle of RuCl3•xH2O used. It is important to quench the 








Indole 315: To a flame-dried 500-mL round-bottom flask with stir bar was added carboxylic 
acid 314 (3.02 g, 10.1 mmol, 1.0 equiv) and methanol (210 mL). Phenylhydrazine hydrochloride 
salt (3.10 g, 21.4 mmol, 2.0 equiv) and p-toluenesulfonic acid monohydrate (4.78 g, 32.1 mmol, 
3.0 equiv) were added sequentially. The flask was equipped with a reflux condenser and heated 
to reflux for 12 hours. After this, additional phenylhydrazine hydrochloride salt was added 
(1.00g, 6.89 mmol, 0.68 equiv) and the reaction was stirred at reflux for an additional four hours. 
Upon completion, as determined by LCMS analysis, the reaction was cooled to room 
temperature, quenched with 1M aqueous hydrochloric acid, and transferred to a separatory 
funnel. The mixture was extracted with dichloromethane (5X), before the combined organic 
extracts were washed with brine, dried with sodium sulfate, and concentrated in vacuo onto silica 
gel. Flash column chromatography (50% ethyl acetate/hexanes) afforded indole 315 (1.85 g, 
53% yield) as a viscous orange oil. 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.69 (ddt, J = 
7.8, 1.5, 0.7 Hz, 1H), 7.36 (dt, J = 8.1, 1.0 Hz, 1H), 7.19 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.15 – 
7.10 (m, 1H), 7.09 – 7.06 (m, 1H), 3.68 – 3.62 (m, 5H), 3.44 – 3.36 (m, 1H), 3.20 (dtd, J = 10.9, 
4.7, 2.2 Hz, 1H), 3.07 – 3.00 (m, 2H), 2.96 (d, J = 16.1 Hz, 1H), 2.35 (d, J = 16.0 Hz, 1H), 1.99 
– 1.89 (m, 1H), 1.83 – 1.60 (m, 5H), 0.88 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
173.8, 172.6, 136.2, 127.5, 122.0, 121.9, 119.3, 118.9, 113.6, 111.1, 51.4, 49.0, 48.8, 43.4, 42.0, 
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1434, 1358, 1290, 1198, 1172, 1011, 744, cm-1; HRMS (FAB+) m/z calculated for C20H26N2O3 
[M + H+] 343.2022, found 343.2006; [α]D22.4 –10.3° (c 0.28, CHCl3, 92% ee). 
 
 
Iminium perchlorate 261: To a flame-dried, 250-mL round-bottom flask with stir bar was 
added indole 315 (1.85g, 5.39 mmol, 1.0 equiv) in acetonitrile (110 mL). Freshly distilled 
phosphoryl chloride (15.0 mL, 153 mmol, 30.0 equiv) was then added, before the flask was 
equipped with a reflux condenser and heated to 100 °C for 14 hours. When the starting material 
was consumed, as determined by LCMS, the reaction mixture was cooled to room temperature 
and concentrated in vacuo. Residual phosphoryl chloride was removed azeotropically with 
acetonitrile (3 X 20 mL) to yield a brown, amorphous solid. 
 The crude mixture was redissolved in dichloromethane (27 mL) and stirred at room 
temperature. 1M aq. lithium perchlorate was added and the heterogeneous mixture was rapidly 
stirred for 30 minutes. The mixture was transferred to a separatory funnel and extracted with 
dichloromethane (3X). The combined organic extracts were washed with 1M lithium perchlorate 
(2X), dried with sodium sulfate, and concentrated in vacuo to afford crude iminium perchlorate 
261 (2.18 g, 95% crude yield) as a light brown solid without any further purification. 1H NMR 
(500 MHz, CD2Cl2) δ 10.34 (s, 1H), 7.83 (dt, J = 8.6, 0.9 Hz, 1H), 7.59 (dq, J = 8.2, 0.9 Hz, 1H), 
7.46 (ddd, J = 8.4, 6.9, 1.1 Hz, 1H), 7.20 (ddd, J = 8.1, 7.0, 0.9 Hz, 1H), 4.08 – 3.94 (m, 3H), 
3.87 (d, J = 14.9 Hz, 1H), 3.61 (dd, J = 18.6, 2.8 Hz, 1H), 3.45 (s, 3H), 3.20 (dd, J = 9.9, 6.6 Hz, 
95% yield
POCl3
MeCN, reflux, 14 h
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2H), 2.84 (d, J = 18.4 Hz, 1H), 2.30 – 2.20 (m, 1H), 2.14 – 1.98 (m, 4H), 1.93 – 1.82 (m, 1H), 
1.09 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.2, 171.9, 141.2, 129.0, 125.4, 124.9, 
123.0, 121.7, 121.1, 114.7, 54.6, 53.7, 52.1, 42.3, 42.0, 28.9, 27.8, 19.1, 17.8, 8.2; IR (Neat Film, 
NaCl) 3332, 2954, 1731, 1600, 1527, 1435, 1336, 1236, 1201, 1096, 752, 622 cm-1; HRMS 
(FAB+) m/z calculated for C20H25N2O2 [M – OCH3] XXX, found 295.1835; [α]D22.4 10.4° (c 2.1, 
CHCl3, 92% ee). 
 
 
Amines 317a and 317b: To an oven-dried one-dram vial with stir bar was added iminium 
perchlorate 261 (21.2 mg, 0.050 mmol, 1.0 equiv) and DMF (0.1 mL). 10% palladium on carbon 
(11.6 mg, 0.010 mmol with respect to palladium, 0.2 equiv) was added, and the vial was 
evacuated and backfilled with hydrogen (5X). The solution was sparged with hydrogen for 1 
minute, then allowed to stir at 23 °C for 1 hour.  
After the reaction was complete (as determined by HPLC), the mixture was diluted with 
ethyl acetate and filtered through a pad of Celite. The solution was transferred to a separatory 
funnel, washed with 10% lithium chloride, brine, and water, dried with sodium sulfate, and 
concentrated in vacuo.  Flash column chromatography (10 → 20 → 50 → 100% ethyl acetate) 
afforded cis-fused amine 317a (11.7 mg, 71% yield) and trans-fused amine 317b (1.5 mg, 9% 
yield) as colorless oils. 
cis-fused amine 317a: 1H NMR (400 MHz, CDCl3) δ 7.83 (s, 1H), 7.47 (dd, J = 7.7, 1.1 Hz, 1H), 
7.32 (dt, J = 8.0, 0.9 Hz, 1H), 7.15 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 7.09 (ddd, J = 8.0, 7.0, 1.1 Hz, 
81% yield, 8:1 d.r.
H2, 10% Pd/C
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1H), 3.49 (s, 3H), 3.38 (t, J = 1.9 Hz, 1H), 3.07 – 2.97 (m, 3H), 2.94 – 2.84 (m, 1H), 2.66 – 2.59 
(m, 1H), 2.56 (dd, J = 11.2, 3.5 Hz, 1H), 2.40 (ddd, J = 12.4, 11.1, 2.8 Hz, 1H), 2.08 – 1.87 (m, 
4H), 1.85 – 1.76 (m, 1H), 1.67 – 1.55 (m, 2H), 1.18 (t, J = 7.7 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 173.8, 136.1, 132.7, 126.8, 121.8, 119.5, 118.0, 112.5, 110.9, 66.3, 57.0, 54.0, 51.2, 
40.5, 38.2, 32.4, 31.5, 22.3, 22.1, 8.2; IR (Neat Film, NaCl) 3432, 2943, 1729, 1463, 1346, 1319, 
1295, 1196, 1017, 743 cm-1; HRMS (FAB+) m/z calculated for C20H27N22O [M + H+] 327.2073, 
found 327.2084; [α]D22.4 6.8° (c 0.44, CHCl3, 92% ee). 
trans-fused amine 317b: 1H NMR (400 MHz, CDCl3) δ 9.51 (s, 1H), 7.47 (ddt, J = 7.7, 1.4, 0.7 
Hz, 1H), 7.36 (dt, J = 8.0, 0.9 Hz, 1H), 7.16 – 7.05 (m, 2H), 3.81 (s, 3H), 3.31 (d, J = 1.7 Hz, 
1H), 3.02 – 2.87 (m, 3H), 2.82 (d, J = 13.0 Hz, 1H), 2.66 – 2.54 (m, 2H), 2.51 – 2.37 (m, 2H), 
2.22 (dd, J = 14.8, 7.6 Hz, 1H), 1.90 – 1.65 (m, 3H), 1.56 – 1.48 (m, 1H), 1.02 (ddd, J = 14.7, 
7.6, 1.1 Hz, 1H), 0.67 (t, J = 7.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) 13C NMR (101 MHz, 
CDCl3) δ 175.2, 136.9, 133.8, 127.4, 121.3, 119.2, 117.9, 112.5, 111.4, 67.0, 56.7, 53.6, 52.2, 
43.1, 41.5, 32.9, 25.0, 22.6, 22.5, 7.3; IR (Neat Film, NaCl) 3333, 2934, 2796, 2749, 1709, 1456, 
1341, 1305, 1195, 1160, 936, 738 cm -1; HRMS (FAB+) m/z calculated for C20H27N22O [M + 
H+] 327.2073, found 327.2078; [α]D22.4 13.4° (c 0.17, CHCl3, 92% ee). 
 
 
Eburnamonine (91) and epi-eburnamonine (251): To a flame-dried, 100 mL round-bottom 
flask with stir bar was added iminium perchlorate 261 (1.92 g, 4.52 mmol, 1.0 equiv) and DMF 
(9.0 mL). 10% palladium on carbon (960 mg, 0.90 mmol with respect to palladium, 0.2 equiv) 
78% yield, 3.4:1 d.r.
H2, 10% Pd/C
DMF, 23 °C, 3.5 h
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was added, and the flask was evacuated and backfilled with hydrogen (5X). The solution was 
sparged with hydrogen for 10 minutes, then allowed to stir at 23 °C for 3.5 hours. 
 The flask was then evacuated and backfilled with nitrogen (3X) and sparged for 5 
minutes. DBU (1.42 mL, 9.49 mmol, 2.1 equiv) was added dropwise, and the reaction was stirred 
at 23 °C for 2.5 hours. Additional DBU was added (0.27 mL, 1.81 mmol, 0.4 equiv) and the 
reaction was stirred at 23 °C for another 0.5 hours.  
 After the reaction was complete (as determined by HPLC), the mixture was diluted with 
ethyl acetate and filtered through a pad of Celite. The solution was transferred to a separatory 
funnel, washed with 10% lithium chloride, brine, and water, dried with sodium sulfate, and 
concentrated in vacuo. Flash column chromatography (5 → 25% ethyl acetate/chloroform) 
afforded eburnamonine 91 (0.82 g, 62%) as a light brown solid and epi-eburnamonine 251 
(0.23g, 17%) as an orange solid. Eburnamonine 91 was recrystallized from methanol to afford a 
white solid.  
Eburnamonine: 1H NMR (400 MHz, CDCl3) δ 8.39 – 8.35 (m, 1H), 7.46 – 7.41 (m, 1H), 7.37 – 
7.27 (m, 2H), 4.05 (s, 1H), 3.38 (dd, J = 13.9, 6.7 Hz, 1H), 3.29 (ddd, J = 13.9, 11.3, 5.8 Hz, 
1H), 2.92 (dddd, J = 16.9, 11.3, 6.7, 2.9 Hz, 1H), 2.69 (d, J = 16.8 Hz, 1H), 2.66 (bs, 1H), 2.60 
(d, J = 16.8 Hz, 1H), 2.58 – 2.41 (m, 2H), 2.09 (dq, J = 15.1, 7.6 Hz, 1H), 1.81 (qt, J = 13.2, 3.9 
Hz, 1H), 1.68 (dq, J = 14.7, 7.4 Hz, 1H), 1.51 (ddt, J = 13.6, 3.6, 1.9 Hz, 1H), 1.46 – 1.38 (m, 
1H), 1.05 (td, J = 13.6, 3.9 Hz, 1H), 0.94 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
167.6, 134.4, 131.6, 130.0, 124.7, 124.1, 118.3, 116.4, 112.7, 57.9, 50.9, 44.5, 44.4, 38.7, 28.5, 
26.9, 20.6, 16.7, 7.8; IR (Neat Film, NaCl) 3051,, 2933, 2856, 1704, 1627, 1454, 1375, 1332, 
1262, 1208, ; HRMS (FAB+) m/z calculated for C19H23N2O [M + H+] 295.1810, found 
295.1787; [α]D22.4 93.1° (c 0.55, CHCl3, 92% ee). Data were consistent with literature values.10 
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epi-Eburnamonine: 1H NMR (600 MHz, CDCl3) δ 8.35 – 8.31 (m, 1H), 7.40 (dd, J = 7.3, 1.6 Hz, 
1H), 7.31 – 7.24 (m, 3H), 3.14 – 3.05 (m, 3H), 3.03 (s, 1H), 2.88 (s, 1H), 2.80 (d, J = 16.7 Hz, 
1H), 2.65 (dq, J = 15.9, 2.5, 2.0 Hz, 1H), 2.52 (td, J = 11.4, 4.3 Hz, 1H), 2.37 – 2.28 (m, 2H), 
1.89 (hd, J = 8.4, 4.4 Hz, 3H), 1.63 (dtd, J = 13.5, 4.9, 4.3, 2.3 Hz, 1H), 1.23 – 1.15 (m, 1H), 
0.87 – 0.80 (m, 1H), 0.78 (t, J = 7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 167.6, 135.1, 
133.3, 129.9, 124.1, 123.8, 118.1, 116.2, 113.0, 66.0, 55.4, 52.3, 44.3, 39.4, 31.8, 21.6, 21.3, 
20.7, 7.4; IR (Neat Film, NaCl) 3050, 2935, 2796, 1708, 1655, 1600, 1457, 1365, 1324, 1301, 
1149, 1118, 1042, 958, 746, 688 cm-1; HRMS (FAB+) m/z calculated for for C19H23N2O [M + 




Eburnamine (92) and isoeburnamine (93): To a flame-dried 25 mL flask with stir bar was 
added lithium aluminum hydride (6.8 mg, 0.20 mmol, 2.0 equiv) and THF (1.18 mL). The flask 
was cooled to 0 °C and a solution of eburnamonine (91) (29.5 mg, 0.10 mmol, 1.0 equiv) in THF 
(1.78 mL) was slowly added dropwise. The solution was stirred at 0 °C for 45 minutes. 
 The reaction mixture was quenched with cool brine, transferred to a separatory funnel, 
and extracted with ethyl acetate (3X). The combined organic extracts were washed once with 
cool brine, dried with sodium sulfate, and concentrated in vacuo. Flash column chromatography 
afforded an inseparable mixture of eburnamine (92) and isoeburnamine (93) (24.1 mg, 81% 
81% yield, 2.2:1 d.r.
LiAlH4
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yield, 2.2:1 d.r.). The ratio of eburnamine to epi-eburnamine was determined by integration of 
the diagnostic peaks in the 1H NMR for 92 (5.59) and 93 (6.05), respectively. Data were 
consistent with literature values.11 
 Eburnamine 92 (major diastereomer): 1H NMR (400 MHz, CDCl3) δ δ 7.78 – 7.71 (m, 1H), 7.54 
– 7.45 (m, 1H), 7.25 – 7.14 (m, 2H), 5.59 (dd, J = 9.5, 5.2 Hz, 1H), 3.84 (bs, 1H), 3.37 – 3.15 
(m, 2H), 3.05 – 2.88 (m, 1H), 2.69 – 2.47 (m, 3H), 2.39 – 2.27 (m, 1H), 2.25 – 2.13 (m, 1H), 
2.12 – 1.95 (m, 1H), 1.85 – 1.24 (m, 4H), 0.96 – 0.80 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 
136.8, 132.8, 128.8, 121.4, 120.3, 118.2, 112.3, 105.8, 76.8, 58.9, 50.9, 44.5, 43.7, 37.0, 28.7, 
25.3, 20.6, 16.9, 7.7.  
iso-Eburnamine 93 (minor diastereomer): 1H NMR (400 MHz, CDCl3) δ 7.78 – 7.71 (m, 1H), 
7.54 – 7.45 (m, 1H), 7.43 – 7.37 (m, 1H), 7.25 – 7.14 (m, 2H), 6.05 (dd, J = 4.8, 1.3 Hz, 0H), 
5.59 (dd, J = 9.5, 5.2 Hz, 1H), 3.87 – 3.82 (m, 1H), 3.37 – 3.15 (m, 2H), 3.05 – 2.88 (m, 1H), 
2.69 – 2.47 (m, 3H), 2.39 – 2.27 (m, 2H), 2.25 – 2.13 (m, 1H), 2.12 – 1.95 (m, 1H), 1.85 – 1.62 
(m, 1H), 1.62 – 1.42 (m, 2H), 1.42 – 1.24 (m, 2H), 0.96 – 0.80 (m, 4H). 13C NMR (101 MHz, 
CDCl3) δ 134.8, 131.3, 129.0, 121.4, 120.3, 118.6, 109.9, 105.7, 74.8, 59.4, 51.4, 45.0, 40.0, 
34.8, 29.1, 26.7, 21.1, 16.9, 7.8. 
IR (Neat Film, NaCl) 3356, 2921, 2714, 1694, 1668, 1455, 1366, 1301, 1272, 1165, 1057, 741 








Piperidine 324: To a flame-dried 500 mL round-bottom flask with stir bar was added lactam 
300 (2.47 g, 14.8 mmol, 1.0 equiv) in diethyl ether (150 mL). The flask was cooled to 0 °C 
before lithium aluminum hydride (1.64 g, 44.4 mmol, 3.0 equiv) was added portionwise. The 
flask was equipped with a reflux condenser and heated to reflux for 24 hours.  
After the reaction is complete, as determined by TLC, the flask is re-cooled to 0 °C and 
quenched with saturated sodium carbonate. The flask was then removed from the bath and stirred 
at 23 °C for 20 minutes. The mixture was transferred to a separatory funnel and extracted with 
diethyl ether (5X). The combined organic extracts were washed with brine (2X), dried with 
sodium sulfate, and concentrated in vacuo to yield a brown oil, which was used immediately in 
the next step without further purification. 
The 500 mL round bottomed flask was equipped with a stir bar, placed under nitrogen 
atmosphere, and charged with acetonitrile (75 mL). The flask was cooled to 0 °C before di-tert-
butyldicarbonate (4.08 mL, 17.8 mmol, 1.2 equiv) and DMAP (180 mg, 1.48 mmol, 0.1 equiv) 
were added sequentially. The flask was warmed slowly to 23 °C over 12 hours. Additional di-
tert-butyldicarbonate (2.0 mL, 8.9 mmol, 0.6 equiv) was added and the reaction was stirred for 
an additional 6 hours.  
After the reaction was complete, as determined by TLC, the reaction was quenched with 
2,2,2-trifluoroethanol (~ 5mL) and stirred for 30 minutes. The stir bar was then removed and the 
reaction mixture is concentrated in vacuo onto silica gel. Flash column chromatography (5% 
ethyl acetate/hexane) afforded piperidine 324 (2.59 grams, 70% yield) as a colorless oil. 1H 
70% yield, 2 steps
1. LiAlH4 
    Et2O, 0°C → reflux, 24 hr
2. Boc2O, DMAP (10 mol %)
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NMR (400 MHz, CDCl3) δ 5.77 (ddt, J = 15.6, 11.6, 7.5 Hz, 1H), 5.08 – 4.98 (m, 2H), 3.34 (t, J 
= 5.8 Hz, 2H), 3.10 (m, 2H), 2.05 (dd, J = 14.1, 7.1 Hz, 1H), 1.95 (bs, 1H), 1.51 (m, 2H), 1.46 
(bs, 9H), 1.38 (t, J = 6.2 Hz, 2H), 1.33 – 1.14 (m, 2H), 0.82 (t, J = 7.5 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 155.2, 134.3, 117.4, 79.2, 52.5, 52.0, 44.9, 44.0, 38.7, 36.1, 33.9, 33.5, 28.6, 
27.2, 21.1, 7.4; IR (Neat Film, NaCl) 2973, 2933, 2857, 1695, 1426, 1365, 1274, 1250, 1162, 
1101, 912, 767 cm-1; HRMS (FAB+) m/z calculated for C15H28NO2 [M + H+] 254.2120, found 
254.2101; [α]D22.5 9.3° (c 1.8, CHCl3, 92% ee). 
 
 
Aldehyde 321: To a flame-dried 500-mL round-bottom flask with stir bar was added 
bis(benzonitrile) palladium(II) chloride (460 mg, 1.2 mmol, 0.15 equiv), copper (II) chloride 
dihydrate (205 mg, 1.2 mmol, 0.15 equiv), and silver (I) nitrite (92.4 mg, 0.6 mmol, 0.075 
equiv). Nitromethane (10 mL) and tert-butanol (150 mL) were sequentially added and stirred at 
23 °C. The flask was evacuated and backfilled with oxygen (3X) before the reaction mixture was 
sparged for 10 minutes. Piperidine 321 (2.02 g, 8.0 mmol, 1.0 equiv) was added neat, and the 
reaction was sparged at 23 °C for another 5 minutes. The reaction mixture was stirred at 23 °C 
for 16 hours. 
 The reaction was quenched with water, transferred to a separatory funnel, and extracted 
with ethyl acetate (4X). The combined organic extracts were washed with brine, dried with 
sodium suflate, and concentrated in vacuo (rotary evaporator with bath at 40 °C to remove t-
BuOH). Flash column chromatography (15 → 20% ethyl acetate/hexanes) afforded aldehyde 321 
72% yield 321324
NBoc
MePd(PhCN)2Cl2 (15 mol %)CuCl2•2H2O (15 mol %)
AgNO2 (7.5 mol %), O2
tBuOH/MeNO2 (15:1)
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(1.52 g, 72% yield) as a colorless oil 1H NMR (400 MHz, CD2Cl2) δ 9.75 (s, 1H), 3.17 (m, 4H), 
2.51 – 2.15 (m, 2H), 1.70 – 1.46 (m, 4H), 1.42 (s, 9H), 1.34 – 1.10 (m, 4H), 0.80 (t, J = 7.5 Hz, 
3H); 13C NMR (101 MHz, CD2Cl2) δ 202.7, 155.1, 79.4, 52.5, 51.7, 45.3, 44.2, 38.5, 35.6, 34.4, 
28.7, 28.5, 27.5, 27.1, 25.9, 25.5, 21.4, 7.4. IR (Neat Film, NaCl) 2973, 2933, 2857, 1695, 1426, 
1365, 1274, 1250, 1162, 1101, 912, 767 cm-1; HRMS (FAB+) m/z calculated for C15H28NO3 [M 
+ H+] 270.2069, found 270.2056; [α]D25 13.0° (c 1.92, CHCl3). 
 
 
Methyl 2-amino-5-bromo-4-methoxybenzoate 326: To a flame-dried 250 mL round-bottom 
flask with stir bar was added 2-amino, 4-methoxybenzoic acid 323 (3.00 g, 18.0 mmol, 1.0 
equiv) and DMF (90 mL). The flask was cooled to 0 °C, and N-bromosuccinimide (1.1 equiv, 
19.8 mmol. 1.1 equiv) was added in a single portion. The flask was removed from the bath and 
warmed to 23 °C over 90 minutes. 
 The reaction was quenched with saturated sodium sulfite and acidified to pH ~3 with 
concentrated hydrochloric acid. The solution was transferred to a separatory funnel and extracted 
with diethyl ether (3X). The combined organic extracts were washed with 10% sat. lithium 
chloride, water, and brine, then concentrated in vacuo to yield a white solid. This was used in the 
next reaction immediately without further purification. 
 To a flame-dried 250 mL round-bottom flask with stir bar was added the crude reaction 







74% yield, 2 steps
1. NBS (1.1 equiv)
    DMF, 0 °C, 1.5 hr
2. K2CO3, MeI
    DMF, 0 → 23 °C, 1 hr
326323
Br
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36.0 mmol, 2.0 equiv) and methyl iodide (1.68 mL, 27.0 mmol, 1.5 equiv) were added 
sequentially. The flask was removed from the cooling bath and warmed to 23 °C over 1 hour. 
 The reaction was quenched with cool water, transferred to a separatory funnel, and 
extracted with ethyl acetate (3x). The combined organic extracts were washed with 10% 
saturated lithium chloride and brine, dried with sodium sulfate, and concentrated in vacuo. Flash 
column chromatography (20 → 30% ethyl acetate/hexanes) afforded methyl ester 326 as a light 
yellow, amorphous solid (3.47 g, 74% yield over 2 steps). 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 
1H), 6.11 (s, 1H), 5.85 (s, 2H), 3.86 (s, 3H), 3.84 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 167.5, 
160.1, 151.8, 135.7, 105.2, 98.7, 98.3, 56.3, 51.7, 31.1; IR (Neat Film, NaCl) 3478, 3467, 2948, 
1687, 1610, 1589, 1485, 1446, 1277, 1224, 1109, 1050, 822, 555 cm-1; HRMS (FAB+) m/z 
calculated for C9H10BrNO3 [M + •] 258.9844, found 258.9851. 
 
 
(2-amino-5-bromo-4-methoxyphenyl)methanol 327: To a flame-dried 250 mL round-bottom 
flask with stir bar was charged lithium aluminum hydride (798 mg, 21.0 mmol, 800 mg) and 
diethyl ether (30 mL). The flask was cooled to 0 °C before a solution of ester 326 (2.60 g, 10.0 
mmol, 1.0 equiv) in diethyl ether (30 mL) was added dropwise via cannula. The flask was stirred 
at 0 °C for 10 minutes. The reaction was quenched with methanol and saturated Rochelle’s salt 
solution, then warmed to 23 °C over 20 minutes. The mixture was transferred to a separatory 
funnel and extracted with diethyl ether (3X). The combined organic extracts are washed with 








Et2O, 0 °C, 45 min
327326
BrBr
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white solid with no further purification. 1H NMR (400 MHz, CD2Cl2) δ 7.17 (s, 1H), 6.29 (s, 
1H), 4.54 (s, 2H), 3.81 (s, 3H); 13C NMR (101 MHz, CD2Cl2) δ 156.74, 147.45, 133.53, 119.01, 
100.28, 98.18, 63.44, 56.51; IR (Neat Film, NaCl) 3370, 2926, 1605,0501, 1446, 1407, 1307, 
1217, 1050, 999, 888, 827 cm-1; HRMS (FAB+) m/z calculated for C8H10BrNO2 [M + •] 
230.9895, found 230.9908. 
 
2-amino-4-methoxybenzaldehyde 322: To prepare a stock solution, an oven-dried 20 mL 
scintillation vial with stir bar was charged with 4-4’-dimethoxy-2-2’bipyridine (108 mg), 
TEMPO (78 mg), NMI (92 mg) and acetonitrile (2.5 mL). A separate flame-dried 100 mL round-
bottom flask was charged sequentially with alcohol 327 (232 mg, 1.0 mmol, 1.0 equiv), 
acetonitrile (10 mL), and tetrakis(acetonitrile) copper (I) triflate (18.8 mg, 0.050 mmol, 0.050 
equiv). 0.25 mL of stock solution was then added and the reaction was stirred under air for 2 
hours. 
 The reaction was diluted with ethyl acetate, filtered through a plug of silica gel, and 
concentrated in vacuo. Flash column chromatography (20 → 25 → 30% ethyl acetate/hexanes) 
yielded aldehyde 322 as a white solid (200 mg, 87% yield). 1H NMR (400 MHz, CDCl3) δ 9.66 
(d, J = 0.6 Hz, 1H), 7.59 (s, 1H), 6.28 (s, 2H), 6.09 (s, 1H), 3.90 (s, 3H); 13C NMR (101 MHz, 
CDCl3) 13C NMR (101 MHz, CDCl3) δ 191.1, 161.0, 151.4, 139.7, 114.4, 98.5, 97.9, 56.4; IR 
(Neat Film, NaCl) 3431, 3313, 2843, 1652, 1611, 1228, 1198, 1048, 818 cm-1; HRMS (FAB+) 







[Cu(MeCN)4]OTf (5 mol %)
(MeO)-bpy (5 mol%)
TEMPO (5 mol %)
NMI (10 mol %)
air










Quinoline 320: To a flame-dried 50 mL round-bottom flask with stir bar was added alcohol 327 
(1.10 g, 4.75 mmol, 1.3 equiv) and a solution of aldehyde 321 (985 mg, 3.66 mmol, 1.0 equiv) in 
1,4-dioxane (11 mL). The reaction was then heated to 80 °C for 1 hour. Benzophenone (3.33 g, 
18.3 mmol, 5 equiv) was then added at 80 °C in a single portion, and the reaction mixture was 
stirred at that temperature for 5 minutes. A solution of potassium tert-butoxide (1.03g, 9.15 
mmol, 2.5 equiv) in 1,4-dioxane (9.2 mL) was then added over 30 minutes via syringe pump. 
The reaction mixture was then stirred for an additional 15 minutes. 
Upon completion, the reaction mixture was cooled to 23 °C, quenched with saturated 
sodium bicarbonate solution, and transferred to a separatory funnel. The mixture was extracted 
with ethyl acetate (3X) before the combined organic extracts were washed with brine, dried with 
sodium sulfate, and concentrated in vacuo. Flash column chromatography (30% ethyl 
acetate/hexanes) afforded quinoline 320 (1.26 g, 74% yield) as a yellow foam. 1H NMR (400 
MHz, CDCl3) δ 8.63 (d, J = 2.2 Hz, 1H), 7.99 (s, 1H), 7.76 (s, 1H), 7.41 (s, 1H), 4.00 (s, 3H), 
3.48 – 3.06 (m, 4H), 2.75 (d, J = 13.8 Hz, 1H), 2.65 (d, J = 13.8 Hz, 1H), 1.67 – 1.51 (m, 2H) 
(H2O peak overlapping), 1.42 (s, 9H), 1.40 – 1.34 (m, 12), 1.22 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H); 
13C NMR (101 MHz, DMSO) δ 155.3, 154.1, 153.4, 146.8, 135.1, 131.3, 129.4, 123.2, 113.1, 
108.3, 78.5, 56.6, 51.3, 50.8, 37.4, 36.8, 32.4, 28.0, 25.5, 20.8, 7.5; IR (Neat Film, NaCl) 2969, 










80 °C, 1 h
then Ph2CO, t-BuOK
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732 cm-1; HRMS (FAB+) m/z calculated for C23H32BrN2O3 [M + H+] 463.1596, found 463.1623; 
[α]D22.6° 21.2° (c 0.21, CHCl3). 
 
 
Amine 330: To a 10-mL round-bottom flask with stir bar was added quinoline 320 (46.3 mg, 
0.10 mmol, 1.0 equiv) in dichloromethane (1.8 mL). The flask was cooled to 0 °C and 
trifluoroacetic acid (0.2 mL) was added dropwise. The flask was warmed slowly to 23 °C over 
12 hours. 
 Upon completion, as determined by LCMS analysis, the solution was diluted with water, 
transferred to a scintillation vial, and extracted with diethyl ether (3X). The mixture was then 
basified to pH = 7 by addition of 1M NaOH. The aqueous layer was extracted with 
dichloromethane (3X), then 3:1 chloroform/isopropanol (3X), dried with sodium sulfate, then 
concentrated in vacuo. Preparative TLC (5% methanol/dichloromethane) afforded amine 330 
(30.8 mg, 85% yield) as a white, amorphous solid. 1H NMR (400 MHz, CDCl3) δ 8.67 (d, J = 2.2 
Hz, 1H), 7.98 (s, 1H), 7.78 (d, J = 2.2 Hz, 1H), 7.41 (s, 1H), 4.03 (s, 3H), 3.33 – 3.00 (bs, 1H), 
2.91 – 2.83 (m, 3H), 2.77 (d, J = 13.8 Hz, 1H), 2.70 – 2.60 (m, 2H), 1.80 – 1.69 (m, 1H), 1.68 – 
1.57 (m, 1H), 1.43 (t, J = 6.2 Hz, 2H), 1.33 (q, J = 7.8 Hz, 2H), 0.97 (t, J = 7.5 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) 13C NMR (101 MHz, CDCl3) δ 156.2, 153.6, 147.4, 135.3, 131.3, 
129.9, 123.8, 114.3, 108.3, 56.6, 53.8, 46.5, 38.0, 36.6, 32.9, 27.2, 21.6, 14.3, 8.2, 7.6; IR (Neat 
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HRMS (FAB+) m/z calculated for C23H32BrN2O3 [M + H+] 363.1072, found 363.1098;; [α]D22.6 
3.5 (c 1.21, CHCl3). 
 
 
Fluoroquinolines 327a and 327: To an oven-dried one-dram vial with stir bar in a nitrogen 
filled glove box was added quinoline 320 (27.5 mg, 0.0593 mmol, 1.0 equiv) and acetonitrile 
(2.4 mL). Silver (II) fluoride (43.0 mg, 0.297 mmol, 5.0 equiv) was then added in a single 
portion. The vial was removed from the glovebox and heated to 50 °C in the dark for 1.5 hours. 
After completion of the reaction, the reaction mixture was filtered through a pad of Celite 
and concentrated in vacuo. The crude mixture was dissolved in ethyl acetate and treated with 
saturated sodium bicarbonate. The organic extracts were separated and the aqueous layer was 
extracted with ethyl acetate (5X). The combined organic extracts were then washed with brine, 
dried with sodium sulfate, and concentrated in vacuo. Preparative TLC (30% ethyl 
acetate/hexanes) afforded both 2-fluoroquinoline 329a (7.0mg, 24% yield) and 4-fluoroquinoline 
329b (6.8 mg, 24% yield) both as amorphous white solids.  
2-fluoroquinoline 329a: 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.27 (s, 1H), 
4.01 (s, 3H), 3.78 – 3.25 (m, 2H), 3.00 (d, J = 70.6 Hz, 2H), 2.72 (s, 2H), 1.60 (s, 1H), 1.46 (s, 
11H), 1.33 (dt, J = 13.4, 6.9 Hz, 3H), 0.95 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) 13C 
NMR (101 MHz, CDCl3) δ 162.6, 160.2, 157.2, 155.3, 145.7, 141.4, 131.0, 122.9, 118.4, 113.3, 















C2:C4 1:1 329b, 4-F
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1249, 1157, 1041, 758 cm -1 (Neat Film, NaCl); HRMS (FAB+) m/z calculated for 
C23H31FBrN2O3 [M + H+] 481.1502, found 481.1523; [α]D25° 27.2° (c 0.35, CHCl3). 
4-fluoroquinoline 327a: 1H NMR (400 MHz, CDCl3) 1H NMR (400 MHz, Chloroform-d) δ 8.74 
(d, J = 2.1 Hz, 1H), 7.82 (d, J = 2.0 Hz, 1H), 7.80 (s, 1H), 4.15 (d, J = 2.1 Hz, 3H), 3.35 (d, J = 
108.0 Hz, 4H), 2.80 (d, J = 14.0 Hz, 1H), 2.71 (d, J = 13.8 Hz, 1H), 1.71 – 1.61 (m, 1H), 1.46 (s, 
10H), 1.38 (dd, J = 11.0, 5.1 Hz, 1H), 1.29 – 1.16 (m, 2H), 0.97 (t, J = 7.4 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) 13C NMR (101 MHz, CDCl3) δ 155.3, 153.6, 151.0, 148.4, 143.7, 137.7, 
135.1, 131.9, 125.7, 125.5, 117.6, 79.7, 62.1, 52.3, 38.0, 37.6, 33.1, 28.6, 26.8, 21.4, 7.8; IR 
2930, 2862, 1686, 1474, 1428, 1365, 1273, 1248, 1154, 1039, 754 cm -1(Neat Film, NaCl); 
HRMS (FAB+) m/z calculated for C23H31FBrN2O3 [M + H+] 481.1502, found 481.1491; [α]D22.6 
17.9° (c 0.32, CHCl3). 
 
 
Quinoline N-oxide 332:  To a 50-mL round-bottom flask with stir bar was added quinoline 320 
(1.60 g, 3.44 mmol, 1.0 equiv) and dichloromethane (3.5 mL). 35% hydrogen peroxide solution 
(1.67 mL, 17.2 mmol, 5.0 equiv) was added, followed by methyltrioxorhenium(VII) (171 mg, 
0.688 mmol, 0.20 equiv). The biphasic reaction mixture was rapidly stirred at 23 °C for 12 hours. 
The reaction was quenched with 5 mg of manganese dioxide and stirred rapidly for 30 minutes 
until evolution of oxygen ceased. The solution was transferred to a separatory funnel and 
extracted with dichloromethane, before the combined organic extracts were dried with sodium 






MeRhO3 (20 mol %) 
H2O2
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quinoline N-oxide 332 to precipitate as a white, amorphous solid (1.32 g, 80% yield). 1H NMR 
(400 MHz, CDCl3) δ 8.38 (d, J = 1.5 Hz, 1H), 8.06 (s, 1H), 8.04 (s, 1H), 7.40 (s, 1H), 4.08 (s, 
3H), 3.52 – 3.00 (m, 4H), 2.71 (d, J = 13.9 Hz, 1H), 2.58 (d, J = 13.9 Hz, 1H), 1.59 (dp, J = 14.0, 
7.3, 6.8 Hz, 2H), 1.47 (s, 9H), 1.43 – 1.36 (m, 2H), 1.26 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) 13C NMR (101 MHz, CDCl3) δ 157.5, 155.2, 140.3, 138.2, 131.9, 
130.6, 126.3, 125.6, 117.0, 99.3, 79.9, 57.2, 51.9, 44.8, 43.9, 38.1, 37.5, 33.2, 28.6, 26.9, 21.4, 
7.8; IR (Neat Film, NaCl) 2967, 2934, 2868, 1687, 1573, 1470, 1428, 1343, 1306, 1273, 1247, 
1203, 1155, 1038, 863, 754 cm-1; HRMS (FAB+) m/z calculated for C23H31BrN2O4 [M + H+] 
479.1545, found 479.1538; [α]D25° 16.8° (c 0.46, CHCl3). 
 
 
Tetracycle 332: To an oven-dried 1-dram vial in a nitrogen-filled glove box was added N-oxide 
332 (96.0 mg, 0.20 mmol, 1.0 equiv), dichloromethane (1.0 mL), and tin (II) 
trifluoromethanesulfonate (2.5 equiv, 0.50 mmol, 2.5 equiv). This was repeated nine times and 
the reactions were stirred rapidly for 3 hours, during which time the solution turned from a clear 
yellow to a cloudy white. Triethylamine (1.39 mL, 1.00 mmol, 5.0 equiv) was added to each of 
the vials, which were then quickly sealed and heated to 40 °C for 1 hour. 
 After the reaction was complete, the vials were removed from the glovebox, diluted with 
dichloromethane, and transferred to a separatory funnel containing 0.5M aqueous sodium 
hydroxide. The solution was extracted with dichloromethane (5X), before the combined organic 





CH2Cl2, 23 °C, 3 h
then Et3N (5.0 equiv) 
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column chromatography (1% methanol/0.5% triethylamine/ethyl acetate → 3% methanol/0.5% 
triethylamine/ethyl acetate) afforded tetracycle 319 as a white solid. 1H NMR (600 MHz, CDCl3) 
jδ 7.88 (s, 1H), 7.70 (s, 1H), 7.32 (s, 1H), 3.99 (s, 3H), 3.77 – 3.69 (m, 1H), 3.26 – 3.16 (m, 1H), 
3.08 (dd, J = 13.3, 2.2 Hz, 1H), 2.94 (ddd, J = 13.4, 2.9, 1.2 Hz, 1H), 2.89 (dt, J = 17.4, 1.7 Hz, 
1H), 2.73 (dt, J = 17.3, 1.5 Hz, 1H), 1.84 – 1.74 (m, 1H), 1.62 – 1.53 (m, 1H), 1.38 – 1.29 (m, 
4H), 0.95 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 162.9 156.1, 147.1, 134.5, 130.5, 
126.1, 122.1, 112.0, 107.5, 58.1, 56.5, 56.0, 37.4, 36.1, 35.1, 30.9, 19.7, 7.3; IR (Neat Film, 
NaCl) 2928, 1612, 1477 1449, 1371, 1234, 11127, 1040, 859, 755, 674, 649 cm-1; HRMS 
(FAB+) m/z calculated for C18H22N2OBr [M + H+] 361.0916, found 363.0936; [α]D22.7 83.7° (c 
0.99, CHCl3, 92% ee). 
 
 
Alcohol 340: To a flame-dried, 25 mL round-bottom flask with stir bar was added tetracycle 319 
(337 mg, 0.93 mmol, 1.0 equiv), benzoyl peroxide (451 mg, 1.87 mmol, 2.0 equiv), and 
methanol (9.3 mL). The reaction mixture is sparged with argon for 20 minutes before 
trifluoroacetic acid (0.71 mL, 9.34 mmol, 10.0 equiv) is added dropwise. The flask is placed in a 
Hepatochem© setup and irradiated with blue LED’s for 45 minutes.  
 The mixture was quenched with sodium bicarbonate solution, transferred to a separatory 
funnel, and extracted with dichloromethane (3X). The combined organic extracts were washed 
with brine, dried, and concentrated in vacuo. Flash column chromatography (1→ 2 → 3 → 4 
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white amorphous solid. 1H NMR (400 MHz, CD2Cl2) δ 8.24 (s, 1H), 7.16 (s, 1H), 5.03 – 4.88 
(m, 2H), 3.90 (s, 3H), 3.62 (ddt, J = 13.1, 4.2, 2.1 Hz, 1H), 3.12 – 3.03 (m, 1H), 3.03 – 2.91 (m, 
1H), 2.88 – 2.64 (m, 3H), 2.39 – 1.97 (bs, 1H), 1.72 – 1.60 (m, 1H), 1.57 – 1.44 (m, 1H), 1.29 (q, 
J = 7.5 Hz, 2H), 1.22 (dd, J = 6.3, 3.5 Hz, 2H), 0.88 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, 
CD2Cl2); δ 163.1, 156.1, 147.8, 142.0, 128.3, 124.6, 120.9, 112.2, 108.0, 57.6, 57.3, 56.7, 56.3, 
36.2, 35.8, 35.5, 31.1, 20.1, 7.4. IR (Neat Film, NaCl) 3178, 2923, 2853, 1606, 0580, 1463, 
1451, 1410, 1369, 1236, 1046, 756 cm-1; HRMS (FAB+) m/z calculated for C19H24BrN2O2 [M + 
H+] 391.1021, found 391.1013; [α]D22.7 83.6 (c 0.19, CHCl3, 92% ee). 
Figure 2.6. Reaction Setup for Photoredox-mediated Minisci Reaction. 
 




Aldehyde 342: To a 50-mL round bottom flask with stir bar was added alcohol 340 (280 mg, 
0.716 mmol, 1.0 equiv), non-dried dichloromethane (14.2 mL), and sodium bicarbonate (420 mg, 
5.01 mmol, 7.0 equiv). The flask was cooled to 0 °C and Dess-Martin periodinane (424 mg, 1.00 
mmol, 1.4 equiv) was added as a single portion. The reaction mixture was stirred at 0 °C for 1 
hour. 
 The reaction mixture was quenched with water, transferred to a separatory funnel, and 
extracted with dichloromethane (3X). The combined organic extracts were washed with brine, 
dried with sodium sulfate, and concentrated in vacuo. Flash column chromatography (0 → 20 → 
30% ethyl acetate/dichloromethane) afforded aldehyde 342 (235 mg, 85% yield) as an 
amorphous, yellow solid. 1H NMR (600 MHz, CD2Cl2) δ 10.88 (s, 1H), 8.82 (s, 1H), 7.31 (s, 
1H), 4.01 (s, 3H), 3.79 – 3.74 (m, 1H), 3.25 (dd, J = 18.1, 1.5 Hz, 1H), 3.23 – 3.17 (m, 1H), 3.12 
(dd, J = 13.3, 2.3 Hz, 1H), 3.02 (dd, J = 18.1, 2.3 Hz, 1H), 2.94 (ddd, J = 13.5, 2.8, 1.3 Hz, 1H)., 
1.80 – 1.73 (m, 1H), 1.66 – 1.59 (m, 1H), 1.41 (q, J = 7.6 Hz, 2H), 1.34 (tt, J = 10.5, 3.1 Hz, 
2H), 0.98 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, CD2Cl3) δ 193.6, 163.6, 156.5, 148.5, 133.8, 
128.5, 128.4, 117.7, 114.7, 107.9, 57.2, 56.79, 56.46, 36.0, 35.8, 35.4, 31.1, 20.2, 7.4; IR (Neat 
Film, NaCl) 2926, 1692, 1603, 1567, 1478, 1363, 1230, 1215, 1043, 752 cm -1; HRMS (FAB+) 
m/z calculated for C19H22BrN2O2 [M + H+] 389.0865, found 389.0854; [α]D22.7° 311.7° (c 0.05, 



















Alkene 318: To an oven-dried 1-dram vial with stir bar was added aldehyde 342 (50 mg, 0.128 
mmol, 1.0 equiv), sulfone 343 (31.5 mg, 0.154 mmol, 1.2 equiv), and tetrahydrofuran (1.28 mL). 
The vial is cooled to –78 °C and sodium hexamethyldisilizane (30.4 mg, 0.166 mmol, 1.3 equiv) 
was added quickly as a single portion. The reaction mixture was stirred at –78 °C for 30 minutes 
and monitored by TLC.  
 The reaction was quenched with saturated ammonium chloride and warmed up to 23 °C. 
The mixture was extracted with ethyl acetate (5X) before the combined organic extracts were 
washed with brine, dried with sodium sulfate, and concentrated in vacuo. Flash column 
chromatography (0.5% triethylamine in ethyl acetate) afforded alkene 318 (42.7 mg, 87% yield) 
as a light yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H), 7.32 (s, 1H), 6.80 (ddt, J = 
17.9, 11.7, 0.9 Hz, 1H), 5.88 (dd, J = 11.7, 1.6 Hz, 1H), 5.56 (dd, J = 18.0, 1.7 Hz, 1H), 4.00 (s, 
3H), 3.79 (dd, J = 14.0, 3.8 Hz, 1H), 3.20 (ddd, J = 13.4, 11.3, 4.8 Hz, 1H), 3.07 (dd, J = 13.3, 
2.2 Hz, 1H), 2.93 (ddd, J = 13.5, 2.7, 1.3 Hz, 1H), 2.72 (dt, J = 17.9, 1.2 Hz, 1H), 2.58 – 2.51 (m, 
1H), 1.81 – 1.71 (m, 1H), 1.62 – 1.50 (m, 1H), 1.41 – 1.27 (m, 4H), 0.95 (t, J = 7.5 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 162.1, 156.0, 147.4, 142.9, 131.6, 129.1, 123.4, 122.8, 120.1, 111.9, 
107.8, 57.6, 56.5, 56.0, 36.8, 36.2, 35.3, 30.9, 19.8, 7.4; IR (Neat Film, NaCl) 2957, 2932, 1603, 
1560, 1479, 1449, 1412, 1367, 1229, 1045, 1001, 847, 754 cm-1; HRMS (FAB+) m/z calculated 


















O-methyleucophylline 344: To an oven-dried, 1-dram vial with stir bar was added alkene 318 
(15.5 mg, 0.040 mmol, 1.0 equiv) in THF (0.4 mL). The vial was cooled to –78 °C and stirred 
for 10 minutes. n-BuLi (2.30 M in hexanes, 0.0480 mmol, 24 µL, 1.1 equiv) was added dropwise 
and the reaction mixture was stirred for an additional 10 minutes. 
The reaction was then diluted with diethyl ether, quenched with saturated ammonium 
chloride solution and warmed to 23 °C over 30 minutes. The organic extracts were separated and 
the aqueous layer was extracted with ethyl acetate (3X). The combined organic extracts were 
washed with brine, dried with sodium sulfate, and concentrated in vacuo. Preparative TLC 
(100% ethyl acetate) affords O-methyleucophylline 344 (5.1 mg, 41% yield) as a light yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 9.2 Hz, 1H), 7.27 (d, J = 2.6 Hz, 1H), 7.03 (dd, J 
= 9.2, 2.6 Hz, 1H), 6.84 (ddt, J = 17.9, 11.6, 0.9 Hz, 1H), 5.84 (dd, J = 11.7, 1.8 Hz, 1H), 5.54 
(dd, J = 18.0, 1.8 Hz, 1H), 3.91 (s, 3H), 3.81 – 3.72 (m, 1H), 3.18 (ddd, J = 13.5, 12.4, 3.7 Hz, 
1H), 3.07 (dd, J = 13.2, 2.1 Hz, 1H), 2.94 (ddd, J = 13.2, 3.0, 1.1 Hz, 1H), 2.72 (dt, J = 17.7, 1.3 
Hz, 1H), 2.60 – 2.51 (m, 1H), 1.80 – 1.31 (m, 6H), 0.95 (t, J = 7.6 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 161.8, 160.1, 148.5, 143.7, 132.1, 126.1, 122.7, 121.9, 119.4, 117.7, 106.7, 57.8, 55.9, 
55.5, 36.8, 36.3, 35.3, 30.8, 19.7, 7.4; IR (Neat Film, NaCl) 3730, 2919, 1620, 1557, 1452, 1370, 
1226, 1159, 1026, 941, 848 cm -1; HRMS (FAB+) m/z calculated for C20H54N2O [M + H+] 
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2.5.3   Comparison of NMR Data to Known Samples  





(This research, 400 MHz) 
Synthetic Eburnamonine 
(Panday) 
8.37 (m, 1H) 
 
8.38 (m, 1H) 
7.44 (m, 1H) 
 
7.45 (m, 1H) 
7.32 (m, 2H) 
 
7.33 (m, 2H) 
4.05 (bs) 
 
3.99 (bs, 1H) 
3.38 (dd, J = 13.9, 6.7 Hz) 
 
3.30 (m, 2H) 
3.29 (ddd, J = 13.9, 11.3, 5.8 Hz) 
 
3.30 (m, 2H) 
2.92 (dddd, J = 16.9, 11.3, 6.7, 2.9 Hz, 1H) 
 
2.91 (m, 1H) 
2.69 (d, J = 16.8 Hz, 1H) 
 
2.64 (m, 3H) 
2.66 (bs, 1H) 
 
2.64 (m, 3H) 
2.60 (d, J = 16.8 Hz, 1H) 
 
2.64 (m, 3H) 
2.50 (m, 2H) 
 
2.46 (m, 2H) 
2.09 (dq, J = 15.1, 7.6 Hz, 1H) 
 
2.06 (m, 1H) 
1.81 (qt, J = 13.2, 3.9 Hz, 1H) 
 
1.72 (m, 2H) 
1.68 (dq, J = 14.7, 7.4 Hz, 1H) 
 
1.72 (m, 1H) 
1.51 (ddt, J = 13.6, 3.6, 1.9 Hz, 1H) 
 
1.50 (d, J = 13.7, 1H) 
1.42 (m, 1H) 
 
1.40 (m, 1H) 
1.05 (td, J = 13.6, 3.9 Hz, 1H) 
 
1.05 (dt, J = 13.5, 3.8 Hz, 1H) 
0.94 (t, J = 7.6 Hz, 3H) 
 
0.94 (t, J = 7.6 Hz, 3 H) 









(This research, 101 MHz) 
Synthetic Eburnamonine 
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(This research, 400 MHz) 
Synthetic O-methyleucophylline 
(Landais, 300 MHz) 
7.92 (d, J = 9.2 Hz, 1H) 7.91 (d, 1H, J = 9.3 Hz) 
 
7.27 (d, J = 2.6 Hz, 1H), 7.27 ( d, 1H , J = 2.7 Hz) 
 
7.03 (dd, J = 9.2, 2.6 Hz, 1H) 7.02 (dd, 1H , J = 2.7, 9.3 Hz) 
 
6.84 (ddt, J = 17.9, 11.6, 0.9 Hz, 1H) 6.83 (dd, 1H, J = 11.7, 18 Hz) 
 
5.84 (dd, J = 11.7, 1.8 Hz, 1H 5.83 (dd, 1H, J = 1.8, 11.7 Hz) 
 
5.54 (dd, J = 18.0, 1.8 Hz, 1H) 5.53 (dd, 1H, J = 1.8, 18 Hz) 
 
3.91 (s, 3H) 
 
3.90 (s, 3H),  
3.81 – 3.72 (m, 1H) 3.84-3.73 (m, 1H) 
 
3.18 (ddd, J = 13.5, 12.4, 3.7 Hz, 1H) 3.24-3.12 (m, 1H) 
 
3.07 (dd, J = 13.2, 2.1 Hz, 1H) 3.06 (dd, 1H, J = 1.8, 13.2 Hz), 
 
2.94 (ddd, J = 13.2, 3.0, 1.1 Hz, 1H) 2.93 (dd, 1H, J = 1.5, 13.2 Hz) 
 
2.72 (dt, J = 17.7, 1.3 Hz, 1H) 2.71 (d, 1H, J = 17.7 Hz), 
 
2.60 – 2.51 (m, 1H) 2.54 (dd, 1H, J = 1.5, 17.7 Hz) 
 
1.80-1.31 (m, 6H) 1.80-1.25 (m, 4H) 
 
“ 1.35 (q, 2H, J = 7.5 Hz), 
 
0.95 (t, J = 7.6 Hz, 4H). 0.94 (t, 3H, J = 7.5 Hz). 
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(This research, 101 MHz) 
Synthetic O-
methyleucophylline 
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THF, –78 → –30 °C
then
 allyl cyanoformate, 
–78 → 23 °C
Cs2CO3, EtI
CH2Cl2, 23 °C
Pd(OAc)2 (1 mol %)
XX (5 mol %)
















0 → 23 °C
then XX
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1. LiAlH4, Et2O, reflux
2. Boc2O, DMAP




































Pd(PhCN)2Cl2 (15 mol %)
CuCl2•2H2O (15 mol %)































69% yield, 2 steps 74% yield










79% yield 77% yield
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Figure A2.3. 13C NMR (101 MHz, CDCl3) of compound 303. 
 
Figure A2.2. Infrared spectrum (Thin Film, NaCl) of compound 303. 
 
























































































Figure A2.6. 13C NMR (101 MHz, CDCl3) of compound 304. 
 
Figure A2.5. Infrared spectrum (Thin Film, NaCl) of compound 304. 
 
























































































Figure A2.9. 13C NMR (101 MHz, CDCl3) of compound 284. 
 
Figure A2.8. Infrared spectrum (Thin Film, NaCl) of compound 284. 
 
























































































 Figure A2.12.13C NMR (101 MHz, CDCl3) of compound 286. 
Figure A2.11. Infrared spectrum (Thin Film, NaCl) of compound 286. 
 

























































































Figure A2.15. 13C NMR (101 MHz, CDCl3) of compound 300. 
 
Figure A2.14. Infrared spectrum (Thin Film, NaCl) of compound 300. 
 


























































































Figure A2.18. 13C NMR (101 MHz, CDCl3) of compound 306. 
 
Figure A2.17. Infrared spectrum (Thin Film, NaCl) of compound 306. 
 

























































































Figure A2.21. 13C NMR (101 MHz, CDCl3) of compound 301. 
 
Figure A2.20. Infrared spectrum (Thin Film, NaCl) of compound 301. 
 


























































































Figure A2.24. 13C NMR (101 MHz, CDCl3) of compound 307. 
 
Figure A2.23. Infrared spectrum (Thin Film, NaCl) of compound 307. 
 




























































































Figure A2.27. 13C NMR (101 MHz, CD3CN) of compound 308. 
 
Figure A2.26. Infrared spectrum (Thin Film, NaCl) of compound 308. 
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Figure A2.30. 13C NMR (101 MHz, CDCl3) of compound 314. 
 
Figure A2.29. Infrared spectrum (Thin Film, NaCl) of compound 314. 
 






























































































 Figure A2.33.13C NMR (101 MHz, CDCl3) of compound 315. 
 
Figure A2.32. Infrared spectrum (Thin Film, NaCl) of compound 315. 
 
































































































Figure A2.36. 13C NMR (101 MHz, CDCl3) of compound 261. 
 
Figure A2.35. Infrared spectrum (Thin Film, NaCl) of compound 261. 
 






























































































 Figure A2.39. 13C NMR (101 MHz, CDCl3) of compound 317b. 
 
Figure A2.38. Infrared spectrum (Thin Film, NaCl) of compound 317a. 
 





























































































Figure A2.42. 13C NMR (101 MHz, CDCl3) of compound 317b. 
 
Figure A2.41. Infrared spectrum (Thin Film, NaCl) of compound 317b. 
 

























































































Figure A2.45. 13C NMR (101 MHz, CDCl3) of compound 91. 
 
Figure A2.44. Infrared spectrum (Thin Film, NaCl) of compound 91. 
 



























































































Figure A2.48. 13C NMR (101 MHz, CDCl3) of compound 251. 
 
Figure A2.47. Infrared spectrum (Thin Film, NaCl) of compound 251. 
 



































































































 Figure A2.51. 13C NMR (101 MHz, CDCl3) of compound 92 and 93. 
 
Figure A2.50. Infrared spectrum (Thin Film, NaCl) of compound 92 and 93. 
 
























































































 Figure A2.54. 13C NMR (101 MHz, CDCl3) of compound 324. 
 
Figure A2.53. Infrared spectrum (Thin Film, NaCl) of compound 324. 
 



























































































Figure A2.57. 13C NMR (101 MHz, CD2Cl2) of compound 321. 
 
Figure A2.56. Infrared spectrum (Thin Film, NaCl) of compound 321. 
 






























































































Figure A2.60. 13C NMR (101 MHz, CDCl3) of compound 326. 
 
Figure A2.59. Infrared spectrum (Thin Film, NaCl) of compound 326. 
 



























































































Figure A2.63. 13C NMR (101 MHz, CD2Cl2) of compound 327. 
 
Figure A2.62. Infrared spectrum (Thin Film, NaCl) of compound 327. 
 
























































































Figure A2.66. 13C NMR (101 MHz, CDCl3) of compound 322. 
 
Figure A2.65. Infrared spectrum (Thin Film, NaCl) of compound 322. 
 





























































































Figure A2.69. 13C NMR (101 MHz, d6-DMSO) of compound 320. 
 
Figure A2.68. Infrared spectrum (Thin Film, NaCl) of compound 320. 
 






























































































Figure A2.72. 13C NMR (101 MHz, CDCl3) of compound 330. 
 
Figure A2.71. Infrared spectrum (Thin Film, NaCl) of compound 330. 
 































































































Figure A2.75. 13C NMR (101 MHz, CDCl3) of compound 329a. 
 
Figure A2.74. Infrared spectrum (Thin Film, NaCl) of compound 329a. 
 






















































































Figure A2.78. 13C NMR (101 MHz, CDCl3) of compound 329b. 
 
Figure A2.77. Infrared spectrum (Thin Film, NaCl) of compound 329b. 
 






























































































Figure A2.80. Infrared spectrum (Thin Film, NaCl) of compound 332. 
 
Figure A2.81. 13C NMR (101 MHz, CDCl3) of compound 332. 
 




























































































Figure A2.83. Infrared spectrum (Thin Film, NaCl) of compound 319. 
 
Figure A2.84. 13C NMR (101 MHz, CDCl3) of compound 319. 
 












































































































































































Figure A2.88. 13C NMR (101 MHz, CD2Cl2) of compound 340. 
 
Figure A2.87. Infrared spectrum (Thin Film, NaCl) of compound 340. 
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Figure A2.91. 13C NMR (101 MHz, CD2Cl2) of compound 342. 
 
Figure A2.90. Infrared spectrum (Thin Film, NaCl) of compound 342. 
 



























































































Figure A2.94 13C NMR (101 MHz, CDCl3) of compound 318. 
 
Figure A2.93. Infrared spectrum (Thin Film, NaCl) of compound 318. 
 

























































































Figure A2.97. 13C NMR (101 MHz, CDCl3) of compound 344. 
 
Figure A2.96 Infrared spectrum (Thin Film, NaCl) of compound 344. 
 






Progress toward a Convergent  
Total Synthesis of Leucophyllidine 
 
3.1  INTRODUCTION 
Having successfully completed the synthesis of both monomeric precursors, eburnamonine 
(91) and eucophylline (231), we then turned our attention toward the second phase of our synthetic 
endeavor: the convergent coupling and completion of the dimeric bisindole alkaloid 
leucophyllidine (230) (Scheme 3.1).1 As our long-term goal remained to develop a general strategy 
for the synthesis of other related natural products and synthetic analogues, we remained cognizant 
of the fact that the α-amino stereogenic center was a conserved motif at the site of 
heterodimerization; as such, the development of a generalizable coupling strategy that was reliant 
on reagent- or catalyst-control, rather than substrate-control, would have immense benefit if 
applied to future synthetic efforts.  
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Scheme 3.1. The divergent-convergent strategy to access leucophyllidine. 
 
At the onset of this project, we identified three broad coupling strategies that could 
potentially be exploited to access leucophyllidine (230). The first was a “biomimetic” Friedel-
Crafts acylation strategy from eburnamine (91) and eucophylline (231) directly (Scheme 3.2A); 
this would rely on an electrophilic aromatic substitution at C(6) of eucophylline into an in-situ 
generated iminium ion under acidic conditions to forge both the final C–C bond and stereogenic 
center of the natural product in a single operation. The second was a “bio-inspired” organometallic 
addition strategy from a metallated eucophylline-derivative and a masked eburnamine hemiaminal 
(Scheme 3.2B); this strategy would exploit reactive organometallic species generated at C(6) of 
eucophylline and add it into the eburnamine-derived iminium ion under Lewis acidic conditions. 
The third was a “transition metal-catalyzed” cross-coupling approach between an isolable 
eucophylline organometallic and an eburnamine-derived alkenyl electrophile (Scheme 3.2C). This 
would first involve a C(sp)2–C(sp)2 cross coupling to build the final C–C bond before a subsequent 
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3.2  BIOMIMETIC FRIEDEL-CRAFTS STRATEGY 
The first strategy we planned to investigate was a biomimetic Friedel-Crafts approach. We 
were encouraged by reports from Magnus2 and coworkers who successfully accessed the bisindole 
alkaloid norpleiomutine (10) from the component alkaloids kopsinine (87) and eburnamine (91) 
in aqueous acid (Scheme 3.3A). Though this strategy would be insufficient for a general coupling 
strategy, we predicted this would have the highest probability of success, while providing some 
information about the inherent reactivity of the substrates. Before we could test this hypothesis, 
however, the Panday group3 reported a failed biomimetic coupling of leucophyllidine, which 
generated C(8) coupling product 360 (Scheme 3.3B). As the authors attributed this regioselectivity 














































Strategy 1: “Biomimetic” Friedel-Crafts Acylation
Strategy 2: “Bio-inspired” Organometallic Addition
Strategy 3: “Transition-metal catalyzed” cross-coupling and reduction
R = -Me, -H
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Scheme 3.3. Literature precedent for biomimetic coupling approach. 
 
 
3.3  BIOINSPIRED ORGANOMETALLIC ADDITION STRATEGY 
 We subsequently turned our attention to the organometallic addition strategy. In order to 
investigate this reactivity while material access to monomeric subunits was limited, we developed 
model systems to investigate bond formation through this manifold. Following a procedure 
described by Wang,4 N-benzyl tryptamine 361 was condensed with α-ketoglutaric acid to promote 
a tandem Pictet-Spengler/lactamization sequence and afford tetracycle 362 in 89% yield (Scheme 
3.4). Hydrogenolysis of the benzyl protecting group generates secondary amine 363 before 
subsequent N-alkylation with n-propyl bromide affords eburnamonine model 364 which is then 
reduced to eburnamine model 365. A eucophylline model is accessed by condensation of our 





































B. Panday’s unsuccessful “biomimetic” coupling of leucophyllindine (2017)
A. Magnus’s acid-mediated “biomimetic” coupling of norpleiomutine (1985)
+
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Scheme 3.4. Synthesis of eburnamine and eucophylline model substrates. 
 
We were encouraged by a report from Movassaghi5 showing that alkaloid-derived iminium 
electrophiles (368 → 369, Scheme 3.5A) could be intercepted by a Grignard reagent to afford 
quaternary adduct  370 (Scheme 3.5A); however, as our desired iminium is enolizable, we 
surmised that milder, less basic organometallic reagents would be necessary to conduct the desired 
transformation. We were surprised to find few reports of organometallic additions into in-situ 
formed iminium ions, as the majority of reported examples required α-directing groups (e.g Petasis 
reactions)6 to promote this reactivity. However, we did find two accounts illustrating that 
organozinc reagents could perform the requisite addition in the presence of copper at room 
temperature (Scheme 3.5B)7 or in the absence of copper at elevated temperature (Scheme 3.5C).8 
Much to our delight, we found that phenylzinc bromide, generated through the cobalt-mediated 
procedure developed by Périchon (377 → 378),9 could effectively be added into model eburnamine 
365 to generate arylated product XX, albeit as a mixture of diastereomers (Scheme 3.5D). This 
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Scheme 3.5. Literature precedent and proof-of-principle experiment for bio-inspired strategy. 
 
Encouraged by this result, we then sought to investigate a coupling reaction that more 
closely represented out desired system. To avoid the need for excess organometallic reagent, we 
first sought to mask the hemiaminal with a different iminium surrogate. While O-methyl aminal 
379a formation could be conducted easily,10 we found that this intermediate rapidly decomposed 
while neat under vaccum (Table 3.1, entry 1); ethylation under phase transfer conditions11 afforded 
ethoxylated model 379b (entry 2) but with little improvement in stability. Gratifyingly, we found 
that the ethoxyethyl group 379c12 offered better stability at lower temperatures (entry 3). The 






























A. Movassaghi’s arylative dimerization of aspidosperma alkaloids (2012)
B. Le Gall’s Cu-catalyzed organozinc addition to iminiums (2006)
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proved to be too stable and any attempts to remove the cyano group in the presence of Lewis acids 
and silver salts were ultimately unsuccessful.  
Table 3.1. Protection of the eburnamine model hemiaminal. 
 
We then turned to formation of the organozinc reagent from model bromide 367 using an 
iodine quench to quantify the active amount of organometallic species (as iodide 380), 
protodemetallation (as iodide 381), and recovered starting material 365.14 Using previously 
implemented cobalt conditions9 led to modest conversions (Table 3.2, entry 1), while Périchon’s 
second generation conditions15 (entry 2) effected an increase in zincation and protohalogenation. 
Reike zinc16 (entry 3) lead to limited yield while lithiation-transmetallation17 (entry 4) resulted in 
complete protodemetallation. Returning to the cobalt conditions, increasing the temperature lead 
to greater rates of zincation (entry 5), and doubling the catalyst loading improved our ideal 
conversion to 86% (entry 6). 
With individual conditions for nucleophile and electrophile optimized, we turned our 
attention to coupling the two fragments. Despite an extensive screen of parameters including 
solvent mixtures, copper catalysts, and Lewis acids, the desired coupling product XX was not 














1 PPTS, MeOH, reflux – Decomposes neatMe
2 TBAI, EtI, PhH/NaOH (aq), 23 °C – Decomposes neatEt
3 TBAB, MeOCH2CH2Br, PhH/NaOH(aq), 23 °C 71% Stable at –20 °CEtOCH2CH2O
4 TMSCN, BF3•OEt2, CH2Cl2, –78 °C 85%Me
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hindered, which caused the α-deprotonation pathway to outcompete the corresponding 1,2-
addition. Discouraged by these results, we elected not to investigate further. 
Table 3.2. Synthesis of organozinc coupling partner.  
 




then I2, in THF
Entry Conditions
CoBr2 (10 mol %), ZnBr2 (10 mol %) PhBr (10 mol %) 

























*Relative conversion, monitored by integration of 254 nm peak on LCMS, which roughly correlates to the distribution of 













CoBr2 (5 mol %), AllylCl (15 mol %)  
Zn (3 equiv), MeCN/TFA (400:1), 23 °C, 3 h
Reike Zn (5 equiv) 
THF, 23 → 65 °C, 3 h
n-BuLi, THF, -78°C, 1 h 
then ZnCl2, –78 → 0 °C, 3 h
CoBr2 (10 mol %), ZnBr2 (10 mol %) PhBr (10 mol %) 
Zn (3 equiv), MeCN/TFA (400:1), 80 °C, 1.5 h
CoBr2 (20 mol %), ZnBr2 (20 mol %) PhBr (20 mol %) 











CoBr2 (20 mol %) 
ZnBr2 (20 mol %) 
PhBr (20 mol %) 
Zn0 (3 equiv) 
MeCN/TFA (400:1)
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3.4  TRANSITION METAL-CATALYZED CROSS-COUPLING STRATEGY 
3.4.1 Suzuki Couplings 
 After evaluating the organometallic addition strategy with no success, we turned our 
attention to transition metal-catalyzed cross-coupling strategy. First, we attempted to investigate 
Suzuki coupling conditions due to their established history of success with highly functionalized 
substrates.18 Eburnamonine (91) was easily advanced to the corresponding trifloxyenamine 385 
under optimized conditions for lactam-derived enolates19 (Scheme 3.7A), but attempts to conver 
this to a boronic ester,20 and later a stannane at this position using Pd-catalysis led to complex 
mixtures of products, which we hypothesize is due to severe steric hindrance imposed by the 
benzenoid ring of the indole motif. 
Scheme 3.7. Attempted synthesis of Suzuki coupling partners. 
 
We then elected to install the organometallic handle on the eucophylline-derived fragment. 














































A. Synthesis of eburnamonine-derived triflate
B. Attempted Lithiation-borylation of eucophylline coupling partner










387, X = B(OH)2
389, X = Bpin
Me Me
Me Me
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boronic acid 387, leading only to proto-dehalogenation, as was observed in our aforementioned 
zincation attempts (Scheme 3.7B); we attribute this challenge to likely formation of aryne 
intermediate 388 which competes with the exchange process.21 While Miyaura borylation22 did 
lead to high conversion and significant amount of ester 389, we found that this intermediate was 
unstable to purification, and a significant amount of hydrolyzed boronic acid 387 and 
protodeboronated product was observed via LCMS (Scheme 3.7C). We attribute this 
decomposition to the formation of internal hydrogen bonding with the ortho-methoxy group in 
390, contributing to the build-up of negative charge at quinoline C(6) and boron, which resulted 
in ipso protonation and hydrolysis, respectively.23 
Table 3.3. Optimization of one-pot Miyaura borylation/Suzuki coupling. 
 
 To avoid these isolation issues, we explored a one-pot Miyaura borylation/Suzuki coupling. 



















K2CO3 (anhydrous), 16 h
Condition 2
Modifications
Na2CO3 (anhydrous), 16 h
DMF/H2O (10:1), 16 h
Standard
Cs2CO3 (anhydrous), 16 h
K3PO4 (anhydrous), 16 h










10 “ Et3N (anhydrous), 16 h 0%
* HPLC yields calculated using 2,3,5,6-tetrachloronitrobenzene as an internal standard.
“
Slow decomposition of coupling partners
“





3 “ NMP/H2O (4:1), 16 h 20% “









Pd(dppf)Cl2 • CH2Cl2 (10 mol%)
B2pin2 (1.1 equiv), KOAc (3.0 equiv)
DMF, 90 °C, 4h;
then Na2CO3 (5.0 equiv), 385
DMF/H2O (4:1), 40 °C, 30 min
Me
Me
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followed by the addition of aqueous base and triflate 385 to afford the cross-coupled product in 
24% yield (Table 3.3, entry 1). The remainder of mass balance returned as protodeborylated 
nucleophile 344 and hydrolyzed triflate in the form of eburnamonine (91). Decreasing the 
DMF/water ratio lead to a slight decrease in yield (entry 2). While other polar aprotic solvents led 
to comparable yields (entry 3–4), less polar solvents such as THF and toluene decreased the 
efficiency of the borylation. Attempts to use anhydrous sodium carbonate slowed both the 
decomposition and cross coupling pathways (entry 5). Use of other stronger inorganic bases (entry 
6–8), non-basic fluoride (entry 9), and organic base (entry 10) drastically hindered reactivity in 
almost all cases, causing rapid decomposition of the triflate electrophile.  
 
3.4.2 Stille Couplings 























Ni(OAc)2•4H2O (10 mol %)
Zn (10 mol %), COD (10 mol %)
LiBr (1.5 equiv)
THF/DMA (3:1), 23 °C, 2 h
Ni(COD)2 (10 mol %)
NaI (1.5 equiv)














A. Synthesis of eucophylline-derived stannane
B. Synthesis of eburnamonine-derived halides using Ni-catalyzed triflate/halogen exchange
Me Me
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 Disappointed by this unsuccessful optimization, we turned our attention to Stille couplings. 
Stannylation of bromide 318 afforded trimethylstannane 391 in good yield (Scheme 3.8A). Around 
this time, we became aware of research by Reisman and coworkers24 detailing the conversion of 
alkenyl triflates into their cooresponding halides under Ni-catalysis; gratifyingly, conditions using 
Ni(II) and Ni(0) precatalysts were applied to access both the vinyl bromide 392 and vinyl iodide 
393 in moderate yield (Scheme 3.8B). 
Table 3.4. Optimization of Stille Coupling.  
 
 Turning to our key cross-coupling event, we were disappointed to find canonical Stille 
conditions with triflate 385 in 1,4-dioxane produced little to no cross-coupled product 386 (Table 
3.4, entry 1–3). Implementing Farina’s conditions25 in DMF, we were delighted to observe a boost 
in cross-coupling product (entry 4), though LCMS analysis suggested that methyl transfer from 
the stannane was competitive with aryl transfer of sterically encumbered fragment. To circumvent 
this problem, we investigated copper additives and were delighted to see that use of CuCl26 and 






Pd(PPh3)2Cl2 (10 mol%), 1,4-dioxane, 90 °C
Pd(PPh3)4 (10 mol%), LiCl (4 equiv), 1,4-dioxane, 100 °C
Pd(PPh3)4 (10 mol %), CuI (8 mol %), LiCl (4 equiv), dioxane, 100 °C










Pd(PPh3)4 (10 mol %), CuTC (1.5 equiv), NMP, 23 °C
CuTC (1.5 equiv), NMP, 23 °C












9 < 5%Br Pd2(dba)3 (1 mol %), P(t-Bu)3 (2 mol %), CsF (2 equiv) NMP, 80 °C
* Yields recorded by 1H NMR with 2,3,5,6-tetrachloronitrobenzene as an internal standard
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vinyl iodide electrophile 393 (entry 7), we found that background coupling reactions proceeded in 
the absence of palladium at greatly decreased yield.28 With the vinyl bromide 392, we attempted 
conditions described by Buchwald29 (entry 8) and Fu30 (entry 9), but no reactivity could be 
observed in these cases.    
 
3.5  INVESTIGATION OF TRISUBSTITUTED OLEFIN REDUCTION 
Scheme 3.9. Preparative Stille coupling with vinyl stannane. 
 
 With optimized conditions in hand, we demonstrated that the Stille coupling could be 
performed on preparative scale by decreasing CuTC loading and using a slight excess of triflate 
385,31 accessing sufficient quantities of our cross-coupled product 386, which we termed O-
methyldehydro-leucophyllidine (Scheme 3.9). We hypothesized that the enamine-like 
trisubstituted olefin could be reduced selectively over the monosubstituted vinyl group using 
reductive amination-type conditions to leverage the electron-rich nature of the N-substituted 
alkene. However, we were disappointed to observe quantitative reduction of the exocyclic olefin, 










Pd(PPh3)4 (10 mol %)
CuTC (1.1 equiv)
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vinylpyridines are active conjugate acceptors for a variety of soft nucleophiles32 and are frequently 
exploited in polymerization processes.33 Attempts to over-reduce to O-methyl dihydro-
leucophyllidine 395 were unsuccessful, indicating that chemoselective olefin differentiation was 
not likely a viable approach to the desired natural product. 
Scheme 3.10. Preparative Stille coupling with formyl stannane. 
 
 To circumvent this issue, we advanced aldehyde 342 to the corresponding 
trimethylstannane 396 (Scheme 3.10). We observed an improvement in the yield of coupling 
product 397, which we attribute to two principle factors: 1) a greater electron-withdrawing 
influence of the formyl substituent improves transmetallation rates with CuTC to decrease the 
formation of homocoupled byproducts; 2) undesired decomposition pathways due to the presence 
of the vinylpyridine motif, which led to minor amounts of decomposition observed in acidic 





















Pd(PPh3)4 (10 mol %)
CuTC (1.1 equiv)















342       R = Br
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H2 (60 atm), 10% Pd/C, EtOAc, 23°C, 24 h
8
HCHO (6.5 equiv), 10% Pd/C, MeOH/DMF (7:1), 23 to 50 °C
9
NH4HCHO, 10% Pd/C, EtOH, 80 °C, 10 min
10
Raney Ni (20 wt equiv), i-PrOH/H2O (10 : 1), 80 °C,
H2 (10 atm), 5% Rh/C, MeOH, 23°C, 24 h
H2, (1 → 50 bar) [Ir(COD)pyr(PCy3)]PF6, CH2Cl2, 23 °C, 12 h
H2, (1 → 50 bar) [Ir(COD)pyr(PCy3)]BArF, CH2Cl2, 23 °C, 12 h








Complex MixtureH2, (1 → 50 bar), Ir(COD)Cl2 (1 mol %), I2 (20 mol %), CH2Cl2, 23 °C
Complex mixture





Md(dpm)3 (20 mol %), PhSiH3 3 equiv), TBHP (3 equiv), i-PrOH
Fe(acac)3 (10 equiv), PhSiH3 (25 equiv), EtOH, 60 °C
Aldehyde reduction
Aldehyde reduction
Complex mixtureCo(acac)2, Et3SiH (100 equiv), 1,4-CHD (100 equiv), n-PrOH, 40 °C
Fe(acac)2•6H2O, NaBH4, TFE/H2O (1:300) Aldehyde reduction
18
19
DecompositionLi(0), NH3, THF, –78 °C
Na–SG, THF, 23 °C, then MeOH No reaction




BH3 • THF, Magic Blue, CH2Cl2, 0 to 23 °C Epimerization
Aldehyde reductionNaBH3CN, HCl/MeOH, 23 to reflux


































* Test reactions run with 1.0 mg of aldehyde XX and observed by LCMS.
21 No reactionSmI2, H2O, THF, 23 °C
397 398
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With our key substrate in hand, we then turned our attention to the final diastereoselective 
hydrogenation. Homogeneous hydrogenation (Table 3.5, entry 1–6) quickly caused an undesired 
reduction, likely of the aldehyde motif, while a deoxygenation occured upon use of acid additives 
(formic acid, entry 3)34 or more active catalysts (Raney Ni, entry 6).35 Alternative transfer 
hydrogenations (entry 4) and platinum catalysts (entry 5) led to complex mixtures, likely due to 
additional reduction of the heterocyclic motifs. Homogeneous hydrogenation (entry 7–10) with 
iridium36 or nickel-37 based catalysts were also unsuccessful, which we attributed to catalyst 
poisoning by the basic amines. 
 Moving away to non-hydrogenation approaches, we found that attempts to use 
hydroboration/protonation (entry 11), reductive amination (entry 12), or in-situ formed metal 
hydrides (entry 13) were likewise unsuccessful. Shifting to single electron reductants, we were 
disappointed to see that hydrogen atom transfer reductions described by Shenvi,38 Baran,39 
Herzon,40 and Boger41 (entry 14–17) all failed to reduce the olefin despite their established 
effectiveness in the reduction of highly substituted olefins. Dissolving metal reduction42 (entry 18) 
led to rapid overreduction, while milder silica-supported reductants (entry 19) led to complete 
recovery of starting material. Finally, samarium-based reductions led once again to either 
deoxygenation (entry 20) or no reaction43 (entry 21) based on additive. 
 
3.6  DFT MODELING OF CROSS-COUPLING SUBSTRATE 
Puzzled by this lack of reactivity, we elected to model formyl substrate 397 
computationally using density functional theory (DFT) to investigate the nature of this recalcitrant 
olefin. Our calculations revealed two major atropisomers with respect to the central C–C bond, 
corroborating our observed experimental results by NMR (Figure 3.1). Relaxed surface scans 
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along the biaryl dihedral offer an initial estimation to the rotational barrier of 12.6 kcal mol-1, and 
the “MeO-up” atropisomer 0.6 kcal mol-1 (gas phase) is slightly lower in energy. 
Figure 3.1. DFT models of Stille coupling product. 
 
In these models, we observed two unexpected phenomena. The first is that the trisubstituted 
olefin lies slightly out of conjugation with the π-system of the indole ring, as observed in Newman 
projections 397a–I and 397b–I. The strain of the lactam-derived ring, due to the rigid 
conformation of the eburnan monomer and presence of the bulky eucophylline substituent, forces 
the two carbons of the “enamine” olefin to buckle, thus deactivating the alkene and contributing 
to the lack of expected reactivity. The second observation is that the piperidine ring of the eburan 
monomer adopts a boat-like configuration in both the lowest energy conformations 397a–II and 
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we were concerned that hydrogenation would be preferred from the α-face due to the concave 
nature of the cis-ring fusion, the boat-configuration opens up the desired face of reduction while 
creating an unfavorable flagpole interaction on the undesired face. Furthermore, the close 
proximity of the quinoline C(7) methoxy group in the 397b–II configuration suggests that, 
following demethylation, this oxygen could be used to direct hydrogenation from the desired face, 
thus setting the correct diastereomer. 
 
3.7  FUTURE DIRECTIONS AND CONCLUDING REMARKS 
To complete the synthesis of leucophyllidine (230), our strategy moving forward is to apply 
a directed hydrogenation approach to install the final stereogenic center of leucophyllidine. Given 
the facile reduction of the formyl group, we first protected it with ethylene glycol to ketal 401, 
then demethylated to afford the hydrogenation precursor 402, albeit in low yield over two steps. 
We plan to investigate a number of hydrogenation catalysts to access reduced product 403. Of 
particular interest are Ir-based Crabtree-Pfaltz catalysts36a in the presence of acid to prevent 
poisoning by the substrate’s tertiary amines,44 Rh/phosphines due to success in similar reports by 
Amgen in phenol-directed hydrogenations,45 and organocatalytic transfer hydrogenations.46 If the 
appropriate stereochemistry can be set, only ketal deprotection to aldehyde XX and methylenation 
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Scheme 3.11. Endgame strategy. 
 
 In conclusion, we have developed a highly convergent Stille coupling to cross-couple the 
eburnamine and eucophylline-derived fragments to install the full carbocyclic skeleton of 
leucophyllidine. Initial attempts to forge the key C–C bond and stereogenic center using 
biomimetic and bio-inspired strategies were unsuccessful in model systems. A challenging 
hydrogenation currently prohibits us from completing the natural product. Nevertheless, we 
believe that use of an intramolecular directing group will ultimately help us to achieve the synthesis 
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3.8   EXPERIMENTAL SECTION 
3.8.1   Materials and Methods 
Unless otherwise stated, reactions were performed in flame-dried glassware under an argon 
or nitrogen atmosphere using dry, deoxygenated solvents. Solvents were dried by passage through 
an activated alumina column under argon.1 Reaction progress was monitored by thin-layer 
chromatography (TLC) or Agilent 1290 UHPLC-LCMS. TLC was performed using E. Merck 
silica gel 60 F254 precoated glass plates (0.25 mm) and visualized by UV fluorescence quenching, 
p-anisaldehyde, CAM, or KMnO4 staining. Silicycle SiliaFlash® P60 Academic Silica gel 
(particle size 40–63 nm) was used for flash chromatography. 1H and 13C NMR spectra were 
recorded on a Varian Inova 500 (500 MHz and 126 MHz, respectively) and a Bruker AV III HD 
spectrometer equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 MHz and 101 
MHz, respectively) and are reported in terms of chemical shift relative to CHCl3 (δ 7.26 and δ 
77.16, respectively) and C6D6 (δ 7.16 and δ 128.06, respectively). Data for 1H NMR are reported 
as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities 
are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = septuplet, 
m = multiplet, br s = broad singlet, br d = broad doublet, br t = broad triplet, app = apparent. Some 
reported spectra in chloroform include minor solvent impurities of water (δ 1.56ppm), ethyl acetate 
(δ 4.12, 2.05, 1.26 ppm), methylene chloride (δ 5.30 ppm), acetone (δ 2.17 ppm), grease (δ 1.26, 
0.86 ppm), and/or silicon grease (δ 0.07 ppm), which do not impact product assignments.2 Data for 
13C NMR are reported in terms of chemical shifts (δ ppm). IR spectra were obtained by use of a 
Perkin Elmer Spectrum BXII spectrometer using thin films deposited on NaCl plates and reported 
in frequency of absorption (cm-1). Optical rotations were measured with a Jasco P-2000 
polarimeter operating on the sodium D-line (589 nm), using a 100 mm path-length cell, and are 
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reported as [α] T (concentration in g/100 mL, solvent). Analytical SFC was performed with a 
Mettler SFC supercritical CO2 analytical chromatography system utilizing Chiralpak OD-J column 
(4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd. High resolution mass spectra 
(HRMS) were obtained from the Caltech Mass Spectral Facility using a JEOL JMS-600H High 
Resolution Mass Spectrometer in fast atom bombardment (FAB+) or electron ionization (EI+) 
mode, or Agilent 6200 Series TOF with an Agilent G1978A Multimode source in mixed ionization 
mode (MM: ESI/APCI). Reagents were purchased from Sigma-Aldrich, Acros Organics, Strem, 
or Alfa Aesar and used as received unless otherwise stated. Copper (I) thiophene carboxylate was 
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3.8.2   Experimental Procedures 
 
Lactam 362: Following the procedure described by Wang, to a 1L round-bottom flask equipped 
with stir bar was added N-benzyltryptamine 361 (6.25g, 25.0 mmol, 1.0 equiv), α-ketoglutaric acid 
(5.11g, 35.0 mmol, 1.4 equiv), benzene (340 mL), and 1,4-dioxane (225 mL). The flask was 
equipped with a Dean-Stark apparatus and heated to 100 °C for 4 days.  
After completion, the flask was cooled to room temperature, diluted with ethyl acetate, and 
washed successively with saturated sodium bicarbonate, water, and brine. The organics were dried 
with ethyl acetate, and concentrated in vacuo to afford tetracycle 362 a green solid (7.03g, 89% 
yield). The material is carried forward without further purification. Characterization data are in 
accordance with published values.4	
 
 
Model lactam 364: To a flame dried 100-mL flask with stir bar was charged lactam 362 (1.0 g, 
3.16 mmol, 1.0 equiv) in trifluoroethanol (32 mL). The headspace was evacuated and backfilled 














36468% yield, 2 steps
1. H2, Pd/C 
   TFE, 23 °C, 16 h
2. n-PrBr, K2CO3, KI
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single portion. The headspace was then evacuated and backfilled with hydrogen gas (3X) before 
the flask was stirred for 16 hours.  
Following completion, as determined by LCMS analysis, the solution was sparged with 
nitrogen gas for five minutes. The reaction mixture was then filtered through a pad of Celite, 
washing the filter cake with methanol. The combined organics were then concentrated in vacuo to 
afford a green, amorphous solid. The product was used directly in the next reaction without further 
purification. 
To a separate, flame-dried 100-mL flask with stir bar was added the crude starting material 
in DMF (15 mL), potassium iodide (786 mg, 4.74 mmol, 1.5 equiv), and potassium carbonate (1.31 
g, 9.48 mmol, 3.0 equiv). The reaction mixture was stirred at 23 °C for five minutes before n-
propyl bromide (0.43 mL, 4.74 mmol, 1.5 equiv) was added dropwise. The reaction mixture was 
heated to 50 °C for 16 hours.  
Following completion, as determined by LCMS analysis, the reaction mixture was cooled 
to room temperature and diluted with ethyl acetate. The organic layer was washed sequentially 
with water (1X) and brine (1X), dried with sodium sulfate, and concentrated in vacuo. Flask 
column chromatography (50% → 100% ethyl acetate/hexanes) afforded model lactam 364 (580 
mg, 68% yield as a white, amorphous solid. 1H NMR (400 MHz, CDCl3) δ 8.41 – 8.33 (m, 1H), 
7.44 – 7.36 (m, 1H), 7.33 – 7.22 (m, 2H), 3.46 (ddt, J = 12.0, 4.9, 2.7 Hz, 1H), 3.34 (ddd, J = 11.7, 
6.0, 1.3 Hz, 1H), 2.90 – 2.80 (m, 3H), 2.79 – 2.65 (m, 2H), 2.59 (td, J = 11.6, 4.4 Hz, 1H), 2.47 – 
2.36 (m, 2H), 1.80 (dtd, J = 13.6, 12.2, 4.3 Hz, 1H), 1.71 – 1.50 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H).; 
13C NMR (101 MHz, CDCl3) δ 168.3, 135.0, 134.9, 129.5, 124.5, 124.0, 118.2, 116.3, 113.5, 56.9, 
55.2, 50.2, 33.1, 27.4, 21.6, 20.1, 12.1; IR (neat film, NaCl) 2961, 2801, 1708, 1456, 1385, 1362, 
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1329, 1344, 750 cm-1 (Neat Film, NaCl); HRMS (ESI/APCI) m/z calculated for C17H21N2O [M + 
H+]: 269.1654, found, 269.1669. 
 
 
Model hemiaminal XX: To a flame-dried 100-mL flask with stir bar was added lithium aluminum 
hydride (358 mg, 9.44 mmol, 2.0 equiv) and THF (24 mL) at 0 °C. In a separate flask, eburnan 
model XX (1.27 g, 4.72 mmol, 1.0 equiv) was dissolved in THF (23 mL) and cooled to 0 °C. The 
starting material was added to the flask dropwise via cannula over 10 minutes, and the reaction 
mixture was allowed to stir at 0 °C for 35 additional minutes. 
After the reaction was complete, as determined by TLC, the reaction was quenched with 
cool brine, transferred to a separatory funnel, and extracted with ethyl acetate (3X). The combined 
organics were washed once with cool brine, dried with sodium sulfate, and concentrated in vacuo. 
Flash column chromatography (50% → 100% ethyl acetate/hexanes) afforded a mixture model 
hemiaminal XX epimers (1.02 g, 80% yield, 17.5:1 d.r.) as a white, amorphous solid. The ratio of 
major and minor diastereomers was determined by integration of the diagnostic peaks in the 1H 
NMR for and 5.41 and 5.95, respectively.  
Major diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.68 – 7.58 (m, 1H), 7.50 – 7.42 (m, 1H), 7.21 
– 7.08 (m, 2H), , 5.41 (dd, J = 9.2, 5.6 Hz,), 3.25 (tdd, J = 11.0, 5.2, 1.7 Hz, 2H), 2.93 – 2.62 (m, 
4H), 2.61 – 2.50 (m, 1H), 2.49 – 2.37 (m, 1H), 2.32 (ddd, J = 12.7, 9.7, 5.0 Hz, 1H), 2.15 (dtd, J 
= 12.3, 4.6, 2.9 Hz, 1H), 1.72 – 1.45 (m, 3H), 1.35 – 1.14 (m, 1H), 0.92 (t, J = 7.4 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 138.0, 135.7, 128.3, 121.6, 120.3, 118.2, 112.0, 107.3, 78.9, 58.1, 55.0, 
36580% yield, 17.5:1 d.r.
LiAlH4
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50.4, 33.4, 26.1, 21.7, 19.9, 12.2. IR (Neat Film, NaCl); HRMS (ESI/APCI) m/z calculated for 
CXHXNXOX [M + H+]: C17H23N2O, found, YYY. 
 
 
Aminal 379a: To a flame-dried, one-dram vial with stir bar was added hemiaminal model 365 
(27.0 mg, 0.10 mmol, 1.0 equiv), pyridinium p-toluenesulfonate (2.5 mg, 0.010 mmol, 0.10 equiv) 
and methanol (0.2 mL). The vial was sealed and heated to reflux for 16 hours. Upon completion, 
the reaction mixture was cooled to room temperature, diluted with ethyl acetate, filtered through a 
plug of Celite, and concentrated in vacuo. Preparative TLC (50% ethyl acetate/hexanes) affords 
aminal 379a as a colorless oil. Product characterization data was not obtained due to the Spring 
2020 COVID-19 shutdown of research facilities. 
 
 
Aminal 379b: To a 25 mL round-bottom flask with stir bar was added hemiaminal model 365 
(108 mg, 0.4 mmol, 1.0 equiv) and toluene (10 mL) and 50% aqueous NaOH (10 mL). 
Tetrabutylammonium iodide (664 mg, 1.8 mmol, 4.5 equiv) was added in a single portion before 
and the biphasic mixture was rapidly stirred for 10 minutes. Ethyl iodide (2.17 mL, 27.2 mmol, 68 























Chapter 3: Progress toward a Convergent Total Synthesis of Leucophyllidine 228 
The reaction mixture was diluted with diethyl ether and transferred to a separatory funnel. 
The organic layer was washed with water (3X) and brine (3X), dried with sodium sulfate, and 
concentrated in vacuo. Flash column chromatography on silica gel (0 →  40 → 50% ethyl 
acetate/hexanes) afforded aminal 379c (56.0 mg, 47% yield) as a colorless oil. Product 




Aminal 379c: To a 25 mL round-bottom flask with stir bar was added hemiaminal model 365 (108 
mg, 0.4 mmol, 1.0 equiv) and toluene (10 mL) and 50% aqueous NaOH (10 mL). 
Tetrabutylammonium iodide (664 mg, 1.8 mmol, 4.5 equiv) was added in a single portion before 
being cooled to 0 °C and rapidly stirred for 10 minutes. 2-bromoethyl ethyl ether (3.96 mL, 28 
mmol, 70 equiv) was added dropwise and the reaction was slowly warmed to 23 °C for 16 hours.  
The reaction mixture was diluted with diethyl ether and transferred to a separatory funnel. 
The organic layer was washed with water (3X) and brine (3X), dried with sodium sulfate, and 
concentrated in vacuo. Flash column chromatography on silica gel pre-treated with 0.5% 
triethylamine/hexanes (0 → 30 → 40 → 50% ethyl acetate/hexanes) afforded aminal 379c (97.2 
mg, 71% yield) as a colorless oil which was stored in a –20 °C freezer to avoid decomposition. 
Major Diastereomer: 1H NMR (400 MHz, CD2Cl2) δ, 7.50 – 7.36 (m, 2H), 7.19 – 7.04 (m, 2H), 
5.50 (dd, J = 8.1, 5.6 Hz, 1H), 3.79 – 3.55 (m, 3H), 3.54 – 3.23 (m, 5H), 2.93 – 2.74 (m, 2H), 2.73 
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1.50 (m, 2H), 1.42 – 1.26 (m, 1H), 1.18 (dt, J = 18.2, 7.0 Hz, 3H), 0.94 (td, J = 7.4, 5.6 Hz, 3H). 
13C NMR (101 MHz, CD2Cl2) δ 137.9, 136.4, 128.0, 121.1, 119.8, 117.8, 111.5, 107.1, 83.7, 69.8, 
66.5, 63.9, 57.6, 55.0, 50.2, 27.7, 25.7, 21.8, 20.1, 15.0, 11.8. 
Minor Diastereomer: 1H NMR (400 MHz, CD2Cl2) δ 7.60 (ddd, J = 8.0, 1.4, 0.8 Hz, 2H), 7.19 – 
7.04 (m, 2H), 5.66 (dd, J = 3.0, 2.1 Hz, 1H), 3.79 – 3.55 (m, 3H), 3.54 – 3.23 (m, 5H), 2.93 – 2.74 
(m, 2H), 2.73 – 2.63 (m, 1H), 2.55 (td, J = 11.5, 4.4 Hz, 1H), 2.43 – 2.28 (m, 2H), 2.17 – 1.99 (m, 
2H), 1.84 – 1.70 (m, 1H), 1.68 – 1.50 (m, 1H), 1.42 – 1.26 (m, 1H), 1.18 (dt, J = 18.2, 7.0 Hz, 3H), 
0.94 (td, J = 7.4, 5.6 Hz, 3H). 13C NMR (101 MHz, CD2Cl2) δ 136.8, 136.4, 128.4, 120.8, 119.8, 
118.0, 110.9, 107.1, 81.3, 70.0, 67.7, 66.5, 58.6, 55.0, 50.8, 27.1, 25.7, 21.5, 20.0, 15.0, 11.8. 
Combined: IR (Neat Film, NaCl): 2959, 2866, 2800, 1458, 1345, 1309, 1159, 1120, 743 cm-1. 




Aminonitrile 379d: To a flame-dried one-dram vial with stir bar was added hemiaminal 365 (30 
mg, 0.111 mmol, 1.0 equiv) in dichloromethane (1.1 mL). The vial was cooled to –78 °C before 
trimethylsilyl cyanide (21.1 µL, 0.167 mmol, 1.5 equiv) and boron trifluoride diethyl etherate (21.0 
µL, 0.167 mmol, 1.5 equiv) were successively added. The cooling bath was removed and the vial 
was allowed to warm to 23 °C over 1.5 hours. 
 After the reaction was complete, the solution was quenched with saturated sodium 
bicarbonate solution and extracted with dichloromethane (3X). The combined organic extracts 
85% yield
TMSCN, BF3•OEt2
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were dried with sodium sulfate and concentrated in vacuo. Flash column chromatography (30% 
→ 40% ethyl acetate/hexanes) afforded aminonitrile 379d (26.8 mmol, 85% yield) as an 
amorphous white solid. Product characterization data was not obtained due to the Spring 2020 
COVID-19 shutdown of research facilities. 
	
 
Bromoquinoline 367: To a 100-mL round-bottom flask equipped with stir bar was added aldehyde 
322 (1.20 g, 5.2 mmol, 1.0 equiv), absolute ethanol (17.8 mL), and cyclohexanone 366 (0.59 mL, 
5.7 mmol, 1.1 equiv). Powdered potassium hydroxide (350 mg, 6.3 mmol, 1.2 equiv) was added 
in one portion. The flask was fitted with a reflux condenser and heated to reflux for 30 minutes. 
Following the completion of the reaction, the flask was cooled to room temperature, filtered 
through Celite (washing the cake with absolute ethanol), and concentrated in vacuo. The crude 
mixture was purified by flash column chromatography (40% ethyl acetate/hexanes) to afford 
bromoquinoline 367 (1.34 g, 88% yield) as a light brown, amorphous solid. 1H NMR (500 MHz, 
CD3OD) δ 8.02 (s, 1H), 7.85 (s, 1H), 7.29 (s, 1H), 4.00 (s, 3H), 3.04 (t, J = 6.5 Hz, 2H), 2.98 – 
2.94 (m, 2H), 2.02 – 1.96 (m, 2H), 1.93 – 1.86 (m, 2H); 13C NMR (126 MHz, CD3OD) δ 161.0, 
157.7, 147.7, 136.1, 132.2, 131.2, 124.6, 114.3, 107.0, 56.9, 33.9, 29.8, 24.0, 23.9; IR (Neat Film, 
NaCl) 2937, 2862, 1614, 1599, 1481, 1454, 1361, 1318, 1318, 1240, 1205, 1040, 838 cm-1; HRMS 
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Iodoquinoline 380: To an oven-dried 1-dram vial with stir bar was added bromide 367 (100 mg, 
0.33 mmol, 1.0 equiv), potassium iodide (846 mg, 5.1 mmol, 15.0 equiv), and copper (I) iodide 
(323 mg, 1.7 mmol, 5.0 equiv). The vial was evacuated and backfilled with nitrogen three times 
before HMPA (1.0 mL) was added to the solution. The vial was heated to 150 °C for 3 hours.  
The reaction mixture was transferred to a 20-mL scintillation vial and diluted with 1M HCl 
until homogeneous. The solution was then basified with 1 M NaOH and extracted with ethyl 
acetate (5X). The combined organic extracts were washed with brine, dried with sodium sulfate, 
and concentrated in vacuo. Flash column chromatography (25% → 30% → 40% ethyl 
acetate/hexanes) afforded iodoquinoline 380 (71 mg, 61% yield) as a light brown solid. 1H NMR 
(400 MHz, (1.34 g, 88% yield)) δ 8.17 (s, 1H), 7.62 (d, J = 1.2 Hz, 1H), 7.27 (s, 1H), 3.98 (s, 3H), 
3.07 (t, J = 6.5 Hz, 2H), 2.98 – 2.88 (m, 2H), 2.02 – 1.94 (m, 2H), 1.91 – 1.84 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 160.2, 157.4, 147.8, 137.6, 133.6, 129.4, 123.9, 106.5, 87.4, 56.5, 33.6, 29.1, 
23.2, 22.9. IR (Neat film, NaCl) 2933, 1858, 1611, 1593, 1473, 1452, 1407, 1316, 1238, 1207, 












HMPA, 150 °C, 3 h
380
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Quinoline 381: To a flame-dried, 25-mL round-bottom flask with stir bar was added 
bromoquinoline 367 (146 mg, 0.5 mmol, 1.0 equiv) and THF (5.0  mL). The flask was cooled to 
–78 °C and n-BuLi (0.26 mL, 2.3 M, 1.2 equiv) was added dropwise, turning the solution from 
colorless to red. The reaction mixture was stirred at that temperature for an additional ten minutes. 
Saturated aqueous ammonium chloride (2.0 mL) was then added and the reaction was warmed to 
room temperature over 20 minutes. 
 The reaction mixture was diluted with diethyl ether and the organic layer was separated. 
The aqueous layer was washed with ether (3X) before the combined organic extracts were dried 
with sodium sulfate and concentrated in vacuo. Flash column chromatography (30% → 40% → 
50% ethyl acetate/hexanes) afforded quinoline 381 (89 mg, 83% yield) as a light brown oil. 1H 
NMR (400 MHz, CDCl3) δ 7.72 (d, J = 1.2 Hz, 1H), 7.56 (d, J = 8.9 Hz, 1H), 7.33 (d, J = 2.5 Hz, 
1H), 7.09 (dd, J = 8.9, 2.5 Hz, 1H), 3.91 (s, 3H), 3.09 (t, J = 6.5 Hz, 2H), 2.99 – 2.82 (m, 2H), 2.06 
– 1.91 (m, 2H), 1.91 – 1.78 (m, 2H);  13C NMR (101 MHz, CDCl3) δ 160.1, 159.2, 147.9, 135.1, 
128.6, 127.9, 122.4, 118.9, 106.1, 55.5, 33.4, 29.0, 23.3, 23.0; IR (Neat Film, NaCl) 2928, 1624, 
1602, 1452, 1317, 1231, 1210 1032, 852, 810 cm-1; HRMS (ESI/APCI) m/z calculated for 










THF, –78 °C, 10 min
then NH4Cl (aq.)
–78→ 23 °C, 20 min
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Trifloxyenamine 385: To a flame-dried, 25 mL flask with stir bar was added eburnamonine (91) 
(258 mg, 0.877 mmol, 1.0 equiv) and THF (4.4 mL). The flask was cooled to –78 °C before 1M 
LiHMDS in THF (1.23 mL, 1.23 mmol, 1.4 equiv) was added dropwise via syringe pump over 30 
minutes. The reaction mixture was then stirred at –78 °C for 1 hour, during which time the solution 
turned from light yellow to orange. HMPA (305 µL, 1.75 mmol, 2.0 equiv) was added dropwise 
and stirred at –78 °C for 10 minutes, during which time the solution turned dark brown. N-phenyl 
triflimide (438 mg, 1.23 mmol, 1.4 equiv) in THF (1.0 mL) was then added dropwise. The reaction 
mixture was stirred at –78 °C for 1.5 hours, then allowed to warm slowly to 23 °C over 14.5 hours. 
 The reaction mixture was quenched with water, transferred to a separatory funnel, and 
extracted with diethyl ether (5X). The combined organics were washed with 10% sodium 
hydroxide, dried with potassium carbonate, and concentrated in vacuo. Flash column 
chromatography (30 → 40 → 50% ethyl acetate/hexanes) afforded trifloxyenamine 385 (266 mg, 
71% yield) as a colorless oil, which then solidified to an amorphous white solid after letting stand 
in the freezer (–20 °C) for at least 24 hours. 1H NMR (400 MHz, CDCl3) δ 7.66 (dt, J = 8.3, 0.9 
Hz, 1H), 7.47 (dt, J = 7.6, 1.0 Hz, 1H), 7.27 – 7.22 (m, 2H), 7.18 (ddd, J = 8.2, 7.2, 1.0 Hz, 1H), 
5.03 (s, 1H), 4.28 (s, 1H), 3.38 (dd, J = 13.8, 5.8 Hz, 1H), 3.27 (td, J = 13.8, 12.6, 5.2 Hz, 1H), 
3.00 (dddd, J = 17.2, 11.3, 6.0, 2.9 Hz, 1H), 2.75 – 2.59 (m, 2H), 2.52 (dd, J = 16.2, 5.1 Hz, 1H), 
2.13 – 1.97 (m, 1H), 1.76 (dq, J = 14.8, 7.5 Hz, 1H), 1.57 (d, J = 13.7 Hz, 1H), 1.46 (dt, J = 13.5, 
3.2 Hz, 1H), 1.15 (td, J = 13.7, 3.7 Hz, 1H), 1.01 (t, J = 7.5 Hz, 3H); δ 13C NMR (101 MHz, 
CDCl3) δ 138.9, 133.3, 129.1, 123.5, 121.5, 120.3, 118.9, 117.1, 112.2, 110.7, 105.3, 55.2, 51.7, 
71% yield
LHMDS
THF, –78 °C, 1.5 h
then HMPA, PhNTf2
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45.3, 39.6, 30.6, 27.9, 20.5, 16.3, 9.0. IR (Neat Film, NaCl); HRMS (ESI/APCI) m/z calculated 
for CXHXNXOX [M + H+]: 427.1303, found, 427.1309; [α]D22.2 38.7° (c. 0.07, CHCl3). 
 
 
Alkenyl bromide 392: To an oven-dried 1-dram vial with stir bar in a nitrogen-filled glove box 
was added nickel (II) acetate tetrahydrate (1.2 mg, 0.0050 mmol, 0.1 equiv), zinc dust (0.6 mg, 
0.01 mmol, 0.2 equiv), 1,5-cyclooctadiene (1.2 µL, 0.01 mmol, 0.1 equiv), and lithium bromide 
(8.2 mg, 0.075 equiv, 1.5 mmol). DMA (0.05 mL) and THF (0.15 mL) was added and the reaction 
was stirred at 26 °C for 5 minutes. Trifloxyenamine 385 (22.7 mg, 0.050 mmol, 1.0 equiv) was 
added and the reaction was stirred in the dark for 2 hours. 
 The reaction was removed from the glovebox and quenched with saturated ammonium 
chloride. The solution was extracted with diethyl ether (3X). The combined organics were washed 
with brine, dried with sodium suflate, and concentrated in vacuo. Preparative TLC (40% ethyl 
acetate in hexanes) afforded alkenyl bromide 385 (10.3 mg, 59% yield) as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 8.25 – 8.19 (m, 1H), 7.44 (dt, J = 7.7, 1.0 Hz, 1H), 7.23 – 7.11 (m, 2H), 5.40 
(s, 1H), 4.17 (s, 1H), 3.34 (ddd, J = 13.7, 6.1, 0.8 Hz, 1H), 3.24 (ddd, J = 13.7, 11.3, 5.3 Hz, 1H), 
3.00 (dddd, J = 16.3, 11.4, 6.1, 2.8 Hz, 1H), 2.61 (dd, J = 8.8, 2.8 Hz, 2H), 2.54 – 2.46 (m, 1H), 
1.93 – 1.75 (m, 2H), 1.73 – 1.63 (m, 1H), 1.51 (dt, J = 13.8, 3.3 Hz, 1H), 1.40 (dp, J = 13.2, 3.1 
Hz, 1H), 1.13 (td, J = 13.7, 3.7 Hz, 1H), 0.99 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
135.2, 132.8, 129.2, 122.2, 121.2, 120.8, 118.5, 113.2, 111.7, 109.1, 56.4, 51.5, 45.1, 40.7, 29.2, 
27.5, 20.6, 16.4, 8.8; IR (Neat Film, NaCl) 2931, 1699, 1605, 1452, 1371, 1269, 1065, 739 cm-1; 
59% yield
Ni(OAc)2•4H2O (10 mol%)
Zn (10 mol %), COD (10 mol %)
LiBr (1.5 equiv)
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HRMS (ESI/APCI) m/z calculated for C19H22N2Br [M + H+]: 357.0966, found, 357.0974. [α]D22.2 
13.0° (c 0.27, CHCl3). 
 
 
Alkenyl iodide 393: To an oven-dried 1-dram vial with stir bar in a nitrogen-filled glove box was 
added trifloxyenamine 385 (20.0 mg, 0.050 mmol, 1.0 equiv), bis(1,5-cyclooctadiene)nickel (0) 
(1.3 mg, 0.0050 mmol, 0.1 equiv), and a 3:1 mixture of THF/DMA (0.2 mL). Sodium iodide (10.3 
mg, 0.070 equiv, 1.5 mmol) was added, the reaction was removed from the glovebox and stirred 
in the dark at 23°C for 2 hours. 
 The reaction was quenched with saturated ammonium chloride. The solution was extracted 
with diethyl ether (3X). The combined organics were washed with brine, dried with sodium suflate, 
and concentrated in vacuo. Preparative TLC (50% ethyl acetate/ hexanes) afforded alkenyl iodide 
393 (10.7 mg, 52% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 8.4 Hz, 
1H), 7.50 – 7.39 (m, 1H), 7.20 (dtd, J = 27.0, 7.3, 1.2 Hz, 2H), 5.81 (s, 1H), 4.19 (s, 1H), 3.42 – 
3.21 (m, 2H), 3.00 (dddd, J = 17.3, 11.3, 6.2, 2.7 Hz, 1H), 2.70 – 2.44 (m, 3H), 1.83 (qd, J = 7.5, 
1.6 Hz, 2H), 1.69 (q, J = 12.8 Hz, 1H), 1.50 (dt, J = 13.7, 3.2 Hz, 1H), 1.39 (dp, J = 13.0, 3.1 Hz, 
1H), 1.12 (td, J = 13.7, 3.7 Hz, 1H), 0.99 (t, J = 7.4 Hz, 3H).; 13C NMR (101 MHz, CDCl3) δ 
135.9, 131.9, 129.2, 121.7, 120.8, 118.5, 112.9, 108.5, 79.3, 56.7, 51.4, 44.9, 42.1, 29.9, 28.8, 27.4, 
20.5, 16.4, 8.7; IR (Neat Film, NaCl) 2930, 2860, 1589, 1451,1364, 1271, 1171, 744 cm-1; HRMS 















DMA/THF (1:3), 23 °C, 2 hr
dark
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Vinylquinoline stannane 391. To an oven-dried 1-dram vial in a nitrogen filled glove box was 
added vinylquinoline 318 (25.0 mg, 0.065 mmol, 1.0 equiv), tetrakis-
(triphenylphosphine)palladium (0) (7.6 mg, 0.0065 mmol, 0.10 equiv) and toluene (0.42 mL). 
Hexamethylditin (20.0 µL, 0.153 mmol, 1.5 equiv) was added dropwise. The flask was sealed, 
removed from the glovebox, and heated to 90 °C for 1.5 hours. Upon completion, the reaction 
mixture was subjected directly to flash column chromatography (0%→10%→15% 
acetone/hexanes) to afford stannane 391 (21.2 mg, 70% yield) as a bright yellow oil. 1H NMR (400 
MHz, CDCl3) δ 8.01 (s, 1H), 7.19 (s, 1H), 6.91 – 6.80 (m, 1H), 5.86 (dd, J = 11.7, 1.9 Hz, 1H), 
5.56 (dd, J = 18.0, 1.8 Hz, 1H), 3.89 (s, 3H), 3.82 – 3.71 (m, 1H), 3.23 – 3.12 (m, 1H), 3.06 (dd, J 
= 13.2, 2.1 Hz, 1H), 2.98 – 2.91 (m, 1H), 2.71 (d, J = 17.7 Hz, 1H), 2.59 – 2.49 (m, 1H), 1.75 (dd, 
J = 13.2, 3.1 Hz, 1H), 1.59 – 1.49 (m, 1H), 1.35 (q, J = 7.4 Hz, 3H), 1.28 (m, 1H), 0.95 (t, J = 7.6 
Hz, 3H), 0.30 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 164.3, 161.6, 149.4, 143.3, 133.4, 132.2, 
132.1, 122.6, 121.6, 119.6, 104.6, 104.5, 57.8, 55.9, 55.6, 36.9, 36.3, 35.4, 30.8, 19.6, 7.4, -8.9; IR 
(Neat Film, NaCl) 2918, 1596, 1555, 1455, 1404, 1364, 1210, 1051, 768; HRMS (ESI/APCI) m/z 










Me Pd(PPh3)4 (10 mol %)
Sn2Me6
PhMe, 90 °C, 1.5h
70% yield
Chapter 3: Progress toward a Convergent Total Synthesis of Leucophyllidine 237 
 
Vinyl dimer 386. To an oven-dried 1-dram vial in a nitrogen filled glove box was added triflate 
385 (21.0 mg, 0.0491 mmol, 1.1 equiv), followed by a solution of stannane 391 (21.0 mg, 0.0445 
mmol, 1.0 equiv) in NMP, which had been previously degassed through subjugation to five freeze-
pump-thaw cycles. The solution was allowed to stir in the glovebox for five minutes. 
Tetrakis(triphenylphosphine) palladium (0) (5.2 mg, 0.0045 mmol, 0.10 equiv) and copper (I) 
thiophene-2-carboxylate (9.3 mg, 0.0491 mmol, 1.1 equiv) were added in single portions in quick 
succession. The reaction mixture was allowed to stir at glovebox temperature (26 °C) for 10 
minutes, during which the solution turned from yellow to light brown. 
 The vial was removed from the glovebox, diluted with ethyl acetate, and quenched with 
saturated sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (3X), before the 
combined organics were washed with brine (2X), dried with sodium sulfate, and concentrated in 
vacuo. The crude mixture was passed through a pad of silica gel (eluting with 5% methanol in 
dichloromethane) to remove excess NMP, and the eluent was concentrated again in vacuo. 
Preparative TLC (7% methanol/dichloromethane) afforded vinyl dimer 386 (14.1 mg, 54% yield, 



















Pd(PPh3)4 (10 mol %)
CuTC (1.1 equiv)
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Major atropisomer: 1H NMR (400 MHz, C6D6) δ 8.33 (s, 1H), 7.60 (s, 1H), 7.58 – 7.47 (m, 1H), 
7.09 (ddd, J = 7.9, 7.1, 1.0 Hz, 1H), 6.87 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 6.70 (dt, J = 8.4, 0.9 Hz, 
1H), 6.60 – 6.49 (m, 1H), 5.46 (dd, J = 11.7, 1.9 Hz, 1H), 5.35 (dd, J = 17.9, 1.9 Hz, 1H), 5.25 (s, 
1H), 4.41 (d, J = 2.5 Hz, 1H), 4.25 – 4.14 (m, 1H), 3.15 – 3.05 (m, 2H), 3.12 (s, 3H), 3.05 – 2.95 
(m, 1H), 2.94 – 2.73 (m, 3H), 2.65 – 2.56 (m, 1H), 2.54 – 2.36 (m, 3H), 2.33 – 2.21 (m, 1H), 2.06 
– 1.94 (m, 1H), 1.93 – 1.77 (m, 1H), 1.76 – 1.62 (m, 1H), 1.51 – 1.38 (m, 2H), 1.34 – 1.26 (m, 
2H), 1.26 – 1.15 (m, 3H), 1.09 – 1.00 (m, 2H), 1.00 – 0.92 (m, 3H) 0.79 – 0.73 (m, 3H). 13C NMR 
(101 MHz, C6D6) δ 163.1, 159.3, 150.2, 143.6, 135.6, 134.9, 132.5, 132.0, 131.5, 129.7, 126.9, 
122.6, 122.5, 122.1, 120.1, 119.4, 118.6, 118.2, 111.5, 107.9, 107.5, 57.8, 57.0, 56.1, 55.4, 52.0, 
45.5, 37.6, 37.6, 37.2, 36.1, 35.4, 30.7, 30.3, 28.0, 21.2, 20.0, 16.8, 9.0, 7.3. 
Minor atropisomer:  1H NMR (400 MHz, C6D6) δ 8.32 (s,1H), 7.74 (s, 1H), 7.58 – 7.47 (m, 2H), 
6.76 – 6.60 (m, 2H), 6.39 (dd, J = 17.9, 11.7 Hz, 1H), 5.30 – 5.21 (m, 2H), 5.19 (s, 1H), 4.28 (s, 
1H), 4.25 – 4.14 (m, 1H), 3.36 (s, 3H), 3.15 – 3.05 (m, 2H), 3.05 – 2.95 (m, 1H), 2.94 – 2.73 (m, 
3H), 2.65 – 2.56 (m, 1H), 2.54 – 2.36 (m, 3H), 2.33 – 2.21 (m, 1H), 2.06 – 1.94 (m, 1H), 1.93 – 
1.77 (m, 1H), 1.76 – 1.62 (m, 1H), 1.51 – 1.38 (m, 2H), 1.34 – 1.26 (m, 2H), 1.26 – 1.15 (m, 3H), 
1.09 – 1.00 (m, 2H), 1.00 – 0.92 (m, 3H) 0.73 – 0.66 (m, 3H).13C NMR (101 MHz, C6D6) δ 163.2, 
159.2, 149.8, 143.7, 135.1, 134.5, 130.0, 129.6, 127.8, 125.6, 122.9, 121.9, 121.9, 120.6, 120.0, 
119.9, 119.1, 118.8, 113.3, 112.4, 109.0, 108.1, 57.7, 56.9, 56.8, 55.5, 52.2, 45.4, 37.6, 37.1, 36.0, 
35.3, 28.9, 27.6, 20.9, 20.1, 16.8, 9.1, 8.7, 7.3. 
IR: 2930, 2854, 1618, 1453, 1417, 1371, 1226, 1216, 1195, 752 cm. HRMS (ESI/APCI) m/z 
calculated for C39H45N4O [M + H+]: 585.3515, found, 585.3582. [α]D22.4 131.0° (c 0.45, CHCl3). 
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Ethylquinoline 402. To a flame-dried, one-dram vial with stir bar was charged vinyl dimer 392 
(1.0 mg, 0.0017 mmol, 1.0 equiv) and methanol (0.17 mL). Sodium borohydride (6.4 mg, 0.17 
mmol, 100.0 equiv) was added and the reaction was heated to 60 °C for 20 minutes. The reaction 
mixture was cooled to room temperature, quenched with saturated sodium bicarbonate, and 
extracted with ethyl acetate (3X). The combined organic extracts were dried with sodium sulfate 
and concentrated in vacuo. Preparative TLC (7% methanol/dichloromethane) afforded ethyl 
quinoline 402 (1.0 mg, 99% yield) as an amorphous white solid. Product characterization data was 
not obtained due to the Spring 2020 COVID-19 shutdown of research facilities. 
 
	
Formylquinoline stannane 396. To a flame-dried 1-dram vial in a nitrogen filled glove box was 
added formylquinoline 342 (122.0 mg, 0.315 mmol, 1.0 equiv), tetrakis(triphenylphosphine) 
palladium (0) (37.0 mg, 0.0320 mmol, 0.10 equiv) and toluene (2.1 mL). Hexamethylditin (98.0 
µL, 0.473 mmol, 1.5 equiv) was added dropwise. The vial was sealed, removed from the glovebox, 
and heated to 90 °C for 3 hours. Upon completion, the reaction mixture was subjected directly to 
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stannane 396 (112.1 mg, 75% yield) as a bright yellow oil. 1H NMR (600 MHz, CDCl3) δ 11.03 
(s, 1H), 8.43 (s, 1H), 7.23 (s, 1H), 3.91 (s, 3H), 3.81 (d, J = 13.6 Hz, 1H), 3.25 – 3.17 (m, 2H), 
3.13 (dd, J = 13.3, 2.2 Hz, 1H), 3.02 – 2.95 (m, 2H), 1.78 (d, J = 13.5 Hz, 1H), 1.64 – 1.57 (m, 
1H), 1.40 (q, J = 7.6 Hz, 2H), 1.33 (hept, J = 4.2 Hz, 1H), 0.99 (t, J = 7.6 Hz, 3H), 0.34 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 194.2, 164.5, 162.4, 150.0, 135.8, 134., 131.3, 125.9, 118.2, 104.7, 
57.3, 56.2, 55.6, 36.0, 35.3, 31.1, 30.7, 19.7, 7.4, -8.8. IR (Neat Film, NaCl) 2924, 2852, 2363, 
1698, 1596, 1456, 1403, 1363, 1211, 1046, 758 cm-1; HRMS (ESI/APCI) m/z calculated for 
CXHXNXOX [M + H+]: 475.1408, found, 475.1434. [α]D22.4 142.7° (c 0.09, CHCl3). 
	
 
Formyl dimer 397. To a flame-dried 10 mL round-bottom flask with stir bar in a nitrogen filled 
glove box was added triflate 385 (30.0 mg, 0.0698 mmol, 1.1 equiv), followed by a solution of 
stannane 396 (30.0 mg, 0.0634 mmol, 1.0 equiv) in NMP (1.25 mL), which had been previously 
degassed through subjugation to five freeze-pump-thaw cycles. The solution was allowed to stir 
in the glovebox for five minutes. Tetrakis(triphenylphosphine) palladium (0) (7.3 mg, 0.0064 
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added in a single portion in quick succession. The reaction mixture was allowed to stir at glovebox 
temperature (26 °C) for 10 minutes, during which the solution turned from yellow to light brown. 
 The vial was removed from the glovebox, diluted with ethyl acetate, and quenched with 
saturated sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (3X), before the 
combined organics were washed with brine (2X), dried with sodium sulfate, and concentrated in 
vacuo. The crude mixture was passed through a pad of silica gel (eluting with 5% methanol in 
dichloromethane) to remove excess NMP, and the eluent was concentrated again in vacuo. 
Preparative TLC (7% methanol/dichloromethane) afforded formyl dimer 397 (25.5 mg, 69% yield) 
as a light yellow foam. 
Major atropisomer: 1H NMR (400 MHz, CDCl3) δ 11.01 (s, 1H), 8.49 (s, 1H), 7.44 – 7.37 (m, 1H), 
7.33 (s, 1H), 7.01 – 6.91 (m, 1H), 6.79 – 6.68 (m, 1H), 6.09 (dt, J = 8.4, 0.9 Hz, 1H), 5.14 (s, 1H), 
4.41 (s, 1H), 3.94 – 3.82 (m, 1H), 3.61 (s, 3H), 3.49 – 3.34 (m, 2H), 3.32 – 3.14 (m, 3H), 3.14 – 
2.94 (m, 3H), 2.90 – 2.69 (m, 2H), 2.66 – 2.53 (m, 1H), 1.95 (dp, J = 29.2, 7.3 Hz, 2H), 1.85 – 
1.75 (m, 2H), 1.72 – 1.55 (m, 2H), 1.54 – 1.23 (m, 6H), 1.01 (q, J = 7.6 Hz, 6H). 13C NMR (101 
MHz, CDCl3) δ 193.5, 163.5, 159.1, 149.2, 134.8, 134.3, 131.1, 130.7, 128.9, 127.5, 127.1, 126.2, 
121.6, 119.6, 119.0, 118.2, 117.3, 111.8, 107.7, 107.1, 57.1, 56.7, 56.3, 56.0, 52.1, 45.4, 37.5, 35.9, 
35.9, 35.2, 30.8, 30.0, 27.6, 20.8, 20.0, 16.6, 9.0, 7.4. 
Minor atropisomer: 1H NMR (400 MHz, CDCl3) δ 10.85 (s, 1H), 8.39 (s, 1H), 7.46 (s, 1H), 7.44 
– 7.37 (m, 1H), 7.01 – 6.91 (m, 1H), 6.79 – 6.68 (m, 1H), 6.21 (dt, J = 8.4, 0.9 Hz, 1H), 5.01 (s, 
1H), 4.41 (s, 1H), 3.94 – 3.82 (m, 1H), 3.87 (s, 3H), 3.49 – 3.34 (m, 2H), 3.32 – 3.14 (m, 3H), 3.14 
– 2.94 (m, 3H), 2.90 – 2.69 (m, 2H), 2.66 – 2.53 (m, 1H), 1.95 (dp, J = 29.2, 7.3 Hz, 1H), 1.85 – 
1.75 (m, 3H), 1.72 – 1.55 (m, 2H), 1.54 – 1.23 (m, 6H), 1.01 (q, J = 7.6 Hz, 6H). 13C NMR (101 
MHz, CDCl3) δ 193.5, 163.5, 159.1, 149.2, 134.3, 131.3, 131.1, 130.2, 128.9, 127.5, 127.1, 126.2, 
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121.6, 119.6, 119.0, 118.2, 117.3, 111.8, 107.7, 107.1, 57.1, 56.7, 56.3, 56.0, 52.0, 45.4, 37.5, 35.9, 
35.9, 35.2, 30.8, 30.0, 27.6, 20.8, 20.0, 16.6, 9.0, 7.4. 
IR: 2923, 1694, 1456, 1214, 1042, 754, 744 cm -1 HRMS (ESI/APCI) m/z calculated for 




Phenol 402: To a flame dried, 10-mL round-bottom flask with stir bar was added a solution of 
formyl dimer 397 (23.8 mg, 0.405 mmol, 1.0 equiv) in dichloromethane (2.7 mL). Ethylene glycol 
was added (50 µL, 0.41 mmol, 10.0 equiv) before the reaction was cooled to 0 °C. Boron trifluoride 
diethyl etherate (23 µL, .0.41 mmol, 10.0 equiv) was added dropwise and the reaction was stirred 
for 2 hours. Additional ethylene glycol (50 µL, 0.41 mmol, 1.0 equiv) was then added and the 
reaction was stirred for an additional 1 hour.  
After the reaction was complete, as determined by LCMS, the flask was warmed to room 
temperature and quenched with 1M NaOH. The solution was transferred to a separatory funnel, 
the organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3X). The 
combined organic extracts were washed with brine, dried with sodium sulfate, and concentrated in 
vacuo. The combined organic extracts were filtered through a plug of silica gel, eluting with 10% 
methanol in dichloromethane. The eluent was concentrated in vacuo, transferred to a one-dram 










    BF3•OEt2
    CH2Cl2, 0 °C, 3 h
2. NaH, EtSH
    DMF, 150 °C, 1 h
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 The crude material was charged with a stir bar, placed under nitrogen atmosphere, and 
charged with a freshly prepared solution of 0.4M sodium ethanethiol in DMF (2.0 mL, 0.810 
mmol, 20.0 equiv). A teflon-lined cap was quickly added, and the reaction was heated to 150 °C 
for 10 minutes. Upon completion of the reaction, the vial was cooled to room temperature, 
quenched with 1:1 30% ammonium hydroxide solution/brine, and extracted with ethyl acetate 
(5X). The combined organic extracts were washed with 10% lithium chloride solution, brine, and 
water, dried with sodium sulfate, and concentrated in vacuo. Preparative TLC (8% 
methanol/dichloromethane) afforded phenol 402 (9.0 mg, 36% yield) as a light, yellow oil.  
Major atropisomer:  1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1H), 7.86 (s, 1H), 7.36 – 7.30 (m, 1H), 
6.87 (t, J = 7.4 Hz, 1H), 6.36 (s, 1H), 6.28 (t, J = 7.8 Hz, 1H), 5.86 (d, J = 8.5 Hz, 1H), 5.17 (s, 
1H), 4.39 (s, 1H), 4.36 – 4.26 (m, 2H), 4.22 – 4.10 (m, 1H), 3.87 – 3.82 (m, 1H), 3.45 – 3.29 (m, 
3H), 3.12 (td, J = 13.2, 3.4 Hz, 1H), 3.06 – 2.98 (m, 1H), 2.84 – 2.74 (m, 3H), 2.69 (d, J = 11.2 
Hz, 2H), 2.53 (dd, J = 37.2, 15.8 Hz, 1H), 2.20 – 2.14 (m, 1H), 2.04 – 1.82 (m, 2H),  1.81 – 1.60 
(m, 3H), 1.60 – 1.30 (m, 6 H), 1.01 (dt, J = 11.4, 7.4 Hz, 3H), 0.92 (dt, J = 15.1, 7.5 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 160.6, 155.9, 148.9, 137.2, 134.7, 134.6, 130.9, 128.5, 126.7, 126.3, 
124.7, 121.6, 119.5, 118.9, 117.8, 117.6, 113.3, 111.2, 107.1, 100.7, 65.6, 65.6, 56.6, 55.8, 55.6, 
51.6, 45.2, 37.3, 36.0, 35.1, 35.0, 30.5, 29.8, 27.6, 20.8, 19.5, 16.6, 8.9, 7.4. 
Minor atropisomer:  1H NMR (600 MHz, CDCl3) δ 8.04 (s, 1H),  7.60 (s, 2H), 7.43 (d, J = 7.8 Hz, 
1H), 7.02 (t, J = 7.3 Hz, 1H), 6.85 – 6.80 (m, 1H), 6.43 (d, J = 8.4 Hz, 1H), 6.18 (s, 1H), 4.36 – 
4.26 (m, 1H), 4.22 – 4.10 (m, 3H), 3.91 (d, J = 13.6 Hz, 1H), 3.87 – 3.82 (m, 2H), 3.72 (td, J = 
7.7, 6.4 Hz, 1H), 3.45 – 3.29 (m, 1H), 3.20 (td, J = 13.0, 3.3 Hz, 1H), 3.12 (td, J = 13.2, 3.4 Hz, 
1H), 3.06 – 2.98 (m, 1H), 2.93 (d, J = 17.6 Hz, 1H), 2.84 – 2.74 (m, 3H), 2.69 (d, J = 11.2 Hz, 
2H), 2.56 (dd, J = 37.2, 15.8 Hz, 1H), 2.04 – 1.82 (m, 1H),  1.81 – 1.60 (m, 3H), 1.60 – 1.30 (m, 
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6 H), 1.01 (dt, J = 11.4, 7.4 Hz, 3H), 0.92 (dt, J = 15.1, 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 162.3, 154.6, 148.5, 137.7, 134.3, 131.9, 131.2, 128.9, 127.0, 125.1, 122.4, 121.8, 119.9, 119.8, 
118.4, 117.8, 113.5, 111.7, 108.1, 100.4, 65.4, 64.9, 56.7, 56.5, 56.0, 37.5, 35.3, 32.1, 31.9, 30.9, 
29.5, 29.4, 27.6, 22.8, 20.0, 16.7, 14.3, 8.9, 7.4.  
IR: 2924, 1614, 1455, 1214, 968, 757, HRMS (ESI/APCI) m/z calculated for C39H44N4O3 [M + 
H+]: 617.3492, found, 617.3477. [α]D22.4 6.4° (c 0.50, CHCl3). 
 
0.4M Sodium Ethanethiol Stock Solution. To a flame-dried 25-mL round bottom flask with stir 
bar was added DMF (10 mL) and thioethanol (0.29 mL). Sodium hydride (160 mg, 60% dispersion 
in mineral oil) was added portionwise. The solution was then stirred for 10 minutes prior to use. 
Freshly prepared solutions of sodium ethanethiol tend to result in a cleaner reaction profile and 
shorter reaction times.  
3.8.3 Computational Details 
All quantum mechanical calculations were performed with ORCA version 4.2.0.1 
Geometry optimizations and frequency calculations were carried out with the Becke’s three 
parameter B3LYP global hybrid generalized gradient approximation (hybrid-GGA) density 
functional paired with Becke–Johnson damped D4 dispersion corrections (henceforth referred to 
as D4). For optimization and frequency calculation, all atoms are described with the split valence 
def2-SV(P) basis set. Thermal corrections (at 298 K, 1 atm standard state) were calculated from 
the unscaled vibrational frequencies at this level of theory. The Quasi-RRHO method was applied 
to correct for the breakdown of the harmonic oscillator approximation for low frequency 
vibrations. All stationary points are characterized by the appropriate number of imaginary 
vibrational modes (zero for optimized geometries). Triple-z quality single point calculations were 
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carried out on all stationary points with the B3LYP-D4 density functional with the def2-TZVPP 
basis set11 on all atoms. The SMD implicit solvation model for THF was employed in these single 
point calculations to include effects of solvation (CDS corrections included). Gas phase single 
point calculations were carried out for comparison. Thermal corrections obtained at the previous 
level of theory are then applied to these solvated electronic energies to obtain the reported free 
energies (G298). Henceforth this level of theory is denoted as B3LYP-D4/def2-TZVPP–
SMD(THF)//B3LYP-D4/def2-SV(P). 
The resolution of identity (RI) and chain-of-spheres (keyword = RIJCOSX) 
approximations were utilized for coulomb and exchange integrals, respectively. The fitted def2/J 
auxiliary basis sets was employed. The finest integration grid settings (Grid7, GridX9, 
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Figure A4.3. 13C NMR (101 MHz, CDCl3) of compound 364. 
 
Figure A4.2. Infrared spectrum (Thin Film, NaCl) of compound 364. 
 

























































































Figure A4.6. 13C NMR (101 MHz, CDCl3) of compound 364. 
 
Figure A4.5. Infrared spectrum (Thin Film, NaCl) of compound 364. 
 
























































































Figure A4.9. 13C NMR (101 MHz, CD2Cl2) of compound 379c. 
 
Figure A4.8. Infrared spectrum (Thin Film, NaCl) of compound 379c. 
 























































































 Figure A4.12.13C NMR (101 MHz, CDCl3) of compound 367. 
Figure A4.11. Infrared spectrum (Thin Film, NaCl) of compound 367. 
 

























































































Figure A4.14. Infrared spectrum (Thin Film, NaCl) of compound 380. 
 
Figure A4.15. 13C NMR (101 MHz, CDCl3) of compound 380. 
 
























































































Figure A4.18. 13C NMR (101 MHz, CDCl3) of compound 361. 
 
Figure A4.17. Infrared spectrum (Thin Film, NaCl) of compound 361. 
 


























































































Figure A4.21.  13C NMR (101 MHz, CDCl3) of compound 385. 
 
Figure A4.20. Infrared spectrum (Thin Film, NaCl) of compound 385. 
 
























































































Figure A4.24 13C NMR (101 MHz, CDCl3) of compound 392. 
 
Figure A4.23 Infrared spectrum (Thin Film, NaCl) of compound 392. 
 




























































































Figure A4.27 13C NMR (101 MHz, CDCl3) of compound 391. 
 
Figure A4.26 Infrared spectrum (Thin Film, NaCl) of compound 391. 
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Figure A4.30 13C NMR (101 MHz, CDCl3) of compound 391. 
 
Figure A4.29 Infrared spectrum (Thin Film, NaCl) of compound 391. 
 































































































Figure A4.33 13C NMR (101 MHz, C6D6) of compound 386. 
 
Figure A4.32 Infrared spectrum (Thin Film, NaCl) of compound 386. 
 



























































































































































































































































Figure A4.38 13C NMR (101 MHz, CDCl3) of compound 396. 
 
Figure A4.37 Infrared spectrum (Thin Film, NaCl) of compound 396. 
 

































































































Figure A4.41 13C NMR (101 MHz, CDCl3) of compound 397. 
 
Figure A4.40 Infrared spectrum (Thin Film, NaCl) of compound 397. 
 
































































































 Figure A4.44 13C NMR (101 MHz, CDCl3) of compound 403. 
 
Figure A4.43 Infrared spectrum (Thin Film, NaCl) of compound 402. 
 









































The Total Synthesis of (–)-Scabrolide A 
 
 
4.1  INTRODUCTION 
4.1.1.  Isolation, Bioactivity, and Biosynthetic Hypotheses  
 The soft corals of the genus Sinularia have attracted immense scientific interest as a fertile 
source of bioactive natural products. The rich chemodiversity of compounds isolated from these 
marine organisms has inspired a substantial body of research from natural products chemists, 
synthetic chemists, and biochemists alike.1 Sinularia-derived secondary metabolites demonstrate 
an exceptional array of macrocyclic and polycyclic architectures noted for their various fused ring 
systems and complicated patterns of oxidation.2 Biologically, these compounds display potent 
biological activities such as cytotoxicity, which is hypothesized to account for the low natural 
predation of the parent organisms.3 
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Figure 4.1. Furanobutenolide-derived norcembranoid diterpenoids. 
 
 The furanobutenolide-derived cembranoid and norcembranoid diterpenoids are a particular 
subclass which has attracted significant attention within the synthetic community. The name arises 
from the furanobutenolide scaffold (415) from which the C20 cembranoid (R = Me, CHO, COOMe) 
and C19 norcembranoid (R = H) diterpenoids arise (Figure 4.1).2 This intermediate serves as a 
biogenic precursor for the various tricarbocyclic norcembranoid frameworks observed in these 
natural products; these include the fused-[5,6,7] ring system observed in scabrolide A (416),4 
scabrolide B (417),4 12-hydroxyscabrolide A (418),5 sinulochmodin C (419),6 yonarolide (420),7 
and dissectolide (421),8 the fused-[5,7,6] ring system observed in ineleganolde (422),9 the fused-
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Scheme 4.1. Proposed biosynthesis of fused tricyclic norcembranoid diterpenoids. 
 
 Biosynthetically, the diverse set of ring systems are hypothesized to arise from a series of 
transannular Michael additions from 5-epi-sinuleptolide (424) (Scheme 4.1A). Deprotonation at 
C(5), for example, is believed to promote a 7-exo-trig cyclization with concomitant elimination of 
the allylic alcohol to establish butenolide 425. Deprotonation at C(7) then initiates a 5-exo trig 
cyclization to establish the fused-[5,6,7] core of sinulochmodin C (419). A retro oxa-Michael 
addition then generates scabrolide B (417), which can isomerize to scabrolide A (416) and 
eliminate to yonarolide (420).1,2  
 In contrast, deprotonation at C(4) of 5-epi-sinulariolide (424) and subsequent 6-exo-trig 




































































































A. Proposed biosynthetic origin of the [5,6,7]-fused norcembranoid diterpenoids.
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exo-trig cyclization generates the fused-[5,7,6] core of ineleganolide (422) (Scheme 4.1B). 1,2 
These hypotheses are supported by research by Pattenden and coworkers,11 who reported in 2011 
that treatment of 5-epi sinulariolide with LHMDS generated a mixture of ineleganolide (422) and 
sinulochmodin C (419) (Scheme 4.2). 
Scheme 4.2. Pattenden’s semi-synthesis of ineleganolide and sinulochmodin C (2011). 
 
 
4.1.2.  Previous Synthetic Efforts toward Polycyclic (Nor)cembranoid Diterpenoids  
 Cembranoid and norcembranoid diterpenoids have been the subject of extensive synthetic 
efforts over the years. However, it was not until the late 2010’s that the first of these natural 
products succumbed to total synthesis, highlighting the difficulty accessing these targets. By 
examining the strategies implemented in successful synthetic efforts, we gained key insight to 
guide our own eventual synthetic strategy. 
 In 2017, Yang and coworkers12 disclosed the first total synthesis of a cembranoid 
diterpenoid pavidolide B (426). (E,E)-2,4-hexadienal 427 is advanced in 5 steps to cyclopropane 
428 via an asymmetric domino Michael addition (Scheme 4.3). This is coupled through a 
convergent Mitsonobu reaction with allylic alcohol 429, available in two steps from (R)-carvone, 
to access key ester 430. This substrate then undergoes a photoredox-catalyzed [3+2] cycloaddition 
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acetal cleavage affords aldehyde 432. A Ni-catalyzed aldehyde-diene coupling with isoprene and 
subsequent DMP oxidation affords ketone 433, which is then advanced through a ring-closing 
metathesis and Rh-catalyzed isomerization to access pavidolide B (426) in 10 steps LLS. 
Scheme 4.3. Yang’s asymmetric synthesis of pavidolide B (2017). 
 
 
 The Carriera group13 followed up shortly after with a successful synthesis of the tricyclic 
cembranoid terpenoid sarcophytin (434). (S)-citronellal (435) is first advanced to acid 436 in five 
steps, before a convergent Mitsonobu coupling with carvone-derived alcohol 429 accesses key 
ester 437 (Scheme 4.4). A thermal Diels-Alder then forges the tricyclic core 438 in 76% yield. 
Allylic alcohol 439 is installed through an epoxidation/base-mediated elimination sequence. 
Addition of ruthenium (III) chloride and potassium persulfate then accesses key hemiaminal 440 































































1. Ni(acac)2, Et2Zn 
    isoprene
    THF, 23 °C
2. DMP, NaHCO3
















    CH2Cl2, reflux
2. RhCl3 • 3H2O
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hemiaminal formation, and epimerization of the isopropyl fragment. Alkylation with TMS-
diazomethane then advances this intermediate to sarcophytin (434). 
Scheme 4.4. Carriera’s asymmetric synthesis of sarcophytin (2018). 
 
 
Later that year, Ding and coworkers14 disclosed a divergent route to several polycyclic 
cembranoids (Scheme 4.5). A formal [4+2] cycloaddition between Rawal’s diene 441 and carvone-
derivative 442 affords bicycle 443 in 84% yield. This is followed by a lactonization using dimethyl 
carbonate to afford ester 444, which is subjected to Helquist annulation15 with Grignard 445 to 
afford key carbotricyclic intermediate 446. This would serve as a divergence point for the synthesis 
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Scheme 4.5. Ding’s asymmetric synthesis of several cembranoids (2018). 
 
 In 2019, the Fürstner group16 completed the first total synthesis of a polycyclic 
norcembranoid in the natural product sinulariadiolide (448).  Geranic acid (449) is advanced to 
enantioenriched tertiary alcohol 451 through a five-step sequence involving an organocatalyzed 
asymmetric oxyamination to set the absolute stereochemistry; (R)-carvone (450) is then advanced 
to acid 452 over three steps through an Eschenmoser-Tanabe fragmentation strategy. A convergent 
esterification, followed by protecting group manipulations is advanced to diyne 453 in 73% yield 
over three steps before a Mo-catalyzed ring-closing alkyne metathesis with catalyst (454) affords 
macrocycle 455. This is advanced over three steps to carbonate 456, which is converted to tricycle 
core 457 through a one-pot procedure involving five individual transformations: deacetylation, 
transannular Michael addition, carbonate elimination, butenolide formation, and oxa-Michael 
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CH2Cl2, –78 → 23 °C
84% yield
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Scheme 4.6. Fürstner’s asymmetric synthesis of sinulariadiolide (2019). 
 
 Finally, Zhu and coworkers17 published a four-step synthesis of pavidolide B (426) in early 
2020. Cycloheptenone 457 is treated first with methyllithium, followed by Dauben transposition 
to afford methylcycloheptenone 458 (Scheme 4.7). Aldol condensation with glyxolic acid affords 
trans enoic acid 459 in 30% yield, which is coupled with hydroxycarvone 429 under Mitsunobu 
conditions to afford a mixture of exo- and endo- enones 460 and 461, before the exo- intermediate 
is isomerized to the endo- enone with additional DBU. Finally, a base-inititated double Michael 



























1. DCC, DMAP, Et3N
    PhMe, 60 °C
2. Ac2O, Et3N
    DMAP (20 mol %)
    CH2Cl2, –40 °C
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2. Zn, AcOH
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76% yield,
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Scheme 4.7. Zhu’s asymmetric synthesis of pavidolide B (2020). 
 
 
4.1.3.  Inspiration  
 By analyzing the successful synthetic efforts toward (nor)cembranoid diterpenoids, several 
trends have become apparent. First, given the high degree of structural analogy between natural 
products and commercial monoterpenes, the chiral pool provides an intuitive source of starting 
materials for synthetic efforts.18 Second, convergent strategies are frequently exploited to install a 
majority, if not all, of requisite carbons at an early stage; in most cases, an esterification is 
frequently used to accomplish this unification prior to intramolecular C–C bond forming steps. 
Finally, cycloadditions or biomimetic Michael cascades are the most frequently implemented 
transformations for the installation of stereocomplexity in fused systems. Therefore, the design 
and incorporation of unsaturation within cyclization precursors is critical for execution of the most 
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 In 2017, our lab published our progress toward the synthesis of the furanobutenolide-
derived norcembranoid diterpenoid ent-ineleganolide (422).19 Ester 462, accessible in 8 steps from 
(S)-carvone, is hydrolyzed, coupled to cyclopentendiol 464, and subjected to Regitz diazo transfer 
to afford diazo 465 (Scheme 4.8). Treatment with catalytic Rh(II) then promotes a tandem 
cyclopropanation-Cope rearrangement to construct the fused [5,7,6] core 466 in 53% yield. SmI2 
reduces to cyclohexanone 467, which undergoes a three-step sequence of epoxidation, reductive 
epoxide cleavage, and oxidation to afford ketone 468. Unfortunately, all attempts to advance this 
intermediate to the natural product (422) were unsuccessful. Other late-stage strategies, including 
isomerization of the tetrasubstituted olefin before oxa-Michael addition, were also unsuccessful.   

















462, R = Et
463, R = H
464 465
1. EDC • HCl, DMAP (cat.)
    CH2Cl2, 23 °C
2. PABSA, Et3N 
    CH3CN, 0 °C
75% yield, 3 steps
466






























1. VO(acac) (1 mol %)
    TBHP, PhH, 23 °C
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     THF, H2O –78 → 23 °C
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 Though our strategy did not afford access to ineleganolide (422), the tactics developed for 
these late-stage manipulations remained informative and provided key insights into the reactivity 
of complex terpenoid scaffolds. While the cyclopropanation-Cope strategy to access a [5,7,6]-ring 
system would only be applicable to ineleganolide (422), we reasoned that a strategy to access the 
[5,6,7]-ring system could be applied to several natural products of varying degrees of complexity 
(e.g. 416 – 420), benefiting from the expertise gained through unsuccessful pathways. To develop 
this strategy, we elected to target the norcembranoid diterpenoid scabrolide A (416). 
 Scabrolide A (416) (Figure 4.1), a flagship member of the polycyclic furanobutenolide-
derived natural product family, was first isolated by Sheu and coworkers from the Taiwanese soft 
coral Sinularia scabra in 2002 alongside four other novel norcembranoids (scabrolides B–D) and 
four known norcembranoids, including the closely related inelganolide (422).4 Since its initial 
isolation, 1 has been demonstrated to inhibit IL-6 and IL-12 production in vitro, suggesting its 
potential as an anti-inflammatory agent.5 Structurally, scabrolide A (416) is characterized by a 
fused [5,6,7] carbocyclic framework featuring six stereogenic centers, five of which are 
contiguously situated about the compact and densely functionalized western portion of the 
molecule. The eastern portion possesses a synthetically challenging cycloheptenone with its ketone 
positioned in an electronically dissonant 1,4-relationship to the central ring ketone, and a distal 
stereocenter in the form of an isopropenyl substituent. 
 
4.1.4.  Retrosynthetic Analysis  
 We envisioned that the challenging cycloheptenone moiety of scabrolide A (416) could 
arise from a Tamao-Fleming oxidation and oxidative fragmentation20 of the cyclobutane moiety 
observed in silane 469 (Scheme 4.9); this would be generated, in turn, from a 
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hydrosilylation/photochemical [2+2] cycloaddition21 of alkyne 470. Late-stage installation of the 
C(3) ketone was crucial, as a number of earlier strategies had found that the basic C(12) proton 
would frequently initiate an intramolecular aldol condensation.22 The central cyclohexanone 
would be formed through a thermal [4+2] cycloaddition and subsequent oxidative manipulations 
of ester 471. Disconnection across the ester moiety provides two fragments: cyclopentendiol 464 
which would serve as the diene and acyclic diyne 472 which would serve as the dienophile. These 
would be formed through derivatization of (–)-linalool (473) and (R)-carvone (450). 
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4.2  SYNTHESIS OF THE CYCLOHEXENONE CORE 
4.2.1 Synthesis of the Cyclopentendiol 
In 2012, our group first published a route to access cyclopentendiol ent-464 using 
asymmetric catalysis.23 Tris • HCl (474) is first advanced to silyl enol ether 475 over six steps 
(Scheme 4.10). A Pd-catalyzed allylic alkylation with 2-chloroallyl mesylate then establishes the 
tertiary alcohol stereogenic center of dioxolane 477 in 82% yield and 92% ee. This is then 
advanced through α bromination/intramolecular Wittig cyclization to cyclopenteone 478, before 
reduction with DIBAL–H forges secondary alcohol 479 as a single diastereomer. With both 
stereogenic centers now installed, this intermediate is advanced through five additional steps to 
cyclopentendiol ent-464.  
Scheme 4.10. First generation route to cyclopentendiol building block (2011). 
 
 While this approach was successfully employed to deliver the key building block on gram-
scale, the route proved to be step-inefficient, as the time required to complete the sequence greatly 
limited material throughput. Furthermore, the established route accessed the ent-enantiomeric 
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derived from a substantially more expensive D-tert-leucine. To circumvent these challenges, we 
looked to develop a revised route to our building block from chiral pool starting materials.  
Scheme 4.11. Second generation synthesis of cyclopentendiol from linalool.  
 
 Following a procedure by Maimone and coworkers,24 (–)-Linalool (473) is treated with 
Hoveyda-Grubbs II catalyst to promote a ring-closing metathesis and TBS-protected to afford 
cyclopentene 480 (Scheme 4.11). This intermediate is then subjected to Ru-catalyzed allylic 
oxidation to access key cyclopentenone 481 in 52% yield over two steps. Cu-catalyzed conjugate 
addition with vinyl magnesium bromide affords 1,4-addition product 482, before transformation 
to the corresponding silyl enol ether 483.25 While Saegusa-Ito oxidation to dienone 484 was low 
yielding, we were delighted to obtain the desired product in excellent yield upon oxidation with 
DDQ.26 Secondary alcohol 485 is forged through a diastereoselective Luche reduction before 
TBAF-mediated deprotection of the tertiary alcohol affords key building block 464 in seven steps 
OTBSMe







HG-II (0.1 mol %)
neat, 23 °C
then NaH, TBSCl
THF, 23 °C → reflux
RuCl3 (1 mol %)
    MgOAc2 • 4H2O
    t-BuOOH
    CH2Cl2/H2O (10:1)
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from commercial material. This sequence provides equivalent amounts of material to our 
previously published sequence23 in fewer than half the number of steps.  
 
4.2.2 Synthesis of the Acyclic Diyne 
Scheme 4.12. Synthesis of acyclic diyne from carvone 
 
  Following a procedure described by Mulzer27, we begin with nucleophilic epoxidation of 
(R)-carvone (450) to form epoxide 486 in 98% yield (Scheme 4.12). This is hydrolyzed using 










   THF/H2O (9:1), reflux
2. NaIO4, SiO2
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Simultaneous Fischer esterification/acetal protection of the aldehyde affords fragment 488 which 
is subsequently reduced with DIBAL–H to afford differentially protected dialdehyde 489 in five 
steps.  
Aldehyde 489 is first converted to gem-dibromide 490 under Wittig conditions. n-BuLi 
then promotes the Corey-Fuchs elimination, and the resultant alkynyllithium is quenched with 
TMSCl, generating acetylide 491. Subsequent treatment with aqueous acid then cleaves the acetal 
in one-pot, affording aldehyde 492 in 73% yield. In a similar fashion, aldehyde 493 is converted 
to dibromide 494 before Corey-Fuchs elimination generates an alkynyllithium species that is 
quenched with carbon dioxide to afford carboxylate 494. Subjugation to TBAF deprotects the 
acetylide in one-pot and generates diyne 472 in 49% yield. 
 
4.2.3 Convergent Esterification/Diels–Alder 
 With both fragments in hand, we turned our attention to the synthesis of the central six-
membered ring (Scheme 4.13). Equimolar quantities of diol 464 and acid 472 could be effectively 
coupled under Steglich esterification conditions28 generating Diels–Alder precursor 471 in 79% 
yield. Gratifyingly, we found that heating this intermediate for three hours in xylenes afforded 
cyclohexadiene 495 in 75% yield as a single diastereomer.  
Following the precedent of our ineleganolide route, 18 directed epoxidation with vanadium 
afforded selective epoxidation of the Δ-6,7 olefin in 94% yield as a single diasteromer29 496 before 
reductive cleavage with catalytic Ti30 generated secondary alcohol 497 stereoselectively. The 
oxidation of secondary alcohol 497 proved to be unexpectedly challenging, with our previously 
optimized DMP conditions providing inconsistent and poorly scalable yields. Other mild and 
robust oxidations (e.g., TPAP/NMO,31 CuOTf/ABNO/O232)  failed to effect this transformation in 
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synthetically useful yields. After further screening, we discovered that IBX in MeCN at 50 °C was 
uniquely effective in providing enone 470 in good yield with olefin migration occurring 
spontaneously upon purification on silica gel. We attribute this challenging oxidation to two 
factors: 1) steric hindrance, as the alcohol is buried in the concave face of intermediate 497, and 
2) potential hydrogen bonding within the syn-1,3-diol, which confers further stability.  
Scheme 4.13. Thermal [4+2] cycloaddition and oxidative manipulations. 
 
  
4.3  SYNTHESIS OF THE CYCLOHEPTENONE RING 
4.3.1  Initial Investigations of the Photochemical [2+2] Cycloaddition  
 With the western hemisphere of the natural product complete, we turned our attention to 
the appendage of the seven-membered ring. While Trost’s Ru-catalyzed hydrosilylation33 
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subsequent photocycloaddition upon irradiation with 350 nm light primarily yielded formation of 
the fused [5,6,4,4] system 500, which was confirmed through x-ray crystallography. No detectable 
quantity of the desired [5,6,4,5]-system 469a was observed. While we were aware that this 
undesired enone-isopropenyl olefin cycloaddition could occur, we predicted that the strained 
nature of these products would occlude formation in significant quantity. The exclusive formation 
of intermediate 500 indicated that optimization to select for desired tetracycle 469a was unlikely.  
Scheme 4.14. Hydrosilylation and unexpected photocycloaddition 
 
 Mechanistically, photoexcitation of enone 499 generates a triplet-state enone, best 
represented as a diradical species which can exist in a variety of conformers (Scheme 4.15). 
Conformation 501a would enable facile 6-exo-trig cyclization onto the isopropenyl fragment to 
generate 1,4-diradical 502 before radical recombination would then collapse to the observed [4,4]-
fused ring system 500; though enone-olefin photocycloadditions heavily favor five-membered ring 
formation, this reactivity has been previously observed for 1,1-disubstituted olefins.34 To obtain 
the desired product, the diradical would likely need to adopt conformation 501b prior to 5-exo trig 
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dimethylphenylsilyl substituent creates undesired steric interactions, which dissuades the adoption 
of this conformation.  
Scheme 4.15. Mechanistic rationale for the observed photocycloaddition 
 
 
4.3.2  Development of an Olefin Protection Strategy 
 To avoid this competitive reactivity, we elected to modify our route slightly by 
functionalizing the isopropenyl fragment prior to hydrosilylation; by removing this problematic 
unsaturation temporarily, we could realize our key cycloaddition/fragmentation sequence before 
unveiling this olefin at a later stage.  
 We first attempted to perform a Mukaiyama hydration (Table 4.1, Entry 1), but were 
disappointed to observe enone reduction as the major product (vida infra). 
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acid (Entry 3) or Snyder’s reagent35 (Entry 4) produced dehydration products. Sharpless 
dihydroxylation (Entry 5 and 6) led to modest diastereoselectivity, but a complex mixture of other 
products was also formed. 
Table 4.1. Optimization of the isopropenyl protection strategy. 
  
 We were delighted, however, to see that epoxidation with m-CPBA occurred cleanly in 
high yield but poor d.r. (Entry 7). Performing the reaction at lower temperature lead to decreases 
in yield and d.r. (Entry 8). Though Shi’s catalyst had been reported to promote diastereoselective 
epoxidation of other carvone derivatives,36 we were disappointed to see no improvement with our 
system (Entry 9). Jacobsen epoxidations37 with both enantiomers of catalyst (Entry 10 and 11) 








Mn(dpm)3 (15 mol %), PhSiH3, i-PrOH, 23 °C
2 No reactionTFA (5 equiv), CH2Cl2, 0 → 23°C
3 DehydrationAcCl, EtOH, 23 °C
4 Dehydrationdppe • SbCl5 • Cl2, wet MeNO2, 23 °C
5 18% yield, 2:1 d.r.AD-mix β, tBuOH/H2O (1:1), 23 °C
6 20% yield, 3:1 d.r.AD-mix α, tBuOH/H2O (1:1), 23 °C
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mCPBA, CH2Cl2, 0 → 23 °C
mCPBA, CH2Cl2, –10 °C
87% yield, 1.7:1 d.r.
9 50% yield, 1.5:1 d.r.-O- Shi’s Catalyst, Oxone, 1,4-dioxane/H2O, 0 → 23 °C



















11 No reaction-O- (S,S)-Jacobsen’s Catalyst, NaOCl, 1,4-dioxane/H2O, 0 → 23 °C
470 504–509
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4.3.3  Synthesis of the Cyclobutanol 
Though the diastereoselectivity of the epoxidation could not be improved, epoxide mixture 
509 was carried forward through the hydrosilylation (509 → 510, Scheme 4.16). To our delight, 
the subsequent photocycloaddition occurred smoothly, accessing cyclobutane 511 as a mixture of 
epoxide epimers. Reductive clevage with titanium then generates a seperable mixture of primary 
alcohols 512a and 512b in 1.7:1 d.r.38 Both intermediates can then be oxidized under Tamao-
Fleming conditions to cyclobutanols 513a and 513b.  
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Interestingly, the crystal structures display both intermediates as trans-fused cyclobutanols 
which would not be possible under the 5-exo trig mechanism previously hypothesized. 
Mechanistically, this observation can be explained by invoking a mechanism in which an initial 7-
endo trig between C(4) and C(5) of 514 occurs from the convex α-face of the molecule generating 
diradical 515a (Scheme 4.17). This long-lived radical species does not recombine until rotation of 
the C(5)–C(13) bond to conformation 515b occurs preceding recombination of the 1,4-diradical 
from the β-face; this prevents severe steric interactions between the bulky phenyldimethylsilyl 
substituent and the cyclohexanone ring generating trans-fused product 511. Similar 
stereochemical outcomes (i.e. preferential formation of trans-fused adducts) have been reported in 
analogous systems39 presumably due to the presence of substitution at the internal position of the 
reacting olefin. 
Scheme 4.17. Mechanistic rationale for the trans-fused cyclobutane 
  
 
4.3.4  Oxidative Fragmentation of the Cyclobutanol 
 Oxidation product 513a was subjected to an Ag-mediated fragmentation40 generating a 
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silica gel in methanol promoted elimination to cyclohexenone 518 (Scheme 4.18). We then 
investigated a number of methods to eliminate the primary alcohol including Chugaev elimination 
conditions, mesylation, brominations, iodination, Burgess’ reagent41 and Martin’s sulfurane,42 
though all were ultimately unsuccessful. We attribute this challenging elimination to steric 
hindrance of the unactivated C(15) proton, which is “thexyl”-like. We therefore limited our future 
efforts to unimolecular eliminations.  
Scheme 4.18. Failed fragmentation/elimination approach. 
 
 Turning our attention to the Grieco43 elimination, we were delighted to see that these 
conditions were highly amenable to elimination in this complex system. However, our major 
product was an intriguing ring-contracted cyclopropane 519 with no isolable quantity of scabrolide 
A (416) (Scheme 4.19). Mechanistically, we hypothesize that following displacement of the 
primary alcohol to selenide 520, adventitious cyanide forms cyanohydrin 521 that reacts with a 
second equivalent of the selenophosphonium species, generating oxophosphonium 522. This 
subsequently undergoes E1 elimination to the corresponding tertiary carbocation 523. The 
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carbocation which, upon deprotonation, generates cyclopropane 525. Addition of peroxide then 
completes the oxidation/intramolecular elimination sequence of the Grieco dehydration to generate 
the isolated species 519. 
Scheme 4.19. Unexpected ring contraction and proposed mechanism. 
 
 Given the proclivity of these systems to engage in transannular reactivity, we decided to 
change the order of steps in order to obviate the need to perform reactions in the presence of the 
highly reactive cycloheptenone. Grieco elimination of both 513a and 513b successfully promoted 











































































































Chapter 4: The Total Synthesis of (–)-Scabrolide A 306 
silver-mediated conditions created a complex mixture of products, we discovered that CuI/NIS 
conditions44 successfully promoted a one-pot fragmentation/elimination to access scabrolide A 
(416) in a single operation. 
Scheme 4.20. Completion of scabrolide A. 
 
 
4.4  CONCLUDING REMARKS 
 In summary, we have disclosed the first total synthesis of the norcembranoid diterpenoid 
(–)-scabrolide A. To our knowledge, this report constitutes the first total synthesis of any member 
of the polycyclic C19 furanobutenolide-derived norcembranoid diterpenoid family, a class of 
natural products that have evaded synthetic efforts for the more than two decades since their initial 
isolation. The route exploits the convergent esterification and subsequent intramolecular Diels–
Alder cycloaddition of two enantiopure fragments to introduce each of the 19 carbon atoms of the 
natural product. An initially unsuccessful [2+2] cycloaddition was enabled by an unconventional 
olefin protection strategy, which allows for the correct regiochemical outcome of this key reaction. 





















































0 → 23 °C
74% yield
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cycloheptenone ring and complete the total synthesis. Efforts are currently ongoing to extend this 
strategy toward the synthesis of other norecembranoid diterpenoids, and progress will be reported 
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4.6   EXPERIMENTAL SECTION 
4.6.1   Materials and Methods 
Unless otherwise stated, reactions were performed in flame-dried glassware under a 
nitrogen atmosphere using dry, deoxygenated solvents. Solvents were dried by passage through an 
activated alumina column under argon.1 Reaction progress was monitored by thin-layer 
chromatography (TLC). TLC was performed using E. Merck silica gel 60 F254 precoated glass 
plates (0.25 mm) and visualized by UV fluorescence quenching, p-anisaldehyde, or KMnO4 
staining. Silicycle SiliaFlash® P60 Academic Silica gel (particle size 40–63 µm) was used for 
flash chromatography. 1H NMR spectra were recorded on Varian Inova 500 MHz and 600 MHz 
and Bruker 400 MHz spectrometers and are reported relative to residual CHCl3 (δ 7.26 ppm), C6D6 
(δ 7.16 ppm) or CD3OD (δ 3.31 ppm). 13C NMR spectra were recorded on a Varian Inova 500 
MHz spectrometer (125 MHz) and Bruker 400 MHz spectrometers (100 MHz) and are reported 
relative to CHCl3 (δ 77.16 ppm), C6D6 (δ 128.06 ppm) or CD3OD (δ 49.01 ppm). Data for 1H 
NMR are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), 
integration). Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, 
p = pentet, sept = septuplet, m = multiplet, br s = broad singlet, br d = broad doublet. Data for 13C 
NMR are reported in terms of chemical shifts (δ ppm). IR spectra were obtained by use of a Perkin 
Elmer Spectrum BXII spectrometer or Nicolet 6700 FTIR spectrometer using thin films deposited 
on NaCl plates and reported in frequency of absorption (cm–1). Optical rotations were measured 
with a Jasco P-2000 polarimeter operating on the sodium D-line (589 nm), using a 100 mm path- 
length cell. High resolution mass spectra (HRMS) were obtained from the Caltech Mass Spectral 
Facility using a JEOL JMS-600H High Resolution Mass Spectrometer in fast atom bombardment 
(FAB+) or electron ionization (EI+) mode, or using an Agilent 6200 Series TOF with an Agilent 
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G1978A Multimode source in electrospray ionization (ESI+), atmospheric pressure chemical 
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4.6.2   Experimental Procedures 
 
 
Vinylcyclopentanone 482: To a flame-dried 500 mL three-necked flask is added CuBr • DMS 
(543 mg, 2.65 mmol, 0.12 equiv). The flask is evacuated and back-filled three times with argon, 
and charged with THF (110 mL). The solution is cooled to –78 °C and vinylmagnesium bromide 
in THF (1.0 M, 26.5 mL, 1.2 equiv) is added. The flask is equipped with an addition funnel and 
stirred at –78 °C for 30 minutes, during which time the solution turned from dark to red-brown. In 
a separate 100 mL flask, enone 481, prepared according to the procedure of Maimone2, (5.0 g, 
22.1 mmol, 1.0 equiv) is dissolved in THF (22.1 mL). HMPA (10.97 mL, 66.1 mmol, 3.0 equiv) 
and TMSCl (6.94 mL, 55.2 mmol, 2.5 equiv) are added at room temperature, and stirred for 5 
minutes. This solution is transferred to the addition funnel and slowly added to the flask over 1 
hour; an internal temperature no greater than –70 °C should be maintained and the solution will 
turn orange to yellow to dark brown.  
Upon complete addition, the reaction is stirred at -78 °C for an additional hour, then 
warmed to 0 °C. Saturated aq NH4Cl (125 mL) is added before stirring at 0 °C for 1 hour. The 
layers are separated and the aqueous layer is extracted with diethyl ether (3X). The combined 
organics are washed with brine, dried with MgSO4, and concentrated under reduced pressure. Flash 
column chromatography (10 → 20% Et2O/Hexanes) affords the title compound (3.59 g, 64% yield, 






CuBr•DMS (12 mol %) 
TMSCl, HMPA
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Major Diastereomer: 1H NMR (400 MHz, CDCl3) δ 5.81 (ddd, J = 17.1, 10.4, 7.4 Hz, 1H), 5.26 
– 4.92 (m, 2H), 2.89 (dtd, J = 8.1, 6.7, 1.2 Hz, 1H), 2.64 (ddd, J = 18.7, 8.2, 1.1 Hz, 1H), 2.39 (d, 
J = 17.8 Hz, 1H), 2.32 (dd, J = 17.6, 1.1 Hz, 1H), 2.17 (dd, J = 18.7, 6.6, 1.1 Hz, 1H), 1.27 (s, 
3H), 0.85 (s, 6H), 0.10 (d, J = 8.0 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 216.2, 136.9, 116.6, 
79.7, 53.5, 52.8, 42.2, 25.7, 24.2, 18.0, –2.2, –2.4; IR (Neat film, NaCl) 2956, 2930, 2857, 1750, 
1471, 1462, 1402, 1378, 1257, 1162, 1114, 1025, 997, 918, 836, 774, 617 cm–1; HRMS (FAB+) 
m/z calc’d for C14H27O2Si [M+H]+: 255.1780, found 255.1784; [α]D25.0 –30.0° (c 1.0 , CHCl3).  
 
 
Silyl Enol Ether 483: A 500 mL round-bottom flask is soaked in a base bath overnight, then 
washed, flame-dried, and placed under nitrogen atmosphere. The flask is charged with 2,2,6,6- 
tetramethylpiperidine (4.01 mL, 23.63 mmol, 1.2 equiv) and THF (108 mL) before it is cooled to 
–78 °C. n-BuLi (9.30 mL of 2.33 M, 1.1 equiv) is added to the flask, then stirred at 0 °C for 1 hr. 
The flask is cooled to –78 °C and charged with TESCl (3.96 mL, 23.6 mmol, 1.2 equiv), then 
stirred for 5 minutes. Using a syringe pump, vinylcyclopentanone 482 (5.00 g, 19.69 mmol, 1.0 
equiv) in THF (20 mL) is added dropwise over 1 hour.  
Upon complete addition, the reaction is stirred until complete by TLC (15 minutes.) 
Triethylamine (5 mL) is added and the reaction is quenched with a saturated aqueous sodium 
bicarbonate solution, and gradually warmed to 23 °C. The layers are separated and the aqueous 
layer is extracted with hexanes (5X). The combined organics are washed with water and 0.1 M 
citric acid solution, dried with sodium sulfate, and concentrated under reduced pressure. Flash 
66% yield
LiTMP, TESCl
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column chromatography (2.5% Et2O/Hexanes) affords the title compound (4.78 g, 12.96 mmol, 
66% yield, 9:1 mixture of diastereomers) as a colorless oil.  
Major diastereomer: 1H NMR (400 MHz, C6D6) δ 5.81 (ddd, J = 17.1, 10.1, 7.9 Hz, 1H), 5.16 
(ddd, J = 17.1, 2.2, 1.2 Hz, 1H), 5.05 (ddd, J = 10.1, 2.2, 0.9 Hz, 1H), 4.66 (q, J = 1.8 Hz, 1H), 
3.42 (ddq, J = 6.6, 2.3, 1.2 Hz, 1H), 2.68 (dt, J = 15.7, 1.6 Hz, 1H), 2.41 (dt, J = 15.7, 1.4 Hz, 1H), 
1.27 (s, 3H), 1.04 – 0.99 (m, 18H), 0.73 – 0.61 (m, 6H), 0.15 (s, 3H), 0.14 (s, 3H); 13C NMR (100 
MHz, C6D6) δ 153.9, 139.3, 115.2, 103.2, 81.9, 59.9, 50.7, 26.8, 26.3, 18.5, 7.2, 5.5, –2.0, –1.9. IR 
(Neat film, NaCl) 3078, 2955, 2933, 2477, 2856, 1647, 1459, 1360, 1334, 1250, 1226, 1135, 1091, 
1018 1004, 918, 834, 799, 774, 746 cm–1; HRMS (FAB+) m/z calc’d for C20H39O2Si2 [M–H]+: 
367.2489, found 367.2489; [α]D25.0 –66.8° (c 1.0, CHCl3).  
	
	
Dienone 484: A 1 L round-bottomed flask is charged with silyl enol ether 483 (5.80 g, 15.76 mmol, 
1.0 equiv) in benzene (310 mL). HMDS is added dropwise via syringe and the resulting solution 
is stirred for 5 minutes. DDQ (7.87 g, 34.67 mmol, 2.2 equiv) is added in a single portion, and the 
reaction is stirred for 45 minutes, during which time it turns from black to bright red. Celite (30 g) 
is added to the reaction, then concentrated and dried on high vaccum for 1 h. Flash column 
chromatography (1% → 10% Et2O/Hexanes) affords the title compound as a gold oil (3.35 g, 13.27 
mmol, 84% yield) along with triethylsilanol as a coeluted impurity (1.16 g as determined by 1H 
NMR). A pure sample for characterization is obtained by preparative TLC (30% Et2O/Hexane). 
1H NMR (400 MHz, CDCl3) δ 6.56 (ddd, J = 17.8, 11.1, 0.8 Hz, 1H), 6.14 – 5.99 (m, 2H), 5.70 
DDQ, HMDS
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(dd, J = 11.1, 1.5 Hz, 1H), 2.70 (dd, J = 17.9, 0.7 Hz, 1H), 2.57 (d, J = 17.8 Hz, 1H), 1.53 (d, J = 
0.6 Hz, 3H), 0.86 (s, 9H), 0.13 (s, 3H), 0.07 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 205.0, 175.9, 
129.0, 126.5, 125.5, 78.8, 53.2, 29.2, 25.8, 18.1, –2.3, –2.7; IR (Neat film, NaCl) 2955, 2930, 2857, 
1709, 1603, 1473, 1361, 1336, 1253, 1232, 1206, 1159, 1074, 1004, 938, 862, 834, 776 cm–1; 
HRMS (FAB+) m/z calc’d for C14H25O2Si [M+H]+: 253.1624, found 253.1622; [a]D25.0 –92.1° (c 
0.2, CHCl3).  
	
	
Diol XX: A 500-mL round-bottom flask is charged with dienone 484 (2.69 g, 10.67 mmol, 1.0 
equiv) in MeOH (110 mL) and cooled to –78 °C. CeCl3 • 7 H2O (5.17 g, 13.87 mmol, 1.3 equiv) 
is added, and the solution is stirred for 5 minutes before NaBH4 (534 mg, 13.87 mmol, 1.3 equiv) 
is added in a single portion. The reaction is stirred at –78 °C for 1 hour, warmed to room 
temperature, and quenched with saturated, aqueous ammonium chloride. The mixture is 
concentrated on a rotary evaporator to remove methanol, transferred to a separatory funnel, and 
extracted with diethyl ether (3X). The combined organics are washed with brine, dried with 
MgSO4, and concentrated to afford an orange oil which is used directly in the next step without 
further purification.  
To a 500 mL flame-dried flask is added the crude reduction product in THF (150 mL). 1M 
TBAF in THF (15.0 mL equiv, 15.0 mmol, 1.4 equiv) is added dropwise by syringe. The flask is 
equipped with a reflux condenser and heated to reflux for 8 h. After completion as judged by TLC, 
the reaction is cooled to 23 °C and quenched with brine. The mixture is extracted with ethyl acetate 
1. CeCl3 • 7 H2O, NaBH4
    MeOH, –78 °C, 1h
2. TBAF
    THF, reflux, 8h
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(5X) before the combined organic layers are washed with brine, dried with Na2SO4, and 
concentrated under reduced pressure onto silica gel. The mixture is purified by flash column 
chromatography (50 → 75% → 100% ethyl acetate/hexanes) to afford the title compound (1.17 g, 
8.35 mmol, 78% yield over two steps) as an amorphous white solid. All spectral data for 11 was 
found to be in good accordance with literature values.3 
	
	
Dibromide 490: A 500 mL round-bottom flask is charged with Br2CHPPh3Br•MeCN (55.6 g, 
100.0 mmol, 1.4 equiv; prepared according to the method of Mulzer)4 and THF (238 mL, 0.3 M). 
The reaction mixture is cooled to 0 °C and t-BuOK (9.6 g, 85.7 mmol, 1.2 equiv) is added in one 
portion. This mixture is stirred 1.5 h at 0 °C and then warmed to 23 °C and stirred an additional 
30 min. The mixture is cooled to 23 °C and aldehyde 489 (13.3 g, 71.4 mmol, 1.0 equiv) is added 
dropwise via syringe. The dark suspension is stirred for 2 h at 0 °C until no aldehyde is detected 
by TLC. The mixture is quenched with saturated, aqueous NH4Cl and partitioned between water 
and Et2O. The aqueous phase is extracted with Et2O (3X). The organic extracts are combined, 
washed with brine, dried over magnesium sulfate, filtered through a sand/cotton plug and 
concentrated under reduced pressure. The crude residue is purified by flash chromatography (Dry 
load crude on Celite; 20% Et2O/Hexanes) to afford the title compound (20.9 g, 61.1 mmol, 86% 
yield) as a red/orange oil: 1H NMR (400 MHz, CDCl3) 6.30 (t, J = 7.0 Hz, 1H), 4.83 (dt, J = 2.9, 
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2.30 (m, 1H), 2.24 – 2.07 (m, 2H), 1.72 – 1.62 (m, 5H); 13C NMR (125 MHz, CDCl3) 145.7, 137.0, 
113.0, 102.9, 89.2, 53.3, 52.7, 42.0, 36.9, 35.7, 18.6; IR (Neat film, NaCl) 3073, 2948, 2829, 1645, 
1440, 1377, 1191, 1127, 1060, 896, 787 cm-1; HRMS (FAB+) m/z calc’d for C11H17O2Br2 [M– 
H]+: 340.9575, found 340.9579; [α]D25.0 – 4.5° (c 1.0, CHCl3).  
 
 
Aldehyde 492: A 500 mL round-bottom flask is charged with dibromide 490 (16.6 g, 48.5 mmol, 
1.0 equiv) in THF (100 mL, 0.5 M), and cooled to –78 °C. n-BuLi (2.3 M in hexanes; 42.2 mL, 
97.1 mmol, 2.0 equiv) is added dropwise over 10 min, and the mixture is allowed to stir for 15 min 
at –78 °C after which complete consumption of dibromide 490 is observed by TLC. TMSCl (18.5 
mL, 145.5 mmol, 3.0 equiv) is added dropwise to the reaction mixture, which is then allowed to 
gradually warm to 23 °C over 2 h. The mixture is then cooled to 0 °C and water (100 mL) is added 
followed by 1,4-dioxane (50 mL). HCl (36% w/w, 40 mL, 10.0 equiv) is added and the reaction 
mixture is warmed to room temperature and allowed to stir for 16 h. NaHCO3 (sat. aq.) is added 
until the pH of the solution is roughly 7. The reaction mixture is partitioned between water and 
Et2O, and extracted with Et2O (3X). The combined organic extracts are washed with brine, dried 
over sodium sulfate, and concentrated to afford an orange oil which is purified by flash 
chromatography (10% Et2O/Hexanes). The title compound (7.37 g, 35.4 mmol, 73% yield) is 
isolated as a pale-yellow oil: 1H NMR (400 MHz, CDCl3) δ 9.70 (dd, J = 2.4, 1.6 Hz, 1H), 4.83 – 
4.80 (m, 1H), 4.79 – 4.76 (m, 1H), 2.89 – 2.77 (m, 1H), 2.68 (ddd, J = 16.8, 6.1, 1.7 Hz, 1H), 2.52 
CBr4, PPh3
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(ddd, J = 16.7, 8.4, 2.5 Hz, 1H), 2.40 (dd, J = 16.9, 5.8 Hz, 1H), 2.29 (dd, J = 17.0, 7.9 Hz, 1H), 
1.70 (dd, J = 1.5, 0.9 Hz, 3H), 0.11 (s, 9H); 13C NMR (100 MHz, CDCl3) 201.6, 145.4, 112.3, 
104.5, 87.3, 46.3, 40.2, 24.8, 20.3, 0.1; IR (Neat film, NaCl) 3077, 2959, 2900, 2827, 2720, 1727, 
1648, 1430, 1408, 1377, 1250, 1024, 1038, 896, 760, 644 cm-1; HRMS (MM: ESI-APCI+) m/z 
calc’d for C12H21OSi [M+H]+ 209.1356, found 209.1352.; [α]D25.0 –13.5° (c 1.0, CHCl3).  
 
 
Dibromide 493: A 500 mL round-bottom flask is charged with triphenylphosphine (50.4 g, 192.0 
mmol, 4.0 equiv) in CH2Cl2 (96 mL). The solution is cooled to 0 °C, and CBr4 (31.8 g, 96.0 mmol, 
2.0 equiv) is added in one portion. The colorless solution immediately changes to yellow/orange 
in color. The mixture is allowed to stir for 10 min at 0 °C, after which aldehyde 492 (10.0 g, 48.0 
mmol, 1.0 equiv) is added via syringe. The aldehyde is consumed immediately, as judged by TLC. 
The reaction mixture is then quenched with water, and partitioned between water and CH2Cl2. The 
aqueous phase is extracted with CH2Cl2 (3X), and the combined organic extracts are washed with 
brine and dried over MgSO4. The crude is concentrated onto SiO2, loaded onto a column, and 
purified by flash chromatography (5% Et2O/Hexanes) to afford the title compound (14.48 g, 39.8 
mmol, 83% yield) as a yellow oil: 1H NMR (400 MHz, CDCl3) 6.34 (t, J = 6.9 Hz, 1H), 4.84 (p, 
J = 1.5 Hz, 1H), 4.76 (dt, J = 1.7, 0.8 Hz, 1H), 2.47 – 2.16 (m, 5H), 1.69 (dd, J = 1.5, 0.8 Hz, 3H), 
0.14 (s, 9H); 13C NMR (100 MHz, CDCl3) 145.4, 136.9, 112.7, 105.1, 89.5, 86.75, 44.9, 35.8, 
CBr4, PPh3
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24.7, 19.7, 0.3; IR (Neat film, NaCl) 2958, 2922, 2176,1646, 1441, 1248 cm-1; HRMS (EI+) m/z 
calc’d for C13H20SiBr2 [M+•] 363.9681, found 363.9668; [α]D25.0 +4.1° (c 1.0, CHCl3).  
 
 
Ynoic Acid 472: A 250 mL round bottom flask was charged with dibromide 493 (9.27 g, 25.45 
mmol, 1.0 equiv) in THF (52 mL). The solution was cooled to –78 °C, and n-BuLi (2.3 M in 
hexanes; 16.6 mL, 38.18 mmol, 1.5 equiv) was added dropwise. After 10 min, dibromide 493 had 
been completely consumed (as judged by TLC), and the reaction was then sparged with CO2 from 
a balloon passing through a drying tube full of Dryrite. The solution was allowed to warm to 23 
°C over 30 min with continuous sparging with CO2. The solution was then sparged with N2 for 10 
min at 23 °C, followed by the addition of TBAF (1.0 M in THF; 50.9 mL, 50.9 mmol, 2.0 equiv). 
The solution was allowed to stir for 16 h at 23 °C after which TMS-protected substrate remained, 
as judged by LCMS. TBAF (25.5 mL, 25.5 mmol, 1.0 equiv) was added, and the reaction was 
stirred an additional 1 h at 23 °C. The reaction was quenched with sat. aq. NaHCO3, diluted with 
water and EtOAc, and extracted with EtOAc (1X). The aqueous extract was then acidified with 
conc. HCl until a cloudy precipitate was observed. The aqueous was then extracted with EtOAc 
(3X). The combined organic extracts were then washed with brine and dried over MgSO4. 
Concentration under reduced pressure afforded the title compound (2.20 g, 12.5 mmol, 49% yield) 
as a pale orange oil which was found to be pure by NMR and used in the subsequent step without 








THF, –78 °C, 10 min
then CO2, 40 min
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(q, J = 1.0 Hz, 1H), 2.71 – 2.47 (m, 3H), 2.41 (d, J = 2.7 Hz, 1H), 2.40 – 2.39 (m, 1H), 2.01 (t, J 
= 2.6 Hz, 1H), 1.73 (dd, J = 1.5, 0.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 158.4, 144.1, 113.1, 
90.3, 81.6, 74.1, 70.6, 43.7, 22.5, 22.4, 20.2; IR (Neat film, NaCl) 3302, 2928, 2643, 2236, 2119, 
1964, 1416, 1244, 1078, 899, 775, 792, 759, 641, 648 cm -1; HRMS (MM: ESI-APCI+) m/z calc’d 
for C11H13O2 [M+H]+: 177.0910, found 177.0916; [a]D25.0 –1.6° (c 1.0, CHCl3).  
 
 
Ester XX: A 250 mL round bottom flask is charged with diol 464 (1.03 g, 7.35 mmol, 1.0 equiv), 
acid 472 (1.30 g, 7.35 mmol, 1.0) and DMAP (90 mg, 0.735 mmol, 0.10 equiv) in CH2Cl2 (74 
mL). The solution is cooled to 0 °C, and DIC (1.15 mL, 7.35 mmol, 1.0 equiv) is added dropwise. 
The reaction is stirred for 2 h while gradually warming to 23 °C, and then stirred an additional 3 h 
at 23 °C. The mixture is then partitioned between CH2Cl2 and H2O, and the aqueous phase is 
extracted with CH2Cl2 (3X). The organic extracts are washed with brine, dried over Na2SO4, and 
concentrated. The crude residue was purified by flash chromatography (0% → 5% → 10% → 15% 
→ 20% EtOAc/Hexanes) to afford the title compound (1.74 g, 5.83 mmol, 79% yield) as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 6.43 – 6.20 (m, 1H), 5.82 (d, J = 2.4 Hz, 1H), 5.78 
(dd, J = 17.8, 1.7 Hz, 1H), 5.64 – 5.49 (m, 1H), 5.33 (dd, J = 11.2, 1.6 Hz, 1H), 4.92 (p, J = 1.4 
Hz, 1H), 4.84 (dd, J = 1.4, 0.8 Hz, 1H), 2.77 – 2.46 (m, 4H), 2.44 – 2.39 (m, 2H), 2.05 (dd, J = 
14.7, 4.4 Hz, 1H), 2.01 (t, J = 2.6 Hz, 1H), 1.74 (dd, J = 1.5, 0.8 Hz, 3H), 1.44 (s, 3H); 13C NMR 
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70.5, 49.0, 43.8, 26.8, 22.5, 22.4, 20.3; IR (Neat film, NaCl) 3396, 2938, 2235, 1708, 1252, 1071, 
942, 752 cm-1; HRMS (MM: ESI-APCI+) m/z calc’d for C19H23O3 [M+H]+: 299.1642, found 
299.1632; [α]D25.0 –130.8° (c 1.0, CHCl3).  
 
 
Cyclohexadiene 495: Ester 471 (804 mg, 2.69 mmol, 1.0 equiv) is dissolved in xylenes (270 mL). 
This solution is divided between two 500 mL Schlenk flasks. Each flask is subjected to three 
freeze-pump-thaw cycles, and then back-filled with nitrogen. The flasks are sealed, heated to 140 
°C, and stirred for 3 h. The flasks are then cooled to ambient temperature and the reaction mixtures 
are combined in a 2 L round-bottom flask. The solvent is removed under reduced pressure, and the 
resulting solid is purified by flash chromatography (30% → 40% → 50% EtOAc/Hexanes) to 
afford the title compound (604 mg, 2.02 mmol, 75% yield) as a flakey white solid: 1H NMR (400 
MHz, CDCl3) δ 5.84 (ddd, J = 6.4, 3.0, 1.9 Hz, 1H), 4.97 (ddd, J = 9.1, 8.0, 7.0 Hz, 1H), 4.77 (t, J 
= 1.7 Hz, 1H), 4.69 – 4.65 (m, 1H), 3.31 (t, J = 9.8 Hz, 1H), 3.12 – 2.98 (m, 2H), 2.83 – 2.61 (m, 
2H), 2.63 – 2.41 (m, 2H), 2.33 (d, J = 2.6 Hz, 1H), 2.32 (dd, J = 2.7, 1.4 Hz, 1H), 2.00 (t, J = 2.6 
Hz, 1H), 1.69 (dd, J = 1.4, 0.8 Hz, 3H), 1.67 – 1.60 (m, 1H), 1.41 (d, J = 1.1 Hz, 3H); δ 13C NMR 
(100 MHz, CDCl3) δ 168.2, 155.9, 152.0, 146.1, 125.5, 116.5, 112.8, 82.9, 80.0, 75.3, 69.7, 49.8, 
45.7, 45.7, 35.3, 26.7, 22.9, 18.8 cm-1; IR (Neat film, NaCl) 3305, 2967, 2920, 2360, 2118, 1730, 
1647, 1447, 1374, 1358, 1290, 1219, 1045, 1018, 896, 632 cm-1; HRMS (MM: ESI-APCI+) m/z 













xylenes, 140 °C, 3h
75% yield 
>20:1 d.r.
Chapter 4: The Total Synthesis of (–)-Scabrolide A 324	
 
 
Epoxide 18: A 500 mL round-bottom flask is charged with Diels–Alder adduct 495 (1.75 g, 5.87 
mmol, 1.0 equiv) in a mixture of CH2Cl2 (59 mL) and benzene (196 mL). VO(acac)2 is added (117 
mg, 0.440 mmol, 0.075 equiv) in one portion, and the mixture is stirred 10 min at 23 °C until it is 
pale-green in color. TBHP (5.0 M in decane, 2.30 mL, 11.74 mmol, 2.0 equiv) is added dropwise 
via syringe, and the mixture becomes deep-red in color. The mixture is stirred at 23 °C for 1 h, at 
which point no starting material remained, as judged by TLC. The reaction mixture is poured 
directly onto a flash column and purified by flash chromatography (0% → 50% → 70% → 80% 
EtOAc/Hexanes) to afford the title compound (1.73 g, 5.50 mmol, 94% yield) as an amorphous 
white solid. 1H NMR (400 MHz, CDCl3) δ 4.90 – 4.77 (m, 3H), 3.78 (d, J = 3.4 Hz, 1H), 3.40 – 
3.18 (m, 2H), 2.87 (dd, J = 16.7, 3.4 Hz, 1H), 2.62 – 2.43 (m, 3H), 2.41 – 2.26 (m, 3H), 2.06 – 
1.95 (m, 2H), 1.74 (t, J = 1.1 Hz, 3H), 1.46 – 1.41 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 168.9, 
149.9, 146.1, 120.7, 112.5, 82.9, 76.6, 73.6, 69.8, 69.7, 51.8, 50.1, 45.7, 44.8, 36.7, 36.6, 22.7, 
22.7, 19.4; IR (Neat film, NaCl) 3474, 3267, 1735, 1655, 1421, 1358, 1195, 1120, 1030, 901, 793, 
674 cm-1; HRMS (MM: ESI-APCI+) m/z calc’d for C19H23O4 [M+H]+: 315.1591, found 315.1586; 




VO(acac)2 (12 mol %)
t-BuOOH
PhH/CH2Cl2 
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Diol 497: A 250 mL round bottom flask is charged with epoxide 496 (1.70 g, 5.41 mmol, 1.0 
equiv), titanocene dichloride (269 mg, 1.08 mmol, 0.20 equiv), manganese dust (326 mg, 5.95 
mmol, 1.10 equiv), and collidine•HCl (1.07 g, 6.76 mmol, 1.25 equiv) in THF (54 mL, 0.10 M). 
1,4- cyclohexadiene is then added dropwise to the red suspension, which gradually changes to a 
blue/grey color. The suspension is stirred for 2 h at 23 °C, after which the starting material is 
consumed, as judged by TLC. Celite is added directly to the mixture, and the solvent is removed 
under reduced pressure. The resulting solid is loaded directly onto a flash column and purified by 
flash chromatography (40% → 50% → 60% EtOAc/Hexanes) to afford the title compound (1.47 
g, 4.65 mmol, 86% yield) as an off-white solid: 1H NMR (400 MHz, CDCl3) 4.90 (ddd, J = 8.1, 
6.5, 3.9 Hz, 1H), 4.83 (d, J = 1.4 Hz, 2H), 4.67 (td, J = 5.4, 2.9 Hz, 1H), 3.40 (d, J = 6.0 Hz, 1H), 
3.37 – 3.28 (m, 1H), 3.18 (s, 1H), 3.10 (ddd, J = 9.9, 7.9, 2.1 Hz, 1H), 2.64 – 2.48 (m, 3H), 2.36 
(dd, J = 9.5, 7.8 Hz, 1H), 2.32 (dd, J = 2.7, 1.1 Hz, 1H), 2.31 – 2.29 (m, 1H), 2.13 – 1.98 (m, 3H), 
1.97 (t, J = 2.6 Hz, 1H), 1.80 – 1.71 (m, 3H), 1.43 (s, 3H); δ 13C NMR (100 MHz, CDCl3) δ 169.8, 
151.3, 146.8, 125.2, 112.4, 83.2, 81.7, 79.4, 69.5, 68.3, 49.6, 48.4, 45.2, 44.6, 41.4, 36.8, 28.6, 
22.9, 19.3; IR (Neat film, NaCl) 3296, 3076, 2116, 1738, 1731, 1668, 1424, 1375, 1360, 1306, 
1223, 1198, 1105, 896 cm–1; HRMS (MM: ESI-APCI+) m/z calc’d for C19H25O4 [M+H]+: 
















Cp2TiCl2 (20 mol%) 
1,4-CHD, Mn0
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Note: The success of this procedure was found to be scale-dependent. Consequently, this reaction 
was run with a maximum batch size of 50 mg (497) per reaction flask. When run on scale, reactions 
were set up side-by-side, and combined for purification, as detailed below:  
Enone 470: Diol 497 (1.0 g, 3.16 mmol, 1.0 equiv) is divided into 20 scintillation vials (not flame 
dried, 50 mg, 0.158 mmol per vial) each equipped with a magnetic stir bar and a septum cap. To 
each vial is added IBX (188 mg, 0.671 mmol, 4.25 equiv) and each vial is evacuated and back- 
filled with N2. MeCN (11 mL) is added to each vial after which the vials are sealed, heated to 50 
°C, and stirred for 2 h. The reactions are cooled to 23 °C, combined, and filtered over a plug of 
SiO2, rinsing generously with EtOAc. The filtrate is concentrated under reduced pressure, and the 
residue obtained is purified by flash chromatography (30% → 40% → 50% EtOAc/Hexanes) to 
afford the title compound (716 mg, 2.28 mmol, 72% yield) as a white foam: 1H NMR (400 MHz, 
CDCl3) δ 6.00 (d, J = 1.0 Hz, 1H), 5.11 (dd, J = 6.7, 5.4 Hz, 1H), 4.88 – 4.81 (m, 1H), 4.78 (dt, J 
= 1.6, 0.8 Hz, 1H), 3.68 – 3.45 (m, 2H), 3.16 – 3.05 (m, 1H), 2.79 – 2.59 (m, 2H), 2.48 (d, J = 9.2 
Hz, 1H), 2.39 – 2.28 (m, 3H), 2.03 (t, J = 2.6 Hz, 1H), 1.88 (dd, J = 15.0, 5.5 Hz, 1H), 1.71 (s, 
1H), 1.67 (d, J = 0.7 Hz, 3H), 1.49 (s, 3H); δ 13C NMR (100 MHz, CDCl3) δ 196.1, 173.6, 156.3, 
145.0, 128.8, 113.6, 82.7, 82.6, 82.2, 70.5, 55.2, 47.4, 44.0, 42.1, 41.4, 38.2, 26.3, 23.9, 18.8; IR 
(Neat film, NaCl) 3450, 3290, 2970, 2930, 2118, 1758, 1649, 1376, 1290, 1176, 1161, 1107, 912, 
735 cm–1; HRMS (MM: ESI-APCI+) m/z calc’d for C19H23O4 [M+H]+: 315.1591, found 315.1571; 



















MeCN, 50 °C, 2h
then SiO2
72% yield
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Vinyl Silane 499: A 1-dram vial is charged with enone 470 (7.0 mg, 0.0223 mmol, 1.0 equiv) in 
CH2Cl2 (400 µL). Phenyldimethylsilane (4 µL, 0.0267 mmol, 1.2 equiv) is added, and the mixture 
is cooled to 0 °C. [RuCp*(MeCN)3]PF6 (10 mg/mL stock solution 56 µL, 0.00112 mmol, 0.05 
equiv) is added dropwise. Following the addition, the reaction is stirred 5 min at 0 °C, after which 
alkyne 470 is no longer detectable by TLC. The reaction mixture is loaded directly onto a 
preparatory TLC plate and purified by preparatory TLC (80% EtOAc/Hexanes) to afford the title 
compound (9.0 mg, 0.0200 mmol, 90% yield) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 
7.68 – 7.46 (m, 2H), 7.39 – 7.31 (m, 3H), 5.80 (t, J = 1.4 Hz, 1H), 5.70 – 5.64 (m, 1H), 5.54 (d, J 
= 2.8 Hz, 1H), 5.04 (dd, J = 7.1, 5.3 Hz, 1H), 4.66 – 4.59 (m, 1H), 4.40 – 4.32 (m, 1H), 3.32 (td, J 
= 10.6, 7.1 Hz, 1H), 2.94 – 2.74 (m, 2H), 2.50 – 2.24 (m, 5H), 2.22 – 2.09 (m, 1H), 1.85 (dd, J = 
14.9, 5.5 Hz, 1H), 1.52 (s, 3H), 1.47 (s, 3H), 0.41 (s, 3H), 0.39 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 196.0, 173.4, 157.3, 147.7, 146.3, 138.9, 134.2, 129.0, 128.6, 128.6, 128.0, 112.7, 82.6, 
82.3, 55.1, 47.3, 43.7, 42.1, 41.9, 40.5, 38.3, 26.5, 18.0, -2.7, -3.2; IR (Neat Film NaCl) 3434, 
3049, 2962, 1762, 1654, 1427, 1376, 1290, 1250, 1216, 1173, 1160, 1109, 1030, 992, 933, 891, 
834, 817, 776, 736, 703 cm–1; HRMS (MM: ES+) m/z calc’d for C27H35O4Si [M+H]+: 451.2305, 
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Cyclobutane XX: A 1-dram vial is charged with vinyl silane 499 (22 mg, 0.0488 mmol, 1.0 equiv) 
in PhH (5.0 mL). The solution is sparged with N2 for 5 min, and placed in a photoreactor equipped 
with Hitachi UVA bulbs (F8T5-BLB, ~350 nm). The reaction is stirred under 350 nm irradiation 
for 10 h, after which no starting material remains (as judged by TLC). An 1HNMR spectrum of 
the crude product shows a mixture with 21 as the major constituent. The crude white solid is 
purified by flash chromatography (50% EtOAc/Hexanes), followed by normal-phase (SiO2) 
preparative HPLC (EtOAc/Hexanes, 7.0 mL/min, monitoring wavelength = 254 nm, isocratic– 
50% EtOAc/Hexanes, 10 min) then reverse-phase (C18) preparative HPLC (MeCN/H2O, 9.0 
mL/min, monitoring wavelength = 260 nm, isocratic– 70% MeCN/H2O, 10 min) to afford pure 21 
(5.0 mg, 0.0111 mmol, 23 % yield). X-ray quality crystals are grown by slow cooling from i-PrOH: 
1H NMR (400 MHz, CDCl3) δ 7.54 – 7.46 (m, 2H), 7.38 – 7.32 (m, 3H), 5.68 – 5.61 (m, 1H), 5.40 
(d, J = 2.8 Hz, 1H), 4.95 (ddd, J = 7.0, 5.6, 1.6 Hz, 1H), 3.46 (td, J = 10.2, 6.7 Hz, 1H), 3.09 – 
2.93 (m, 1H), 2.89 – 2.78 (m, 2H), 2.77 – 2.61 (m, 2H), 2.33 – 2.14 (m, 4H), 1.98 (dd, J = 14.8, 
5.6 Hz, 1H), 1.94 – 1.85 (m, 1H), 1.75 (dd, J = 13.1, 4.3 Hz, 1H), 1.41 (s, 3H), 1.00 (s, 3H), 0.37 
(s, 6H); 13C NMR (100 MHz, CDCl3) δ 215.1, 175.7, 148.1, 138.2, 134.1, 129.2, 127.9, 126.9, 
82.0, 81.5, 55.1, 49.2, 46.6, 46.6, 44.5, 43.5, 38.7, 38.6, 36.1, 34.1, 31.0, 27.6, 21.7, -2.8, -2.9; IR 
(Neat Film NaCl) 3453, 2934, 2858, 1759, 1689, 1428, 1375, 1248, 1206, 1106, 1012, 938, 858, 
833, 818, 703 cm–1; HRMS (MM: ES+) m/z calc’d for C27H35O4Si [M+H]+: 451.2305, found 
451.2321; [α]D25.0 –113.4 ° (c 0.12, CHCl3).  
 
hν (350 nm)
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Epoxides 509a and 509b: A 100 mL round-bottom flask is charged with enone 470 (450 mg, 1.43 
mmol, 1.0 equiv) in CH2Cl2 (48 mL). The solution is cooled to 0 °C, and m–CPBA (~70% wt/wt; 
1.06 g, 4.29 mmol, 3.0 equiv) is added in one portion. The mixture is stirred while gradually 
warming to 23 °C over 2 h, and then stirred an additional 10 h at 23 °C, at which point XX has 
been completely consumed as judged by TLC. The reaction mixture is poured directly onto a flash 
column and purified by flash chromatography (50% → 60% → 70% → 80% EtOAc/Hexanes) to 
afford the title compounds (410 mg,1.24 mmol, 87% yield) as a white foam. The products are 
isolated as a 1.7:1 mixture of diastereomers (judged by 1H NMR). A portion of this mixture was 
subjected to normal phase (SiO2) preparative HPLC (EtOAc/Hexanes, 7.0 mL/min, monitor 
wavelength 254 nm, 60% EtOAc/Hexanes) to obtain pure samples of the two products for the 
purposes of characterization:  
Diastereomer 1 (minor): 1H NMR (400 MHz, CDCl3) δ 6.05 (d, J = 1.4 Hz, 1H), 5.12 (dd, J = 6.7, 
5.4 Hz, 1H), 3.75 – 3.42 (m, 2H), 2.99 (ddt, J = 15.6, 6.2, 1.2 Hz, 1H), 2.76 – 2.63 (m, 2H), 2.57 
(d, J = 4.5 Hz, 1H), 2.54 – 2.44 (m, 2H), 2.44 – 2.27 (m, 2H), 2.05 (t, J = 2.7 Hz, 1H), 1.99 – 1.84 
(m, 2H), 1.50 (s, 3H), 1.34 (d, J = 0.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 196.0, 173.6, 156.4, 
128.5, 82.9, 82.7, 81.8, 71.2, 58.6, 55.2, 54.2, 47.5, 42.6, 42.3, 42.2, 36.5, 26.4, 21.0, 18.4; IR 
(Neat film, NaCl) 3436, 3283, 2970, 2926, 1758, 1656, 1378, 1292, 1177, 1109, 735 cm-1; (MM: 


















CH2Cl2, 0 → 23°C, 12h
87% yield, 1.7:1 d.r.
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Diastereomer 2 (major): 1H NMR (400 MHz, CDCl3) δ 6.10 (t, J = 1.6 Hz, 1H), 5.11 (dd, J = 7.1, 
5.4 Hz, 1H), 3.84 (dt, J = 10.9, 1.2 Hz, 1H), 3.76 – 3.57 (m, 1H), 3.35 – 3.16 (m, 1H), 2.70 (dd, J 
= 4.6, 0.8 Hz, 1H), 2.63 – 2.45 (m, 3H), 2.40 – 2.24 (m, 3H), 2.05 (t, J = 2.6 Hz, 1H), 1.95 – 1.84 
(m, 2H), 1.49 (s, 3H), 1.25 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 196.4, 174.1, 156.4, 129.3, 
82.9, 82.9, 81.3, 71.1, 58.5, 55.5, 54.2, 47.5, 42.8, 42.8, 41.3, 38.5, 26.4, 22.5, 16.0; IR (Neat film, 
NaCl) 3436, 3283, 2250, 1758, 1657, 1378, 1109, 735 cm-1; HRMS (MM: ESI-APCI+) m/z calc’d 
for C19H23O5 [M+H]+: 331.1545, found 331.1540; [α]D25.0 –83.5° (c 1.0, CHCl3).  
 
 
Vinyl Silanes 510a and 510b: A 250 mL round bottom flask is charged with a mixture of 509a 
and 509b (725 mg, 2.19 mmol, 1.0 equiv) in CH2Cl2 (22 mL). Phenyldimethylsilane is added, and 
the mixture is cooled to 0 °C. [RuCp*(MeCN)3]PF6 (10 mg/mL stock solution, 5.5 mL, 0.110 
mmol, 0.05 equiv) is added dropwise. Following the addition, the reaction is stirred 5 min at 0 °C, 
after which the starting material is no longer detectable by TLC. The reaction mixture is poured 
directly onto a flash column, and purified by flash chromatography (0% → 50% EtOAc/Hexanes) 
to afford the title compounds (870 mg, 1.86 mmol, 85% yield) as a colorless foam. The products 
are isolated as a 1.7:1 mixture of diastereomers (judged by 1H NMR), which were characterized 
separately:  
Diastereomer 1 (minor): 1H NMR (400 MHz, CDCl3) δ 7.54 (ddd, J = 4.9, 2.4, 1.7 Hz, 2H), 7.37 
– 7.29 (m, 3H), 5.83 (d, J = 1.2 Hz, 1H), 5.71 (dd, J = 2.3, 1.3 Hz, 1H), 5.61 (d, J = 2.7 Hz, 1H), 



















CH2Cl2, 0 °C, 5 min
85% yield
O O
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1H), 2.72 (dt, J = 13.6, 2.2 Hz, 1H), 2.45 (d, J = 4.7 Hz, 1H), 2.39 (d, J = 10.4 Hz, 1H), 2.29 (d, J 
= 15.0 Hz, 1H), 2.20 – 1.98 (m, 5H), 1.84 (dd, J = 15.0, 5.4 Hz, 1H), 1.47 (s, 3H), 1.20 (s, 3H), 
0.46 (s, 3H), 0.38 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 195.7, 173.0, 157.2, 147.4, 139.6, 134.4, 
129.2, 128.7, 128.7, 127.9, 82.7, 82.0, 58.6, 55.2, 54.9, 47.3, 42.3, 41.9, 40.4, 40.0, 36.3, 26.5, 
16.6, -2.7, -3.9; IR (Neat film, NaCl) 3435, 2960, 1762, 1659, 1426, 1376, 1288, 1247, 1217, 1163, 
1106, 1034, 992, 938, 838, 818, 753, 703 cm–1; HRMS (FAB+) m/z calc’d for C27H35O5Si 
[M+H]+: 467.2254, found 467.2265; [α]D25.0 –62.0° (c 1.0, CHCl3).  
Diastereomer 2 (major): 1H NMR (400 MHz, CDCl3) δ 7.63 – 7.44 (m, 2H), 7.39 – 7.31 (m, 3H), 
6.03 (t, J = 1.5 Hz, 1H), 5.73 (dt, J = 2.4, 1.2 Hz, 1H), 5.58 (d, J = 2.6 Hz, 1H), 5.07 (dd, J = 7.1, 
5.3 Hz, 1H), 3.53 (td, J = 10.6, 7.1 Hz, 1H), 3.38 (dt, J = 11.0, 1.2 Hz, 1H), 3.23 – 3.07 (m, 1H), 
2.48 (d, J = 10.3 Hz, 1H), 2.43 – 2.19 (m, 5H), 2.17 – 2.06 (m, 2H), 1.89 (dd, J = 14.9, 5.5 Hz, 
1H), 1.50 (s, 3H), 1.13 (d, J = 0.6 Hz, 3H), 0.40 (d, J = 0.8 Hz, 6H); 13C NMR (100 MHz, CDCl3) 
δ 196.0, 173.8, 157.8, 147.0, 138.2, 134.2, 129.3, 129.3, 129.0, 128.2, 82.7, 82.5, 59.2, 55.3, 53.6, 
47.5, 42.2, 42.1, 40.7, 40.2, 38.3, 26.6, 15.9, -2.8, -2.9; ; IR (Neat film, NaCl) 3439, 2924, 2854, 
2282, 1758, 1656, 1428, 1373, 1291, 1266, 1248, 1214, 1164, 1108, 992, 937, 838, 821, 738  
cm–1; HRMS (FAB+) m/z calc’d for C27H35O5Si [M+H]+: 467.2254, found 467.2265; [α]D25.0 –
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Cyclobutanes 511a and 511b: A mixture of vinyl silanes 509a and 509b (870 mg, 1.86 mmol, 
1.0 equiv) is divided into 11 portions (79 mg each). Each portion is charged into a 40 mL 
scintillation vial, with PhH (34 mL). Each vial is sparged with nitrogen for 5 min, and placed in a 
photoreactor equipped with Hitachi UVA bulbs (F8T5-BLB, ~350 nm). The reactions are stirred 
under 350 nm irradiation for 5 h, after which no starting material remains (as judged by TLC). The 
reactions are combined in a 1 L round bottom flask, and concentrated onto Celite. The resulting 
solid is loaded onto a column, and purified by flash chromatography (30% → 40% → 50% → 
60% → 70% → 80% EtOAc/Hexanes) to afford the title compounds (620 mg, 1.33 mmol, 71% 
yield) as a white solid. The products are isolated as a 1.7:1 mixture of diastereomers (judged by 
1H NMR), which were characterized separately.  
 
Note: The 1H NMR spectra of these intermediates show broadened signals which were difficult to 
assign and integrate properly. Additionally, several signals were found to be missing from the 13C 
NMR spectra. We attribute these observations to hindered rotation of the –Si(Me)2Ph group about 
the highly congested cyclobutane ring. The NMR spectra are reported as observed, and the 
stereochemistry (and identity) of these products is assigned based upon the NMR and X-ray data 
obtained for 512a and 512b.  
Diastereomer 1 (minor): 1H NMR (400 MHz, CDCl3) δ 7.51 (s, 2H), 7.35 – 7.28 (m, 3H), 4.93 (s, 
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= 15.2, 4.8 Hz, 1H), 1.68 (s, 1H), 1.45 (d, J = 2.1 Hz, 3H), 1.34 – 1.17 (m, 4H), 0.56 (d, J = 18.1 
Hz, 4H); 13C NMR (100 MHz, CDCl3) δ 205.8, 134.3, 128.5, 127.6, 82.1, 81.4, 60.3, 57.6, 52.3, 
50.9, 49.0, 47.7, 47.6, 40.1, 38.9, 35.0, 27.5; IR (Neat film, NaCl) 3395, 2958, 1773, 1686, 1369, 
1256, 1202, 1089, 1014, 815, 776, 732 cm–1; HRMS (ES+) m/z calc’d for C27H35O5Si [M+H]+: 
467.2254, found 467.2280; [α]D25.0 –41.1 ° (c 0.19, CHCl3).  
Diastereomer 2 (major): 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.45 (m, 2H), 7.34 – 7.28 (m, 3H), 
4.92 (s, 1H), 3.60 (td, J = 9.8, 6.2 Hz, 1H), 3.47 (s, 1H), 3.02 (d, J = 9.3 Hz, 1H), 2.56 (dd, J = 
10.0, 5.3 Hz, 3H), 2.42 – 2.31 (m, 1H), 1.94 (dd, J = 15.1, 4.8 Hz, 1H), 1.67 (s, 2H), 1.45 (s, 3H), 
1.25 (d, J = 1.7 Hz, 3H), 0.53 (s, 5H); 13C NMR (100 MHz, CDCl3) δ 205.8, 134.3, 128.5, 127.7, 
82.1, 81.5, 60.3, 57.1, 53.9, 50.9, 49.0, 47.7, 40.7, 38.6, 29.8, 27.5; IR (Neat film, NaCl) 3388, 
2960, 2929, 1773, 1686, 1552, 1426, 1368, 1248, 1203, 1178, 1107, 1088, 817, 724, 696 cm–1; 
HRMS (ES+) m/z calc’d for C27H35O5Si [M+H]+: 467.2254, found 467.1853; [α]D25.0 –23.1 ° (c 
0.19, CHCl3).  
 
 
Diols 512a and 512b: A 100 mL round bottom flask is charged with a mixture of epoxides 511a 
and 511b (620 mg, 1.33 mmol, 1.0 equiv), Cp2TiCl2 (66 mg, 0.266 mmol, 0.20 equiv), Mn dust 
(80 mg, 1.46 mmol, 1.10 equiv), and collidine • HCl (262 mg, 1.66 mmol, 1.25 equiv) in THF (27 
mL). To this red suspension is added 1,4-cyclohexadiene (567 µL, 599 mmol, 4.5 equiv) and the 
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which the starting material is completely consumed, as judged by TLC. Celite is then added 
directly to the reaction mixture and the solvent is removed under reduced pressure. The resulting 
solid is loaded directly onto a flash column and purified by flash chromatography (60% → 65% 
→ 70% → 75% → 80% → 90% →100% EtOAc/Hexanes) to afford XX (385 mg, 0.781 mmol, 
62% yield) and epi-XX (224 mg, 0.478 mmol, 36% yield) as white solids.

Note: The 1H NMR spectra of these intermediates show broadened signals which were difficult to 
assign and integrate properly. Additionally, several signals were found to be missing from the 13C 
NMR spectra. We attribute these observations to hindered rotation of the –Si(Me)2Ph group about 
the highly congested cyclobutane ring. The NMR spectra are reported as observed, and the 
stereochemistry (and identity) of these products is assigned based upon the NMR and X-ray data 
obtained for 512a and 512b.  
512a (major): 1H NMR (400 MHz, CD3OD) δ 7.57 – 7.48 (m, 2H), 7.30 – 7.22 (m, 3H), 4.95 (s, 
1H), 3.98 (s, 1H), 3.74 (tt, J = 10.1, 5.1 Hz, 1H), 3.64 (q, J = 10.2, 9.2 Hz, 1H), 3.52 – 3.38 (m, 
1H), 3.30 – 3.15 (m, 1H), 2.76 – 1.38 (m, 11H), 1.34 (s, 3H), 1.10 – 0.83 (m, 3H), 0.52 (s, 4H); 
13C NMR (100 MHz, CD3OD) δ 210.1, 168.5, 151.9, 135.3, 129.2, 128.4, 108.8, 84.4, 81.6, 81.6, 
67.3, 65.6, 61.9, 52.5, 45.9, 41.7, 41.5, 27.3, 15.7; IR (Neat film, NaCl) 3380, 2958, 2924, 2869, 
1770, 1694, 1360, 1254, 1204, 1090, 1416, 828, 736, 730, 702 cm–1; HRMS (ES+) m/z calc’d for 
C27H37O5Si [M+H]+: 469.2410, found 469.2437; [α]D25.0 –37.0 ° (c 0.24, CHCl3).  
512b (major): 1H NMR (400 MHz, CD3OD) δ 7.58 – 7.46 (m, 2H), 7.27 (t, J = 3.2 Hz, 3H), 4.94 
(t, J = 5.7 Hz, 1H), 3.81 – 3.69 (m, 1H), 3.69 – 3.58 (m, 1H), 3.48 (q, J = 7.1, 4.5 Hz, 1H), 3.33 
(d, J = 13.8 Hz, 4H), 3.25 – 3.11 (m, 1H), 2.68 – 1.39 (m, 11H), 1.34 (s, 3H), 1.10 – 0.74 (m, 4H), 
0.52 (d, J = 11.9 Hz, 5H); 13C NMR (100 MHz, CD3OD) δ 210.1, 178.1, 135.3, 129.2, 128.4, 84.3, 
Chapter 4: The Total Synthesis of (–)-Scabrolide A 335	
81.6, 67.4, 61.9, 52.5, 47.8, 47.1, 47.1, 46.2, 44.1, 42.4, 41.8, 40.0, 35.9, 27.3, 15.6, -2.1, -4.9; IR 
(Neat film, NaCl) 3378, 2954, 2937, 2868, 2353, 1771, 1696, 1558, 1364, 1258, 1245, 1086, 827 
cm–1; HRMS (ES+) m/z calc’d for C27H37O5Si [M+H]+: 469.2410, found 469.2440; [α]D25.0 –




Triol 513a: A 20-mL scintillation vial is charged with 512a (80 mg, 0.171 mmol, 1.0 equiv) and 
AcOOH (30% in aqueous AcOH, 3.4 mL). To this solution is added Hg(OAc)2 (100 mg, 0.341 
mmol, 2.0 equiv) in a single portion. The reaction is stirred 45 min at 23 °C, after which no 512a 
remains (as judged by LCMS). The reaction mixture is diluted with EtOAc (10 mL) and pipetted 
over an ice-cold mixture of sat. aq. Na2S2O3 and sat. aq. NaHCO3 (1:4). This aqueous solution is 
then extracted with EtOAc (3X), then CHCl3/i-PrOH (3:1) (2X). The organic extracts are 
combined and dried over Na2SO4, filtered, and concentrated under reduced pressure to afford a 
crude solid which is purified by flash chromatography (80% → 100% EtOAc/Hexanes) to afford 
the title compound (33 mg, 0.942 mmol, 55% yield) as a white solid. X-ray quality crystals were 
obtained by slow cooling from EtOH/CH2Cl2/Hexanes: 1H NMR (400 MHz, CD3OD) δ 5.16 (dd, 
J = 6.2, 4.7 Hz, 1H), 3.88 (dd, J = 9.8, 7.7 Hz, 1H), 3.72 (ddd, J = 10.6, 9.3, 6.3 Hz, 1H), 3.55 – 
3.47 (m, 2H), 3.37 – 3.32 (m, 1H), 2.58 (d, J = 10.6 Hz, 1H), 2.35 (d, J = 15.0 Hz, 1H), 2.23 (dd, 
J = 11.9, 9.7 Hz, 1H), 2.19 – 1.98 (m, 3H), 1.95 (dd, J = 15.1, 4.9 Hz, 1H), 1.85 (ddd, J = 12.9, 
Hg(OAc)2
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6.1, 2.0 Hz, 1H), 1.70 (dd, J = 13.1, 9.9 Hz, 1H), 1.54 – 1.41 (m, 2H), 1.35 (s, 3H), 0.93 (d, J = 
6.8 Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 209.4, 181.7, 89.3, 88.2, 81.6, 67.1, 62.1, 59.0, 51.8, 
51.3, 47.8, 47.3, 45.8, 41.8, 41.3, 41.2, 40.7, 27.3, 15.3; IR (Neat Film NaCl) 3308, 2936, 1694, 
1371, 1217, 1184, 1120, 1016 cm-1; HRMS (MM: ESI-APCI+) m/z calc’d for C19H27O6 
[M+H]+: 351.1802, found 315.1790; [α]D25.0 –61.1° (c 0.5, MeOH).  
 
 
Triol 513b A 20-mL scintillation vial is charged with 512b (80 mg, 0.171 mmol, 1.0 equiv) and 
AcOOH (30% in aqueous AcOH, 3.4 mL). To this solution is added Hg(OAc)2 (100 mg, 0.341 
mmol, 2.0 equiv) in a single portion. The reaction is stirred 45 min at 23 °C, after which no 512b 
remains (as judged by LCMS). The reaction mixture is diluted with EtOAc (10 mL) and pipetted 
over an ice-cold mixture of sat. aq. Na2S2O3 and sat. aq. NaHCO3 (1:4). This aqueous solution is 
then extracted with EtOAc (3X), then CHCl3/i-PrOH (3:1) (2X). The organic extracts are 
combined and dried over Na2SO4, filtered, and concentrated under reduced pressure to afford a 
crude solid which is purified by flash chromatography (80% → 100% EtOAc/Hexanes) to afford 
the title compound (37 mg, 0.0.106 mmol, 62% yield) as a white solid. X-ray quality crystals were 
obtained by layer diffusion of hexanes into CH2Cl2/EtOH: 1H NMR (400 MHz, CD3OD) δ 5.16 
(dd, J = 6.2, 4.7 Hz, 1H), 3.88 (dd, J = 9.8, 7.7 Hz, 1H), 3.79 – 3.64 (m, 1H), 3.57 – 3.45 (m, 2H), 
3.40 – 3.34 (m, 1H), 2.57 (d, J = 10.6 Hz, 1H), 2.35 (d, J = 15.1 Hz, 1H), 2.28 – 2.11 (m, 2H), 
























AcOOH/AcOH, 23 °C, 45 min
62% yield
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(dd, J = 13.1, 10.2 Hz, 1H), 1.57 – 1.43 (m, 2H), 1.35 (s, 3H), 0.94 (d, 3H); 13C NMR (100 MHz, 
CD3OD) δ 209.4, 181.7, 89.0, 88.2, 81.6, 66.9, 62.1, 59.3, 51.8, 51.3, 47.8, 47.3, 45.1, 41.7, 41.5, 
41.4, 40.7, 27.3, 15.4; IR (Neat Film NaCl) 3464, 3292, 2953, 1720, 1693, 1372, 1190, 1104 cm 
-1; HRMS (MM: ESI-APCI+) m/z calc’d for C19H27O6 [M+H]+: 351.1802, found 315.1790; 
[α]D25.0 –42.2° (c 0.5, MeOH).  
 
 
Diol X: To a stirred suspension of triol 513a (21 mg, 0.0599 mmol, 1.0 equiv), AgOTf (6.0 mg, 
0.0240 mmol, 0.40 equiv), and 1,10-phenanthroline (9.0 mg, 0.0479 mmol, 0.80 equiv) in 
acetonitrile (3.2 mL, 0.019 M) was added t-butyl hypochlorite (14 µL, 0.120 mmol, 2.0 equiv) at 
23 °C. The suspension changed from white to red, and then to dark brown. The reaction mixture 
was allowed to stir at 23 °C for 12 h, after which no starting material remained (as judged by TLC 
and LCMS). The reaction mixture was diluted with ethyl acetate, and quenched with 5 drops of 
saturated aqueous sodium thiosulfate after which the dark brown color quickly dissipated. The 
mixture was passed directly over a short plug of silica, and the eluent was concentrated onto SiO2 
and dry loaded onto a column. The crude was purified by flash chromatography (50 – 100% ethyl 
acetate/hexanes) to afford an unstable intermediate (presumed to be the γ-chloroketone) which was 
not characterized further. 
The product from the above reaction was dissolved in methanol (5 mL). TLC SiO2 (scraped from 























    t-BuOCl, MeCN, 23 °C
2. SiO2, MeOH, 23 °C
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to stir for 12 hours at 23 °C, after which the abovementioned product had been completely 
consumed (as judged by TLC). The methanol was removed under reduced pressure, and then 
resuspended in acetone (10 mL) and stirred for 1 hour. The suspension was filtered through a plug 
of Celite® and concentrated to afford diol X (10 mg, 40% yield) as a white solid. Product 




Cyclopropane 518: To a stirred solution of diol 517 (4 mg, 0.0115 mmol, 1.0 equiv) in THF (400 
µL, 0.029 M) cooled to 15 °C in a nitrogen-filled glovebox was added o-NO2PhSeCN (156 mg/mL 
solution in THF, 25 µL, 0.0173 mmol, 1.5 equiv). To this light-brown solution was added n-Bu3P 
(83 mg/mL solution in THF, 42 µL, 0.0173 mmol, 1.5 equiv), at which point the solution rapidly 
changed to deep red in color. The reaction mixture was stirred 20 min at 15 °C and then warmed 
to 23 °C and stirred an additional 2 h. At this point, a small amount of starting material was detected 
by LCMS. An additional portion of o-NO2PhSeCN (156 mg/mL solution in THF, 8 µL, 0.00775 
mmol, 0.5 equiv) was added, followed by n-Bu3P (83 mg/mL solution in THF, 14 µL, 0.00775 
mmol, 0.5 equiv) at 23 °C, and the reaction was subsequently allowed to stir an additional 2 h. The 
reaction was removed from the glovebox and cooled to 0 °C. H2O2 (30%, 60 µL) was added 
dropwise, and the reaction was stirred 1 h at 0 °C. The mixture was allowed to warm to 23 °C, and 





















THF, 23 °C, 7h
then H2O2 
0 → 23 °C, 20h
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X (1 mg, 26% yield) as a white solid. Product characterization data was not obtained due to the 




Note: The Grieco dehydration to cyclobutanol 4a was performed using both 25 and epi-25, with 
both substrates providing similar yields of product. A representative procedure for this reaction 
is provided below:  
 
Cyclobutanol 527: In a nitrogen filled glovebox a 1-dram vial is charged with 513a (8.0 mg, 
0.0228 mmol, 1.0 equiv) and o-NO2PhSeCN (15.5 mg, 0.0685 mmol, 3.0 equiv) in THF (450 µL). 
To this orange solution is added n-Bu3P (17 µL, 0.0685 mmol, 3.0 equiv) dropwise via syringe, at 
which point the reaction mixture becomes deep red/brown in color. This solution is allowed to stir 
in the glovebox at 23 °C for 7 h, at which point 513a has been completely consumed, as judged by 
LCMS. The vial is then removed from the glovebox and cooled to 0 °C after which H2O2 (30% 
w/w, 80 µL) is cautiously added dropwise. This orange solution is then stirred while gradually 






















THF, 23 °C, 7h
then H2O2 






















THF, 23 °C, 7h
then H2O2 
0 → 23 °C, 20h
74% yield
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loaded directly onto a column and purified by flash chromatography (30% → 40% → 50% 
EtOAc/Hexanes) to afford the title compound (6.0 mg, 0.0181 mmol, 79% yield) as a white solid: 
1H NMR (400 MHz, CDCl3) δ 6.08 (s, 1H), 5.14 (dd, J = 6.1, 4.6 Hz, 1H), 4.75 – 4.71 (m, 1H), 
4.71 – 4.68 (m, 1H), 3.83 (dd, J = 9.6, 8.0 Hz, 1H), 3.66 – 3.56 (m, 1H), 3.36 (d, J = 9.1 Hz, 1H), 
2.79 (ddd, J = 15.9, 13.0, 8.0 Hz, 1H), 2.60 (d, J = 10.7 Hz, 1H), 2.43 (d, J = 15.4 Hz, 1H), 2.34 
(dd, J = 12.1, 9.6 Hz, 1H), 2.24 (dd, J = 12.1, 8.0 Hz, 1H), 2.14 (ddd, J = 13.2, 9.8, 2.2 Hz, 1H), 
1.96 (dd, J = 15.3, 4.8 Hz, 1H), 1.90 – 1.78 (m, 2H), 1.74 – 1.67 (m, 5H), 1.48 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 205.8, 179.2, 146.1, 109.9, 88.0, 86.0, 81.3, 60.6, 57.8, 50.3, 50.3, 47.7, 46.3, 
45.3, 44.7, 40.8, 40.5, 27.6, 21.1; IR (Neat Film NaCl) 3346, 2936, 1726, 1710, 1598, 1366, 1325, 
1218, 1194, 1123, 1088, 1011, 850, 822 cm -1; HRMS (MM: ESI-APCI+) m/z calc’d for C19H25O5 
[M+H]+: 333.1697, found 333.1694; [α]D25.0 –31.1° (c 0.4, CHCl3).  
 
  
Scabrolide A (416): In a nitrogen-filled glovebox, a 1-dram vial is charged with cyclobutanol 4a 
(5.0 mg, 0.0151 mmol, 1.0 equiv), CuI (22.0 mg, 0.117 mmol, 7.8 equiv) and NIS (6.7 mg, 0.0300 
mmol, 2.0 equiv) in PhMe (1.5 mL). The vial is stirred at 23 °C for 5 min, and then transferred to 
a preheated, 90 °C aluminum block. The reaction is stirred at 90 °C for 1 h. At this point, an 
additional portion of NIS (3.3 mg, 0.0150 mmol, 1.0 equiv) is added, and the reaction is stirred an 
additional 20 min at 90 °C. The mixture is then cooled to 23 °C and filtered through a pad of Celite, 
washing with EtOAc. This solution is concentrated to a red film, which is directly purified by 
(–)-scabrolide A, (416)527
CuI, NIS
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reverse-phase (C18) preperative HPLC (MeCN/H2O, 5.0 mL/min, monitor wavelength = 260 nm, 
30% MeCN ramp to 45% MeCN over 6 min) to afford scabrolide A (3.0 mg, 0.00909 mmol, 61% 
yield) as a white solid. X-ray quality crystals were obtained by layer-diffusion of hexanes into a 
CH2Cl2 solution of (416): 1H NMR (400 MHz, CDCl3) δ 5.11 (dd, J = 7.1, 5.4 Hz, 1H), 4.87 – 
4.84 (m, 1H), 4.85 – 4.82 (m, 1H), 3.70 (dd, J = 45.1, 17.2 Hz, 1H), 3.61 (ddd, J = 11.1, 10.0, 7.2 
Hz, 1H), 3.51 (d, J = 11.3 Hz, 1H), 3.43 (dd, J = 17.3, 1.6 Hz, 1H), 3.18 – 3.03 (m, 1H), 2.97 – 
2.80 (m, 2H), 2.68 – 2.55 (m, 2H), 2.60 (d, J = 10.1 Hz, 1H), 2.30 (d, J = 15.0 Hz, 1H), 1.93 (dd, 
J = 15.0, 5.6 Hz, 1H), 1.83 (t, J = 1.0 Hz, 3H), 1.50 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 208.2, 
193.1, 173.7, 151.8, 147.2, 132.9, 111.0, 83.2, 82.3, 54.6, 47.6, 46.4, 44.8, 41.7, 41.1, 39.7, 37.3, 
26.3, 21.5; IR (Neat Film NaCl) 3366, 2965, 2930, 2858, 1765, 1696, 1636, 1445, 1374, 1358, 
1275, 1260, 1219, 1182, 1162, 1120, 1090, 1012, 899, 690 cm–1; HRMS (MM: ESI-APCI+) m/z 
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4.6.3 Comparison of Natural and Synthetic Material 
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APPENDIX 7  
Synthetic Summary for Chapter 4:  
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346 
Scheme A5.1. Synthesis of esterification precursors from chiral pool starting materials. 
	
OTBSMe









HG-II (0.1 mol %)
neat, 23 °C
then NaH, TBSCl
THF, 23 °C → reflux
RuCl3 (1 mol %)
    MgOAc2 • 4H2O
    t-BuOOH
    CH2Cl2/H2O (10:1)




CuBr•DMS (12 mol %) 
TMSCl, HMPA





































   THF/H2O (9:1), reflux
2. NaIO4, SiO2
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Cp2TiCl2 (20 mol%) 
1,4-CHD, Mn0
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SiMe2Ph hν (350 nm)
PhH, 23 °C
Cp2TiCl2 (20 mol%) 
1,4-CHD, Mn0
Collidine•HCl
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Figure A6.3 13C NMR (101 MHz, CDCl3) of compound 482. 
 
Figure A6.2 Infrared spectrum (Thin Film, NaCl) of compound 482. 
 
























































































Figure A6.6  13C NMR (101 MHz, C6D6) of compound 483. 
 
Figure A6.5 Infrared spectrum (Thin Film, NaCl) of compound 483. 
 























































































Figure A6.9 13C NMR (101 MHz, CDCl3) of compound 484. 
 
Figure A6.8 Infrared spectrum (Thin Film, NaCl) of compound 484. 
 





























































































Figure A6.12 13C NMR (101 MHz, CDCl3) of compound 490. 
Figure A6.11 Infrared spectrum (Thin Film, NaCl) of compound 490. 
 

























































































 Figure A6.15 13C NMR (101 MHz, CDCl3) of compound 492. 
 
Figure A6.14 Infrared spectrum (Thin Film, NaCl) of compound 492. 
 





























































































Figure A6.18 13C NMR (101 MHz, CDCl3) of compound 493. 
 
Figure A6.17 Infrared spectrum (Thin Film, NaCl) of compound 493. 
 























































































Figure A6.21 13C NMR (101 MHz, CDCl3) of compound 472. 
 
Figure A6.20 Infrared spectrum (Thin Film, NaCl) of compound 472. 
 


























































































 Figure A6.24 13C NMR (101 MHz, CDCl3) of compound 471. 
 
Figure A6.23 Infrared spectrum (Thin Film, NaCl) of compound 471. 
 































































































Figure A6.27 13C NMR (101 MHz, CDCl3) of compound 495. 
 
Figure A6.26 Infrared spectrum (Thin Film, NaCl) of compound 495. 
 






























































































Figure A6.30 13C NMR (101 MHz, CDCl3) of compound 496. 
 
Figure A6.29 Infrared spectrum (Thin Film, NaCl) of compound 496. 
 
































































































Figure A6.33 13C NMR (101 MHz, CDCl3) of compound 497. 
 
Figure A6.32 Infrared spectrum (Thin Film, NaCl) of compound 497. 
 































































































Figure A6.36 13C NMR (101 MHz, CDCl3) of compound 470. 
 
Figure A6.35 Infrared spectrum (Thin Film, NaCl) of compound 470. 
 




































































































Figure A6.39 13C NMR (101 MHz, CDCl3) of compound 499. 
 
Figure A6.38 Infrared spectrum (Thin Film, NaCl) of compound 499. 
 



































































































 Figure A6.42 13C NMR (101 MHz, CDCl3) of compound 500. 
 
Figure A6.41 Infrared spectrum (Thin Film, NaCl) of compound 500. 
 









































































































Figure A6.45 13C NMR (101 MHz, CDCl3) of compound 509a. 
 
Figure A6.44 Infrared spectrum (Thin Film, NaCl) of compound 509a. 
 










































































































Figure A6.48 13C NMR (101 MHz, CDCl3) of compound 509b. 
 
Figure A6.47 Infrared spectrum (Thin Film, NaCl) of compound 509b. 
 













































































































Figure A6.51 13C NMR (101 MHz, CDCl3) of compound 510a. 
 
Figure A6.50 Infrared spectrum (Thin Film, NaCl) of compound 510a. 
 












































































































Figure A6.54 13C NMR (101 MHz, CDCl3) of compound 510b. 
 
Figure A6.53 Infrared spectrum (Thin Film, NaCl) of compound 510b. 
 















































































































Figure A6.57 13C NMR (101 MHz, CDCl3) of compound 511a. 
 
Figure A6.56 Infrared spectrum (Thin Film, NaCl) of compound 511a. 
 














































































































Figure A6.60  13C NMR (101 MHz, CDCl3) of compound 511b. 
 
Figure A6.59 Infrared spectrum (Thin Film, NaCl) of compound 511b. 
 






































































































Figure A6.63 13C NMR (101 MHz, CDCl3) of compound 512a. 
 
Figure A6.62 Infrared spectrum (Thin Film, NaCl) of compound 512a. 
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 Figure A6.66 13C NMR (101 MHz, CD2Cl2) of compound 512b. 
 
Figure A6.65 Infrared spectrum (Thin Film, NaCl) of compound 512b. 
 







































































































Figure A6.69 13C NMR (101 MHz, CDCl3) of compound 513a. 
 
Figure A6.68 Infrared spectrum (Thin Film, NaCl) of compound 513a. 
 






































































































Figure A6.72 13C NMR (101 MHz, CDCl3) of compound 513b. 
 
Figure A6.71 Infrared spectrum (Thin Film, NaCl) of compound 513b. 
 


































































































Figure A6.74  Infrared spectrum (Thin Film, NaCl) of compound 527. 
 
 Figure A6.75 13C NMR (101 MHz, CDCl3) of compound 527. 
 































































































Figure A6.77 Infrared spectrum (Thin Film, NaCl) of compound 416. 
 
 Figure A6.78 13C NMR (101 MHz, CDCl3) of compound 416. 
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A7.1 X-RAY CRYSTAL STRUCTURE ANALYSIS FOR DICYCLOBUTANE 500 
 
Figure A7.1. X-Ray Coordinate of Compound 500. 
   
 
Table A7.1.  Crystal data and structure refinement for dicyclobutane 500. 
 
Identification code  d20010 
Empirical formula  C27 H34 O4 Si 
Formula weight  450.63 
Temperature  100 K 
Wavelength  0.71073 ≈ 
Crystal system  Monoclinic 
Space group  P 1 21 1 (# 4) 
Unit cell dimensions a = 6.9085(14) ≈ α= 90∞ 
 b = 10.3765(19) ≈ β= 90.920(7)∞ 
 c = 17.058(3) ≈ γ = 90∞ 
Volume 1222.7(4) ≈3 




Density (calculated) 1.224 g/cm3 
Absorption coefficient 0.126 mm-1 
F(000) 484 
Crystal size 0.04 x 0.32 x 0.33 mm3 
Theta range for data collection 2.30 to 32.80∞ 
Index ranges -10 ≤ h ≤ 10, -15 ≤ k ≤ 14, -25 ≤ l ≤ 25 
Reflections collected 76181 
Independent reflections 8271 [R(int) = 0.0400] 
Completeness to theta = 25.242∞ 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.9658 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8271 / 1 / 294 
Goodness-of-fit on F2 1.035 
Final R indices [I>2sigma(I)] R1 = 0.0401, wR2 = 0.0827 
R indices (all data) R1 = 0.0511, wR2 = 0.0865 
Absolute structure parameter [Flack] 0.03(2) 
Absolute structure parameter [Hooft] 0.03(2) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.38 and -0.28 e.≈-3 
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Table A7.2.  Atomic coordinates  ( x 105) and equivalent  isotropic displacement 
parameters (≈2x 104) for d20010.  U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Si(1) 84284(6) 63687(4) 52641(3) 131(1) 
O(1) 111852(17) 29694(12) 7683(7) 152(2) 
O(2) 79881(18) 57572(12) 914(7) 147(2) 
O(3) 38726(17) 51229(12) 1471(7) 144(2) 
O(4) 38244(19) 62608(14) 12393(8) 225(3) 
C(1) 82860(30) 50711(17) 60272(10) 171(3) 
C(2) 99300(30) 44260(19) 63105(11) 232(4) 
C(3) 98070(40) 34900(20) 68921(13) 321(5) 
C(4) 80480(40) 31820(20) 72063(12) 351(6) 
C(5) 63960(40) 38080(20) 69452(13) 352(5) 
C(6) 65160(30) 47390(20) 63599(12) 262(4) 
C(7) 110220(30) 66249(18) 50382(11) 186(4) 
C(8) 73000(30) 78492(19) 56752(12) 216(4) 
C(9) 70990(20) 58674(17) 43479(10) 146(3) 
C(10) 54230(20) 64340(20) 41591(10) 198(3) 
C(11) 79900(30) 48322(19) 38422(10) 187(4) 
C(12) 69380(20) 45416(17) 30720(9) 143(3) 
C(13) 78020(20) 35684(16) 24887(9) 141(3) 
C(14) 71910(30) 21741(18) 25210(11) 229(4) 
C(15) 99620(30) 38166(19) 22866(10) 171(3) 
C(16) 93360(20) 44468(16) 14974(9) 125(3) 
C(17) 96770(20) 35768(16) 8123(9) 112(3) 
C(18) 81300(20) 34745(16) 1844(9) 119(3) 
C(19) 80950(20) 46296(17) -3905(9) 134(3) 
C(20) 98020(20) 46930(20) -9383(10) 186(3) 
C(21) 61600(20) 43949(18) -8193(10) 147(3) 
C(22) 47800(20) 39861(16) -1795(10) 131(3) 
C(23) 43930(20) 53252(16) 8983(10) 136(3) 
C(24) 60350(20) 33804(15) 4887(9) 115(3) 
C(25) 55500(20) 41887(15) 12201(10) 116(3) 
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C(26) 72260(20) 44950(16) 17844(9) 109(3) 
C(27) 69120(20) 55650(16) 24121(9) 129(3) 
________________________________________________________________________________ 
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Table A7.3.   Bond lengths [≈] and angles [∞] for dicyclobutane 500. 
_____________________________________________________  
Si(1)-C(1)  1.8765(19) 
Si(1)-C(7)  1.8576(18) 
Si(1)-C(8)  1.8646(19) 
Si(1)-C(9)  1.8736(17) 
O(1)-C(17)  1.221(2) 
O(2)-H(2)  0.8400 
O(2)-C(19)  1.433(2) 
O(3)-C(22)  1.451(2) 
O(3)-C(23)  1.342(2) 
O(4)-C(23)  1.201(2) 
C(1)-C(2)  1.398(3) 
C(1)-C(6)  1.399(3) 
C(2)-H(2A)  0.9500 
C(2)-C(3)  1.392(3) 
C(3)-H(3)  0.9500 
C(3)-C(4)  1.374(4) 
C(4)-H(4)  0.9500 
C(4)-C(5)  1.381(4) 
C(5)-H(5)  0.9500 
C(5)-C(6)  1.392(3) 
C(6)-H(6)  0.9500 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
C(8)-H(8A)  0.9800 
C(8)-H(8B)  0.9800 
C(8)-H(8C)  0.9800 
C(9)-C(10)  1.334(2) 
C(9)-C(11)  1.514(2) 
C(10)-H(10A)  0.9500 
C(10)-H(10B)  0.9500 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(11)-C(12)  1.521(2) 
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C(12)-H(12)  1.0000 
C(12)-C(13)  1.544(2) 
C(12)-C(27)  1.547(2) 
C(13)-C(14)  1.508(3) 
C(13)-C(15)  1.558(2) 
C(13)-C(26)  1.585(2) 
C(14)-H(14A)  0.9800 
C(14)-H(14B)  0.9800 
C(14)-H(14C)  0.9800 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(15)-C(16)  1.552(2) 
C(16)-H(16)  1.0000 
C(16)-C(17)  1.498(2) 
C(16)-C(26)  1.546(2) 
C(17)-C(18)  1.505(2) 
C(18)-H(18)  1.0000 
C(18)-C(19)  1.549(2) 
C(18)-C(24)  1.548(2) 
C(19)-C(20)  1.518(2) 
C(19)-C(21)  1.533(2) 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
C(21)-H(21A)  0.9900 
C(21)-H(21B)  0.9900 
C(21)-C(22)  1.521(2) 
C(22)-H(22)  1.0000 
C(22)-C(24)  1.554(2) 
C(23)-C(25)  1.522(2) 
C(24)-H(24)  1.0000 
C(24)-C(25)  1.544(2) 
C(25)-H(25)  1.0000 
C(25)-C(26)  1.527(2) 
C(26)-C(27)  1.560(2) 
C(27)-H(27A)  0.9900 
Appendix 7: X-Ray Crystallography Reports Relevant to Chapter 4 
	
409 
























































































































































Symmetry transformations used to generate equivalent atoms:  
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Table A7.4.   Anisotropic displacement parameters  (≈2x 104) for dicyclobutane 500.  The 
anisotropic displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k 
a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Si(1) 159(2)  129(2) 106(2)  -10(2) 21(2)  6(2) 
O(1) 118(5)  178(6) 160(6)  -24(5) 17(4)  24(5) 
O(2) 205(6)  121(5) 116(5)  10(4) 11(5)  -30(5) 
O(3) 140(5)  149(6) 142(6)  -6(5) -20(4)  22(4) 
O(4) 247(6)  212(7) 214(6)  -56(6) -47(5)  99(6) 
C(1) 269(9)  143(8) 102(7)  -31(6) 9(6)  -29(7) 
C(2) 332(10)  174(9) 190(9)  -5(7) -24(7)  0(8) 
C(3) 538(14)  193(10) 230(10)  32(8) -100(9)  -2(9) 
C(4) 682(17)  213(10) 157(9)  47(8) -33(10)  -139(10) 
C(5) 521(14)  326(12) 212(10)  7(9) 93(9)  -188(11) 
C(6) 292(10)  287(11) 208(9)  1(8) 36(7)  -79(8) 
C(7) 176(8)  190(9) 194(8)  0(7) 28(6)  -11(6) 
C(8) 256(9)  181(9) 211(9)  -71(7) 48(7)  24(7) 
C(9) 175(8)  169(8) 95(7)  -17(6) 25(6)  3(6) 
C(10) 193(8)  259(9) 143(7)  -44(8) 24(6)  38(8) 
C(11) 230(8)  212(9) 117(7)  -29(6) -24(6)  88(7) 
C(12) 176(7)  150(8) 103(7)  -8(6) 2(6)  21(6) 
C(13) 200(8)  127(7) 94(7)  1(6) -3(6)  25(6) 
C(14) 380(11)  129(8) 177(9)  26(7) 11(8)  6(8) 
C(15) 169(8)  224(9) 120(8)  -34(7) -25(6)  64(7) 
C(16) 117(7)  140(7) 117(7)  -24(6) -9(5)  11(6) 
C(17) 123(7)  106(7) 109(7)  10(6) 17(5)  -21(6) 
C(18) 113(7)  126(7) 118(7)  -20(6) 0(5)  -2(6) 
C(19) 133(7)  158(8) 110(7)  -11(6) 6(6)  -8(6) 
C(20) 152(8)  286(9) 120(7)  -10(7) 19(6)  -22(7) 
C(21) 147(7)  187(8) 108(7)  0(6) -12(6)  -1(6) 
C(22) 124(7)  138(7) 130(8)  -25(6) -22(6)  -5(6) 
C(23) 112(7)  145(8) 150(8)  2(6) 1(6)  -6(6) 
C(24) 110(7)  110(7) 125(7)  -18(6) 4(6)  -24(5) 
C(25) 113(7)  114(7) 121(7)  -7(6) 17(5)  -17(5) 
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C(26) 123(7)  104(7) 100(7)  -2(6) -2(5)  9(6) 
C(27) 162(8)  114(7) 110(7)  -23(6) -5(6)  15(6) 
______________________________________________________________________________ 
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Table A7.5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (≈2x  
10 3) for dicyclobutane 500. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 8157 6416 -185 22 
H(2A) 11158 4631 6101 28 
H(3) 10946 3063 7073 39 
H(4) 7969 2541 7602 42 
H(5) 5179 3604 7165 42 
H(6) 5368 5158 6182 31 
H(7A) 11550 5842 4802 28 
H(7B) 11742 6823 5523 28 
H(7C) 11141 7345 4670 28 
H(8A) 7307 8535 5280 32 
H(8B) 8038 8129 6140 32 
H(8C) 5963 7662 5821 32 
H(10A) 4744 6191 3693 24 
H(10B) 4907 7080 4490 24 
H(11A) 8064 4026 4152 22 
H(11B) 9332 5093 3723 22 
H(12) 5576 4284 3185 17 
H(14A) 5777 2123 2544 34 
H(14B) 7764 1767 2988 34 
H(14C) 7635 1726 2051 34 
H(15A) 10625 4419 2652 21 
H(15B) 10726 3017 2223 21 
H(16) 9907 5324 1425 15 
H(18) 8391 2679 -127 14 
H(20A) 9563 5356 -1337 28 
H(20B) 9968 3855 -1194 28 
H(20C) 10979 4908 -637 28 
H(21A) 5698 5191 -1081 18 
H(21B) 6288 3708 -1218 18 
H(22) 3791 3362 -384 16 
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H(24) 5666 2459 570 14 
H(25) 4617 3660 1526 14 
H(27A) 7993 6189 2452 15 
H(27B) 5656 6017 2353 15 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
  
Appendix 7: X-Ray Crystallography Reports Relevant to Chapter 4 
	
420 
Table A7.7. Hydrogen bonds for dicyclobutane 500  [≈ and ∞]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(2)-H(2)...O(1)#1 0.84 1.95 2.7880(18) 173.8 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+2,y+1/2,-z       
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A7.3 X-RAY CRYSTAL STRUCTURE ANALYSIS FOR TRIOL 513b. 
 
Figure A7.2. X-Ray Coordinate of Compound 513a. 
Table A7.8.  Crystal data and structure refinement for triol 513a. 
Identification code  d19153 
Empirical formula  C19 H26 O6 
Formula weight  350.40 
Temperature  100 K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 10.221(3) Å a= 90° 
 b = 12.581(3) Å b= 90° 
 c = 13.333(4) Å g = 90° 
Volume 1714.4(8) Å3 
Z 4 
Density (calculated) 1.358 g/cm3 
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Absorption coefficient 0.100 mm-1 
F(000) 752 
Crystal size 0.31 x 0.19 x 0.18 mm3 
Theta range for data collection 2.226 to 36.285°. 
Index ranges -16 £ h £ 16, -20 £ k £ 20, -22 £ l £ 22 
Reflections collected 73152 
Independent reflections 7997 [R(int) = 0.0477] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.9208 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7997 / 0 / 231 
Goodness-of-fit on F2 1.069 
Final R indices [I>2sigma(I)] R1 = 0.0424, wR2 = 0.0942 
R indices (all data) R1 = 0.0592, wR2 = 0.1007 
Absolute structure parameter [Flack] 0.21(16) 
Absolute structure parameter [Hooft] 0.26(15) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.383 and -0.250 e.Å-3 
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Table A7.9.  Atomic coordinates  (x 105) and equivalent  isotropic displacement parameters 
(Å2x 104)for triol 513a.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 68042(10) 78131(7) 63641(8) 165(2) 
O(2) 86227(11) 70321(8) 47229(8) 213(2) 
O(3) 70632(11) 61684(9) 39054(7) 213(2) 
O(4) 52317(11) 47286(8) 43910(8) 209(2) 
O(5) 62828(10) 58461(8) 81516(7) 170(2) 
O(6) 61450(11) -568(7) 63049(8) 186(2) 
C(1) 80656(12) 63996(9) 70998(9) 120(2) 
C(2) 79658(13) 76259(9) 69319(10) 142(2) 
C(3) 79192(15) 82417(10) 79130(11) 201(3) 
C(4) 91843(14) 78776(11) 63116(11) 195(3) 
C(5) 94105(14) 69305(11) 56324(11) 193(3) 
C(6) 88652(12) 59459(10) 61866(9) 136(2) 
C(7) 81180(12) 53340(10) 53598(9) 136(2) 
C(8) 78429(13) 61948(11) 45872(10) 170(2) 
C(9) 69363(12) 47732(9) 58110(9) 116(2) 
C(10) 56514(13) 43122(10) 53164(10) 139(2) 
C(11) 48826(13) 48194(11) 62174(10) 181(2) 
C(12) 60524(12) 55734(9) 63681(9) 124(2) 
C(13) 67102(12) 59314(9) 72997(9) 118(2) 
C(14) 73647(13) 38142(9) 64645(9) 139(2) 
C(15) 70260(13) 28115(9) 58468(9) 131(2) 
C(16) 57444(15) 31051(10) 52945(11) 187(3) 
C(17) 68816(13) 17984(9) 64757(9) 127(2) 
C(18) 66587(14) 8454(10) 57824(10) 159(2) 
C(19) 80353(15) 15980(10) 71809(10) 181(2) 
________________________________________________________________________________ 
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 Table A7.10  Bond lengths [≈] and angles [∞] for dicyclobutane 500 
_____________________________________________________  
O(1)-H(1)  0.8400 
O(1)-C(2)  1.4276(16) 
O(2)-C(5)  1.4612(19) 
O(2)-C(8)  1.3333(18) 
O(3)-C(8)  1.2094(17) 
O(4)-H(4)  0.8400 
O(4)-C(10)  1.4075(16) 
O(5)-C(13)  1.2217(15) 
O(6)-H(6)  0.8400 
O(6)-C(18)  1.4316(16) 
C(1)-H(1A)  1.0000 
C(1)-C(2)  1.5623(17) 
C(1)-C(6)  1.5736(18) 
C(1)-C(13)  1.5287(18) 
C(2)-C(3)  1.5210(19) 
C(2)-C(4)  1.528(2) 
C(3)-H(3A)  0.9800 
C(3)-H(3B)  0.9800 
C(3)-H(3C)  0.9800 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(4)-C(5)  1.514(2) 
C(5)-H(5)  1.0000 
C(5)-C(6)  1.5463(18) 
C(6)-H(6A)  1.0000 
C(6)-C(7)  1.5464(18) 
C(7)-H(7)  1.0000 
C(7)-C(8)  1.5209(17) 
C(7)-C(9)  1.5227(17) 
C(9)-C(10)  1.5799(18) 
C(9)-C(12)  1.5432(16) 
C(9)-C(14)  1.5513(17) 
C(10)-C(11)  1.5708(19) 
C(10)-C(16)  1.5219(18) 
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C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(11)-C(12)  1.5394(18) 
C(12)-H(12)  1.0000 
C(12)-C(13)  1.4825(17) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(14)-C(15)  1.5459(17) 
C(15)-H(15)  1.0000 
C(15)-C(16)  1.5474(19) 
C(15)-C(17)  1.5328(17) 
C(16)-H(16A)  0.9900 
C(16)-H(16B)  0.9900 
C(17)-H(17)  1.0000 
C(17)-C(18)  1.5310(17) 
C(17)-C(19)  1.5290(19) 
C(18)-H(18A)  0.9900 
C(18)-H(18B)  0.9900 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 




























































































































Symmetry transformations used to generate equivalent atoms:  
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Table A7.11.  Anisotropic displacement parameters  (Å2x 104) for triol 513a.  The 
anisotropic displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* 
b* U12 ]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 160(4)  78(3) 256(4)  18(3) -73(4)  14(3) 
O(2) 247(5)  195(5) 197(4)  86(4) 30(4)  -22(4) 
O(3) 248(5)  234(5) 155(4)  65(4) 9(4)  49(4) 
O(4) 240(5)  171(5) 217(5)  47(4) -100(4)  13(4) 
O(5) 207(5)  140(4) 162(4)  -7(3) 37(3)  -6(3) 
O(6) 220(5)  90(4) 246(5)  18(3) 38(4)  9(3) 
C(1) 129(5)  80(4) 150(5)  16(4) -14(4)  3(4) 
C(2) 145(5)  78(4) 203(5)  26(4) -39(4)  -7(4) 
C(3) 249(7)  106(5) 248(6)  -17(4) -65(5)  -1(5) 
C(4) 164(6)  138(5) 281(7)  57(5) -14(5)  -46(4) 
C(5) 148(6)  190(6) 241(6)  75(5) 30(5)  -21(5) 
C(6) 119(5)  118(5) 171(5)  28(4) 6(4)  15(4) 
C(7) 150(5)  119(5) 137(5)  24(4) 14(4)  37(4) 
C(8) 183(6)  165(5) 161(5)  45(4) 60(4)  45(5) 
C(9) 146(5)  88(4) 113(4)  2(4) -10(4)  13(4) 
C(10) 175(5)  99(5) 144(5)  -7(4) -40(4)  12(4) 
C(11) 159(5)  160(6) 224(6)  -54(5) 21(5)  -41(5) 
C(12) 124(5)  96(5) 150(5)  -16(4) 10(4)  -5(4) 
C(13) 138(5)  61(4) 156(5)  -1(4) 9(4)  7(4) 
C(14) 199(6)  82(4) 137(5)  6(4) -40(4)  6(4) 
C(15) 180(5)  83(4) 131(5)  -6(4) -18(4)  9(4) 
C(16) 260(7)  97(5) 205(6)  -18(4) -106(5)  11(5) 
C(17) 164(5)  83(4) 135(5)  -1(4) -2(4)  8(4) 
C(18) 225(6)  89(5) 164(5)  -17(4) 14(5)  -7(4) 
C(19) 215(6)  127(5) 201(6)  14(4) -43(5)  19(5) 
______________________________________________________________________________ 
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Table A7.12.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters 
(Å2x 10 3)for dicyclobutane 500. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 6684 8471 6306 25 
H(4) 5784 5170 4181 31 
H(6) 5423 103 6566 28 
H(1A) 8603 6283 7717 14 
H(3A) 7789 8999 7771 30 
H(3B) 8745 8144 8275 30 
H(3C) 7194 7979 8324 30 
H(4A) 9046 8529 5909 23 
H(4B) 9948 7989 6756 23 
H(5) 10360 6843 5470 23 
H(6A) 9606 5501 6439 16 
H(7) 8714 4791 5058 16 
H(11A) 4063 5183 6019 22 
H(11B) 4732 4326 6784 22 
H(12) 5924 6206 5925 15 
H(14A) 8315 3845 6603 17 
H(14B) 6887 3812 7111 17 
H(15) 7729 2696 5337 16 
H(16A) 5768 2845 4594 22 
H(16B) 4982 2784 5637 22 
H(17) 6081 1881 6899 15 
H(18A) 6042 1052 5244 19 
H(18B) 7499 647 5464 19 
H(19A) 7913 917 7525 27 
H(19B) 8084 2171 7677 27 
H(19C) 8849 1578 6792 27 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.14. Hydrogen bonds for triol 513a. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(1)-H(1)...O(6)#1 0.84 1.93 2.7645(15) 170.3 
 O(4)-H(4)...O(3) 0.84 1.85 2.6841(17) 172.0 
 O(6)-H(6)...O(5)#2 0.84 2.01 2.8235(16) 161.6 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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A7.3 X-RAY CRYSTAL STRUCTURE ANALYSIS FOR TRIOL 513b. 
 
Figure A7.3. X-ray Crystal Structure for 513b. 
 
 
Table A7.15. X-Ray Coordinate of Compound 513b. 
Identification code  V20005 
Empirical formula  C19 H32 O9 
Formula weight  404.44 
Temperature  100(2) K 
Wavelength  1.54178 ≈ 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 9.0245(13) ≈ α= 90∞. 
 b = 13.383(2) ≈ β= 90∞. 
 c = 16.329(3) ≈ γ = 90∞. 
Volume 1972.1(5) ≈3 
Z 4 
Density (calculated) 1.362 Mg/m3 
Absorption coefficient 0.906 mm-1 




Crystal size 0.600 x 0.300 x 0.150 mm3 
Theta range for data collection 4.271 to 74.810∞. 
Index ranges -11<=h<=10, -16<=k<=15, -19<=l<=20 
Reflections collected 20468 
Independent reflections 4017 [R(int) = 0.0461] 
Completeness to theta = 67.679∞ 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7538 and 0.5503 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4017 / 9 / 282 
Goodness-of-fit on F2 1.087 
Final R indices [I>2sigma(I)] R1 = 0.0314, wR2 = 0.0874 
R indices (all data) R1 = 0.0315, wR2 = 0.0875 
Absolute structure parameter 0.06(4) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.342 and -0.300 e.≈-3 
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Table A7.16  Atomic coordinates  ( x 105) and equivalent  isotropic displacement parameters 
(≈2x 104) for triol 513b.  U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 7488(2) 5070(1) 8786(1) 20(1) 
C(1) 6251(2) 5178(1) 8340(1) 17(1) 
O(2) 5331(2) 5794(1) 8528(1) 23(1) 
C(2) 6244(2) 4454(1) 7623(1) 14(1) 
C(3) 4778(2) 3952(1) 7419(1) 12(1) 
C(4) 4938(2) 3335(1) 6621(1) 14(1) 
C(5) 4168(2) 3973(1) 5960(1) 14(1) 
C(6) 2780(2) 4388(1) 6396(1) 16(1) 
C(16) 3800(2) 3404(1) 5169(1) 16(1) 
C(17) 5215(2) 3010(1) 4767(1) 19(1) 
O(3) 4944(2) 2495(1) 4010(1) 22(1) 
C(18) 2929(2) 4059(2) 4575(1) 22(1) 
C(7) 3164(2) 4383(1) 7305(1) 14(1) 
O(4) 2807(2) 5300(1) 7691(1) 21(1) 
C(8) 2599(2) 3462(1) 7821(1) 18(1) 
C(9) 4188(2) 3370(1) 8165(1) 14(1) 
C(10) 5111(2) 2472(1) 8330(1) 13(1) 
O(5) 4650(1) 1619(1) 8426(1) 18(1) 
C(11) 6770(2) 2710(1) 8379(1) 13(1) 
C(12) 7370(2) 3649(1) 7898(1) 14(1) 
C(13) 8371(2) 4213(1) 8507(1) 18(1) 
C(14) 8646(2) 3502(2) 9217(1) 18(1) 
C(15) 7232(2) 2868(1) 9288(1) 14(1) 
O(6) 6066(1) 3429(1) 9662(1) 17(1) 
C(19) 7469(2) 1889(1) 9746(1) 19(1) 
O(1W) 4785(2) 3561(1) 2568(1) 28(1) 
O(2W) 6663(2) 3854(1) 1302(1) 21(1) 
O(3W) 3494(2) 756(1) 4427(1) 36(1) 
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Table A7.17  Bond lengths [≈] and angles [∞] for dicyclobutane 513b 
____________________________________________________  
O(1)-C(1)  1.340(2) 
O(1)-C(13)  1.469(2) 
C(1)-O(2)  1.210(2) 
C(1)-C(2)  1.520(2) 
C(2)-C(3)  1.521(2) 
C(2)-C(12)  1.549(2) 
C(2)-H(2)  1.0000 
C(3)-C(9)  1.541(2) 
C(3)-C(4)  1.549(2) 
C(3)-C(7)  1.578(2) 
C(4)-C(5)  1.542(2) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(16)  1.536(2) 
C(5)-C(6)  1.544(2) 
C(5)-H(5)  1.0000 
C(6)-C(7)  1.525(2) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(16)-C(18)  1.525(3) 
C(16)-C(17)  1.529(3) 
C(16)-H(16)  1.0000 
C(17)-O(3)  1.436(2) 
C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 
O(3)-H(3O)  0.80(2) 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(7)-O(4)  1.417(2) 
C(7)-C(8)  1.577(2) 
O(4)-H(4O)  0.82(2) 
C(8)-C(9)  1.545(2) 
C(8)-H(8A)  0.9900 
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C(8)-H(8B)  0.9900 
C(9)-C(10)  1.486(2) 
C(9)-H(9)  1.0000 
C(10)-O(5)  1.226(2) 
C(10)-C(11)  1.533(2) 
C(11)-C(15)  1.557(2) 
C(11)-C(12)  1.577(2) 
C(11)-H(11)  1.0000 
C(12)-C(13)  1.541(2) 
C(12)-H(12)  1.0000 
C(13)-C(14)  1.520(3) 
C(13)-H(13)  1.0000 
C(14)-C(15)  1.536(2) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-O(6)  1.430(2) 
C(15)-C(19)  1.523(2) 
O(6)-H(6O)  0.85(2) 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
O(1W)-H(1W1)  0.85(2) 
O(1W)-H(1W2)  0.85(2) 
O(2W)-H(2W1)  0.84(2) 
O(2W)-H(2W2)  0.86(2) 
O(3W)-H(3W1)  0.84(2) 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.18. Anisotropic displacement parameters  (Å2x 104) for triol 513b.  The 
anisotropic displacement factor exponent takes the form:  -2p2[ h2 a*2U11 +  + 2 h k a* 
b* U12] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 22(1)  15(1) 22(1)  -2(1) -5(1)  -4(1) 
C(1) 22(1)  11(1) 18(1)  2(1) -1(1)  -5(1) 
O(2) 28(1)  16(1) 25(1)  -5(1) 0(1)  1(1) 
C(2) 16(1)  12(1) 13(1)  2(1) 2(1)  -1(1) 
C(3) 14(1)  12(1) 10(1)  2(1) 0(1)  0(1) 
C(4) 17(1)  14(1) 12(1)  0(1) 0(1)  2(1) 
C(5) 18(1)  13(1) 11(1)  1(1) -1(1)  2(1) 
C(6) 19(1)  18(1) 13(1)  2(1) -1(1)  6(1) 
C(16) 18(1)  16(1) 13(1)  0(1) -1(1)  0(1) 
C(17) 23(1)  21(1) 13(1)  -3(1) 0(1)  2(1) 
O(3) 34(1)  19(1) 13(1)  -3(1) 2(1)  1(1) 
C(18) 28(1)  25(1) 14(1)  0(1) -4(1)  5(1) 
C(7) 15(1)  15(1) 14(1)  0(1) 1(1)  2(1) 
O(4) 21(1)  22(1) 21(1)  -8(1) -2(1)  7(1) 
C(8) 14(1)  23(1) 17(1)  5(1) 0(1)  -1(1) 
C(9) 14(1)  15(1) 12(1)  3(1) -1(1)  -2(1) 
C(10) 16(1)  15(1) 8(1)  1(1) -1(1)  -2(1) 
O(5) 20(1)  15(1) 20(1)  4(1) -1(1)  -4(1) 
C(11) 14(1)  14(1) 11(1)  1(1) 0(1)  -1(1) 
C(12) 13(1)  15(1) 15(1)  1(1) 2(1)  -2(1) 
C(13) 15(1)  18(1) 21(1)  0(1) -1(1)  -3(1) 
C(14) 14(1)  21(1) 20(1)  0(1) -5(1)  -2(1) 
C(15) 15(1)  16(1) 13(1)  -1(1) -3(1)  0(1) 
O(6) 17(1)  20(1) 13(1)  -2(1) -1(1)  4(1) 
C(19) 21(1)  19(1) 16(1)  3(1) -4(1)  1(1) 
O(1W) 25(1)  39(1) 20(1)  9(1) 5(1)  12(1) 
O(2W) 22(1)  26(1) 16(1)  0(1) -1(1)  6(1) 
O(3W) 61(1)  22(1) 25(1)  0(1) 8(1)  -2(1) 
______________________________________________________________________________ 
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Table A7.19. Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 
10 3) for dicyclobutane 513b. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 6630 4801 7124 16 
H(4A) 5995 3229 6485 17 
H(4B) 4448 2676 6677 17 
H(5) 4831 4546 5819 17 
H(6A) 2559 5075 6207 20 
H(6B) 1908 3959 6287 20 
H(16) 3168 2818 5316 19 
H(17A) 5892 3578 4662 22 
H(17B) 5717 2549 5152 22 
H(3O) 4480(30) 2009(19) 4146(18) 33 
H(18A) 2013 4285 4839 33 
H(18B) 2685 3673 4084 33 
H(18C) 3528 4640 4422 33 
H(4O) 3520(30) 5530(20) 7947(16) 31 
H(8A) 1843 3633 8237 22 
H(8B) 2282 2884 7485 22 
H(9) 4262 3819 8653 16 
H(11) 7318 2112 8171 16 
H(12) 7970 3424 7418 17 
H(13) 9319 4431 8245 22 
H(14A) 8825 3878 9729 22 
H(14B) 9516 3073 9105 22 
H(6O) 6270(30) 3525(19) 10162(13) 25 
H(19A) 7686 2030 10322 28 
H(19B) 8302 1527 9501 28 
H(19C) 6570 1480 9708 28 
H(1W1) 4840(40) 3250(20) 3020(15) 42 
H(1W2) 4070(30) 3960(20) 2643(19) 42 
H(2W1) 6130(30) 3730(20) 1714(15) 32 
H(2W2) 7530(30) 3640(20) 1429(17) 32 
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H(3W1) 3680(40) 690(30) 4929(15) 54 
H(3W2) 3500(40) 174(19) 4180(20) 54 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table 21.  Hydrogen bonds for V20005  [≈ and ∞]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(3)-H(3O)...O(3W) 0.80(2) 1.95(2) 2.755(2) 175(3) 
 O(4)-H(4O)...O(2) 0.82(2) 1.93(2) 2.737(2) 168(3) 
 C(9)-H(9)...O(6) 1.00 2.37 2.976(2) 117.8 
 O(6)-H(6O)...O(2W)#1 0.85(2) 1.95(2) 2.790(2) 175(3) 
 O(1W)-H(1W1)...O(3) 0.85(2) 1.91(2) 2.758(2) 178(3) 
 O(1W)-H(1W2)...O(4)#2 0.85(2) 1.96(2) 2.799(2) 169(3) 
 O(2W)-H(2W1)...O(1W) 0.84(2) 1.86(2) 2.701(2) 173(3) 
 O(2W)-H(2W2)...O(5)#3 0.86(2) 1.96(2) 2.804(2) 168(3) 
 O(3W)-H(3W1)...O(1)#4 0.84(2) 2.49(3) 3.184(2) 141(3) 
 O(3W)-H(3W2)...O(2W)#5 0.87(2) 1.94(2) 2.814(2) 175(4) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x,y,z+1    #2 -x+1/2,-y+1,z-1/2    #3 x+1/2,-y+1/2,-z+1       
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Figure A7.4. X-ray coordinate of scabrolide a (416) 
 
Table A7.22 Crystal data and structure refinement for scabrolide A (416). 
Identification code  V20018 
Empirical formula  C19 H22 O5 
Formula weight  330.36 
Temperature  100(2) K 
Wavelength  1.54178 ≈ 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.1878(4) ≈ α= 90∞. 
 b = 14.9676(14) ≈ β= 90∞. 
 c = 17.511(2) ≈ γ = 90∞. 
Volume 1621.8(3) ≈3 
Z 4 
Density (calculated) 1.353 Mg/m3 
Absorption coefficient 0.800 mm-1 
F(000) 704 
Crystal size 0.450 x 0.200 x 0.150 mm3 
Theta range for data collection 3.885 to 74.514∞. 
Index ranges -7<=h<=7, -18<=k<=18, -20<=l<=21 
Reflections collected 14706 
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Independent reflections 3306 [R(int) = 0.0575] 
Completeness to theta = 67.679∞ 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7538 and 0.6083 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3306 / 1 / 222 
Goodness-of-fit on F2 1.048 
Final R indices [I>2sigma(I)] R1 = 0.0353, wR2 = 0.0889 
R indices (all data) R1 = 0.0369, wR2 = 0.0906 
Absolute structure parameter 0.00(7) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.657 and -0.199 e.≈-3 
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Table 23.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (≈2x 103) 
for V20018.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 1620(2) 5711(1) 5387(1) 19(1) 
C(1) 2687(3) 6235(1) 4894(1) 16(1) 
O(2) 1762(2) 6741(1) 4470(1) 20(1) 
C(2) 5129(3) 6135(1) 5002(1) 16(1) 
C(3) 6351(3) 6183(1) 4262(1) 14(1) 
C(4) 6411(3) 7080(1) 3873(1) 17(1) 
C(5) 5192(3) 7133(1) 3101(1) 18(1) 
C(16) 5851(4) 7974(2) 2674(1) 22(1) 
C(17) 4347(5) 8604(2) 2509(2) 34(1) 
C(18) 8117(4) 8092(2) 2448(2) 34(1) 
C(6) 5415(4) 6278(2) 2609(1) 21(1) 
C(7) 7669(4) 5905(1) 2542(1) 22(1) 
O(3) 8577(4) 5848(1) 1932(1) 38(1) 
C(8) 8816(3) 5587(2) 3257(1) 18(1) 
C(9) 7470(3) 5491(1) 3974(1) 15(1) 
C(10) 7522(3) 4620(1) 4364(1) 15(1) 
O(4) 8720(2) 4016(1) 4141(1) 19(1) 
C(11) 6084(3) 4457(1) 5040(1) 15(1) 
C(12) 3939(3) 3993(1) 4811(1) 16(1) 
O(5) 3102(2) 4518(1) 4189(1) 15(1) 
C(19) 4176(3) 3021(1) 4572(1) 21(1) 
C(13) 2585(3) 4137(1) 5535(1) 18(1) 
C(14) 3075(3) 5093(1) 5780(1) 19(1) 
C(15) 5399(3) 5298(1) 5486(1) 16(1) 
________________________________________________________________________________ 
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Table 24.   Bond lengths [≈] and angles [∞] for  V20018. 
_____________________________________________________  
O(1)-C(1)  1.341(3) 
O(1)-C(14)  1.462(3) 
C(1)-O(2)  1.206(3) 
C(1)-C(2)  1.530(3) 
C(2)-C(3)  1.502(3) 
C(2)-C(15)  1.522(3) 
C(2)-H(2)  1.0000 
C(3)-C(9)  1.345(3) 
C(3)-C(4)  1.506(3) 
C(4)-C(5)  1.551(3) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(16)  1.519(3) 
C(5)-C(6)  1.549(3) 
C(5)-H(5)  1.0000 
C(16)-C(17)  1.356(4) 
C(16)-C(18)  1.468(4) 
C(17)-H(17A)  0.9500 
C(17)-H(17B)  0.9500 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(6)-C(7)  1.507(3) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-O(3)  1.210(3) 
C(7)-C(8)  1.515(3) 
C(8)-C(9)  1.514(3) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-C(10)  1.472(3) 
C(10)-O(4)  1.232(3) 
C(10)-C(11)  1.501(3) 
C(11)-C(15)  1.540(3) 
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C(11)-C(12)  1.551(3) 
C(11)-H(11)  1.0000 
C(12)-O(5)  1.439(2) 
C(12)-C(19)  1.522(3) 
C(12)-C(13)  1.535(3) 
O(5)-H(5O)  0.84(2) 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(13)-C(14)  1.524(3) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-C(15)  1.558(3) 
C(14)-H(14)  1.0000 











































































































Symmetry transformations used to generate equivalent atoms:  
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Table 25.   Anisotropic displacement parameters  (≈2x 103) for V20018.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 17(1)  21(1) 20(1)  0(1) 4(1)  5(1) 
C(1) 17(1)  18(1) 14(1)  -4(1) 2(1)  1(1) 
O(2) 19(1)  20(1) 21(1)  -2(1) -1(1)  6(1) 
C(2) 16(1)  18(1) 13(1)  -2(1) -2(1)  0(1) 
C(3) 11(1)  18(1) 14(1)  0(1) -3(1)  -4(1) 
C(4) 19(1)  17(1) 16(1)  0(1) -2(1)  -3(1) 
C(5) 16(1)  20(1) 17(1)  2(1) -2(1)  -1(1) 
C(16) 26(1)  23(1) 18(1)  4(1) -3(1)  -4(1) 
C(17) 34(1)  27(1) 41(1)  13(1) 4(1)  4(1) 
C(18) 27(1)  38(1) 35(1)  17(1) -1(1)  -6(1) 
C(6) 24(1)  23(1) 17(1)  -1(1) -7(1)  -3(1) 
C(7) 30(1)  19(1) 17(1)  -3(1) 2(1)  0(1) 
O(3) 49(1)  45(1) 20(1)  -1(1) 10(1)  14(1) 
C(8) 16(1)  21(1) 19(1)  0(1) 4(1)  -1(1) 
C(9) 10(1)  21(1) 14(1)  1(1) -1(1)  -2(1) 
C(10) 8(1)  19(1) 17(1)  -2(1) -3(1)  -1(1) 
O(4) 11(1)  19(1) 27(1)  0(1) 1(1)  1(1) 
C(11) 12(1)  17(1) 16(1)  4(1) -2(1)  2(1) 
C(12) 11(1)  18(1) 17(1)  3(1) 0(1)  1(1) 
O(5) 10(1)  18(1) 17(1)  2(1) -1(1)  -1(1) 
C(19) 15(1)  17(1) 29(1)  2(1) 0(1)  -2(1) 
C(13) 14(1)  22(1) 19(1)  5(1) 3(1)  -1(1) 
C(14) 17(1)  24(1) 15(1)  2(1) 3(1)  2(1) 
C(15) 14(1)  21(1) 14(1)  0(1) -1(1)  -1(1) 
______________________________________________________________________________ 
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Table A7.26. Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 
10 3 )for scabrolide a (416) 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 5617 6652 5321 19 
H(4A) 7940 7245 3785 21 
H(4B) 5787 7530 4224 21 
H(5) 3622 7198 3225 21 
H(17A) 4754 9131 2244 41 
H(17B) 2887 8518 2659 41 
H(18A) 8266 8645 2153 50 
H(18B) 8575 7584 2135 50 
H(18C) 9025 8127 2906 50 
H(6A) 4469 5811 2829 26 
H(6B) 4874 6411 2089 26 
H(8A) 9481 5001 3144 22 
H(8B) 10006 6010 3367 22 
H(11) 6869 4053 5401 18 
H(5O) 1810(40) 4353(19) 4117(16) 22 
H(19A) 2797 2803 4369 31 
H(19B) 4593 2660 5015 31 
H(19C) 5292 2972 4176 31 
H(13A) 1027 4062 5425 22 
H(13B) 3009 3708 5939 22 
H(14) 2975 5162 6347 22 
H(15) 6404 5411 5923 20 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.28. Hydrogen bonds for scabrolide a (416). 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2)-H(2)...O(2)#1 1.00 2.53 3.461(2) 154.0 
 C(8)-H(8B)...O(2)#2 0.99 2.47 3.289(3) 139.6 
 O(5)-H(5O)...O(4)#3 0.84(2) 1.98(2) 2.815(2) 170(3) 
 C(19)-H(19C)...O(4) 0.98 2.64 3.270(3) 122.7 
 C(15)-H(15)...O(3)#4 1.00 2.58 3.123(3) 113.7 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x+1/2,-y+3/2,-z+1    #2 x+1,y,z    #3 x-1,y,z       
#4 -x+3/2,-y+1,z+1/2       
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